PTNS: a new treatment option for lower urinary tract dysfunction. by Vandoninck, V.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/51953
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
PTNS
a new treatment option for
lower urinary tract dysfunction
Vera Vandoninck
POSTERIOR 
TIBIAL NERVE 
STIMULATION 
a new treatment option for
lower urinary tract dysfunction
V. Vandoninck
Ph.D. Thesis, with summary in Dutch
UMC St Radboud, Nijmegen, the Netherlands
Limited edition, 500 copies
Design: re-media.be
Printed by: Optima Grafische Communication
ISBN: 978-90-8559-314-0
© V.Vandoninck, 2007
No part of this book may be reproduced in any form, by 
print, photocopy, microfilm or any other means, without 
written permission of the author, or, when appropriate of 
the publishers of the publications
PTNS | a new treatment option for lower urinary tract dysfunction4
POSTERIOR TIBIAL NERVE STIMULATION
A NEW TREATMENT OPTION FOR LOWER URINARY TRACT DYSFUNCTION 
NERVUS TIBIALIS STIMULATIE
EEN NIEUWE BEHANDELINGSMETHODE VOOR LAGERE URINEWEG DYSFUNCTIE
Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, volgens besluit van het 
College van Decanen in het openbaar te verdedigen op maandag 17 september 2007 
om 15.30 uur precies
door 
Vera Vandoninck
geboren op 12 februari 1974 te Antwerpen
Promotores:
Prof. dr. B.L.H. Bemelmans (VU Medisch Centrum Amsterdam) 
Prof. dr. F.M.J. Debruyne (Andros Mannenkliniek Arnhem)
Copromotor:
Dr. J.P.F.A. Heesakkers
Manuscriptcommissie:
Prof. dr. J.L.H.R. Bosch (UMC Utrecht)
Prof. dr. M.E. Vierhout
Prof. dr. G.W.A.M. Padberg
Paranimfen:
J.W.A. van Dorsten
J.J.G. de Proost
Financial support was greatly appreciated from: Uroplasty 
Additional support was granted by Astellas Pharma, Astra Zeneca, Astra Tech, Bard, 
Glaxo Smith Kline, Hitachi Medical Sysytems, Hoogland Medical, Medireva, Medical 
Measurement Systems, Pfizer, UCB Pharma
PTNS | a new treatment option for lower urinary tract dysfunction6
CONTENTS
Chapter 1 Introduction and outline of this thesis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 7
Chapter 2 Anatomy and physiology of the lower urinary tract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 10
Chapter 3 Voiding dysfunction, pathophysiology and terminology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 18 
Chapter 4  Prevalence of urinary incontinence in community dwelling females: a matter of defi nition  . . . . . . . . . . p. 31
Chapter 5  From electrical fi sh to PTNS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 43
Chapter 6 PTNS as neuromodulative treatment of lower urinary tract dysfunction  . . . . . . . . . . . . . . . . . . . . . . . . . p. 57
Chapter 7 PTNS in the treatment of overactive bladder (OAB) complaints . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 70
Chapter 8 PTNS in the treatment of idiopathic non-obstructive voiding dysfunction.  . . . . . . . . . . . . . . . . . . . . . . . p. 86
Chapter 9 PTNS in the treatment of  OAB syndrome: urodynamic data.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 98
Chapter 10 PTNS in the treatment of idiopathic non-obstructive voiding dysfunction: urodynamic data.  . . . . . . . . . p. 111
Chapter 11 Summary and conclusions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 125
Chapter 12 Samenvatting en besluitvorming  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 130
Addendum List of abbreviations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 136
 Dankwoord  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 137
 Curriculum Vitae  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 139
CHAPTER 1
OUTLINE OF THE THESIS
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Overactive bladder syndrome (OAB) is a very bothersome condition. Abrams estimates that worldwide 
about 200 million people suffer from urinary incontinence [Abrams, 1999]. A recent European study 
reported a prevalence of nearly 17% of subjects describing symptoms consistent with OAB complaints 
[Milson et al., 2001]. Detrusor overactivity is an urodynamic ﬁ nding that can cause OAB complaints. 
It is commonly seen in neurological disease or after neurological injury. Also aging, inﬂ ammation, 
bladder outlet obstruction, or irritation can cause OAB symptoms. When no speciﬁ c cause is found, 
detrusor overactivity is deﬁ ned as idiopathic.  
Failure to empty the bladder results from decreased bladder contractility, increased outlet resistance, 
or both. This condition can also be caused by a neurological disorder or after neurological injury. For 
men, bladder outlet obstruction is most often secondary to prostate hyperplasia. In women it is seen 
after anti-incontinence surgery, urethral stricture or dysfunctional voiding. When no obvious cause 
is found, the term idiopathic voiding dysfunction remains. For OAB as well as voiding dysfunction 
behavioral therapy, life style changes, or pelvic ﬂ oor therapy can be applied with or without the support 
of anticholinergics, spasmolytics or botoxulinum toxine injections. Before recommending irreversible 
surgery, electrical stimulation has gained an important place in treatment ﬂ ow charts. Electrical 
stimulation can be applied on different parts of the body. Percutaneous Tibial Nerve Stimulation (PTNS) 
is a very simple method of stimulating the tibial nerve through needling at the level of the ankle. It is 
thought that stimulation of this large nerve has an effect on the roots and their target organs. PTNS 
can be applied both for OAB symptoms as for voiding dysfunction. It has also been applied for pelvic 
pain syndrome. Since 1999 subjects with OAB complaints and voiding dysfunction have been enrolled 
in the PTNS protocol to investigate the effect of PTNS on their symptoms. The aim of this thesis is to 
investigate if PTNS is a useful alternative treatment option for patients with OAB or voiding dysfunction. 
Analysis of these data will be presented in this thesis.
Chapter 2 provides an introduction in urological anatomy of the lower urinary tract as well as the 
working mechanism of storage of urine. 
Chapter 3 summarizes neurological and non-neurological causes of both OAB and voiding dysfunction. 
Some insights in pathophysiological changes of the bladder and innervation are discussed. During the 
research on PTNS, deﬁ nitions and terms have changed. Deﬁ nitions and terms have been replaced in 
all articles conform the latest International Continence Society (ICS) guidelines [Abrams et al., 2002]. 
New and relevant deﬁ nitions for this thesis have been summarized and explained.
Urinary problems have been discussed more openly in recent years, but the real prevalence of these 
distressing and disabling conditions remains unclear. For the Netherlands, up to 46 % of the married 
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female population has experienced some degree of urinary incontinence according to the Dutch 
national postal questionnaire survey (chapter 4).
Using electrical eels, ancient Egyptians believed in the healing capacity of electric shocks. It was 
Galvani who observed a muscle twitch when he accidentally electrostimulated a frog leg in 1791. Further 
experiments with electricity followed. In the mid nineteenth century, Duchenne conducted extensive 
studies on the use of electricity in medicine. Most physicians had electrotherapeutic machines in 
their ofﬁ ces and prescribed electrotherapeutic baths and belts for home use [Devinsky, 1993]. Soon 
medical applications followed, so that following other organs, the bladder was targeted as an organ 
for stimulation. Electrostimulation therapy has recently been introduced as a promising treatment 
modality for overactive bladder and voiding dysfunction. Dr. Stoller stimulated afferent nerves of 
Macaca apes and found an effect on their micturition pattern. Soon stimulation of the posterior nerve 
in patients with OAB was investigated. PTNS is a simple procedure with an easily accessible stimulation 
site at the level of the ankle. Chapter 5 provides an overview of all kinds of electrical stimulations that 
had been performed to treat voiding complaints. The PTNS protocol, technique, inclusion and exclusion 
criteria are also documented in this section.
In 1999 the ﬁ rst patients were enrolled in the PTNS protocol in the Netherlands. These very ﬁ rst results 
of PTNS are presented in chapter 6.
Stimulated by the promising results, patients all over the Netherlands and patients from the 
collaborating University of Rome, Italy, were enrolled. Protocols were completed and sent back to the 
investigating site the University Medical Centre St. Radboud, Nijmegen. Chapter 7 and 8 present the 
analysis of data from patients with OAB respectively voiding dysfunction, who underwent PTNS in 12 
weekly sessions.
Although the subjective improvement of the patient should be the main goal of a treatment, it is clear 
that in a research setting objectivity should be formost. Regarding bladder function, bladder diaries 
and urodynamics were chosen as objective tools to investigate  the effect of PTNS. In chapter 9 
the urodynamic data of patients with OAB are described and in chapter 10 the data of candidates 
with voiding dysfunctions are presented. For both groups, predictive factors for success were 
investigated.
Finally, conclusions  are drawn and future prospectives are listed in chapter 11.
Chapter 12 contains a Dutch translation of this summary and conclusion.
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2.1 ANATOMY
The main function of the lower urinary tract is to store and expel urine. The urinary bladder is a hollow 
organ with strong muscular walls, the detrusor muscle, which functions as a reservoir. When empty, 
the bladder is entirely located within the pelvis. As it ﬁ lls, it can contain about 500 cc or more while it 
rises into the abdominal cavity. The bladder neck, urethra and pelvic ﬂ oor form the bladder outlet and 
facilitate urine evacuation. From both sides the ureters penetrate the bladder in its posterolateral wall 
after tunnelling the bladder wall obliquely over a 1-2 cm long traject to end as the ureteral oriﬁ ces. 
The posterolateral angles formed by the ureters oriﬁ ces and the internal oriﬁ ce of the urethra form 
a triangular area: trigonium vesicae. The bladder is composed of four layers: serous, muscular, 
submucosal and mucosal layers. The tunica mucosa is continuous with the lining membrane of the 
ureters and renal pelvis, and below with that of the proximal urethra. The areolar tissue of the tunica 
submucosa connects the mucosa only slightly; it makes the bladder look wrinkled when contracted. 
Over the trigonium vesicae the mucous membrane is ﬁ rmly attached to the muscular coat, and thus 
looks smooth and ﬂ at. The tunica muscularis consists of three layers. The internal longitudinal layer 
is thin, ﬁ bres are organised for the most part in a longitudinal direction. In the middle layer, the 
ﬁ bres are irregularly scattered, but circularly arranged toward the lower part forming a thick circular 
sphincter vesicae around the urethral oriﬁ ce. In male the sphincter ﬁ bres are continuous with the 
muscular ﬁ bres of the prostate. The external layer has been named the detrusor urinae muscle and is 
composed of ﬁ bres organised in a longitudinal arrangement. It arises from the posterior pubovesical 
muscle, passes over the vertex and attach to the prostate or anterior vagina. At the lateral sides ﬁ bres 
pass obliquely and intersect one another. The outer tunica serosa is derived from the peritoneum. The 
physiological internal sphincter maintains continence by closure of the bladder neck and proximal 
urethra. Continence is thought to be dependent on a combination of urethral wall tension, the calibre 
of the urethral lumen and the functional length. The striated muscles surrounding the urethra are not 
essential for urinary incontinence but are important in the voluntary termination of urine ﬂ ow and 
prevention of stress incontinence [de Groat W et al., 1993; Gray H, 1995; Steers W, 1998].
2.2 INNERVATION
Storage and expulsion of urine is the result of complex neural network interactions. Different neural 
circuits located in brain, brain stem, spinal cord and peripheral nerves and ganglia regulate bladder 
ﬁ lling and coordinated micturition. Interaction of somatic and autonomic efferent signals, voluntary 
on-off control mechanism and learned behaviour modulate the lower urinary tract’s function.
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The innervation of the lower urinary tract is derived from three sets of peripheral nerves: 
sacral parasympathetic (pelvic nerves)
thoracolumbar (ortho)-sympathetic (hypogastric nerves and sympathetic chain)
sacral somatic (predominantly pudendal nerves)
2.2.1 SACRAL PARASYMPATHETIC (PS) PATHWAY
Sacral parasympathetic efferent outﬂ ow originates from the S2-S3-S4 segments of the spinal cord 
and is conveyed by the pelvic nerve projecting to the bladder, urethra and prostate. The perikarya are 
organised in a viscerotopic manner in the intermediolateral columns of the spinal cord, this explains 
why discrete lesions can spare some of the pelvic visceral functions.  The curvilinear plexus lies in 
the pelvic fascia on either side of the lower genitourinary tract and rectum. It coordinates visceral 
and somatic function of pelvic organs (micturition, defecation, erection, ejaculation and lower limb 
movements) [Steers W, 1998]. Parasympathetic input excites the bladder through preganglionic 
cholinergic neurons to ganglionic cells in the pelvic plexus and bladder wall. Through nicotinic cholinergic 
mechanism, transmission in bladder ganglia is mediated and in turn excites the bladder smooth 
muscle through muscarinic receptors. The human bladder is endowed with M2 and M3 receptors. M2 
receptors are voltage linked as M3 receptors are G protein or Calcium mediated. Blocking one type 
of receptor may not completely abolish bladder contraction. Aside from different types of receptors, 
the binding properties of these receptors may be altered following smooth muscle hypertrophy 
or nerve injury. Changes can be rapid, e.g. in a few hours after bladder outlet obstruction. Therapy 
resistant overactivity of the bladder may also be caused by other non-cholinergic mechanisms. For 
example Adenosine trifosphate (ATP) causes bladder contractions in animal experiments. Zhong et 
al. suggest that ATP may play an important role in mediating urinary bladder ﬁ lling and nociception 
[Zhong Y, et al., 2003]. Most probably, a cascade of mediators, released from the urothelium and the 
suburothelium plexus of nerves in response to bladder distension, can initiate or depress activation 
of the bladder. The ﬁ ring of suburothelial afferent nerves and the threshold for bladder activation may 
be modiﬁ ed by both inhibitory (e.g., nitric oxide) and stimulatory (e.g., ATP, tachykinins, prostanoids) 
mediators. These mechanisms can be involved in the generation of bladder overactivity, causing 
urgency, frequency and incontinence, and thus seems to be interesting targets for pharmacologic 
intervention [Andersson K-E., 2002].
•
•
•
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2.2.2 SOMATIC EFFERENT PATHWAYS
Somatic efferent pathways to the external urethral sphincter are carried in the pudendal nerve from the 
anterior horn cells in the second, third and fourth sacral segments. The motor neurons are topographical 
organised in the nucleus of Onuf. Cells within Onuf’s nucleus are unique in that their properties and 
size more closely resemble autonomic neurons rather than other somatic motoneurons within the 
spinal cord. The pudendal nerve divides into two terminal branches; the perineal nerve (innervating 
the skin of the scrotum or labia) and the dorsal nerve of the penis or clitoris. Muscular branches are 
distributed to the superﬁ cial transverse perineal muscle, bulbocavernous muscle, ischiocavernosous 
muscle and urethral constrictor muscle. Visceral branches arise from the fourth and third and 
sometimes second sacral nerve and are supplying the bladder and rectum, and in women the vagina. 
They communicate with the pelvic plexuses of the sympathetic pathway. Before its division it gives off 
the inferior hemorrhoidal nerve [Gray H, 1995].
2.2.3 (ORTHO) SYMPATHETIC (OS) PATHWAY
Sympathetic preganglionic pathways arise from Th10-L2 spinal segments; pass to the sympathetic 
chain ganglia and then to the prevertebral ganglia in the superior hypogastric and pelvic plexuses. 
Efferent signals reach adrenergic neurons in the bladder and urethra. Adrenergic receptors are 
classiﬁ ed according to their responses to norepinephrine and its compounds. α-receptors are 
found in the smooth muscles of small arterioles and sphincter muscles of the bladder; activation 
produces smooth muscle contraction. Stimulation of β-receptors found in the bladder wall muscles 
causes bladder relaxation. Sympathetic postganglionic nerves release norepinephrine and provide an 
excitatory input to smooth muscle of the urethra and bladder base, an inhibitory  input to smooth 
muscle in the body of the bladder, as well as inhibitory and facilitary input to vesical parasympathetic 
ganglia. The vesicosympathetic reﬂ ex is a negative feedback mechanism: an increase in bladder 
pressure results in an increase in inhibitory input, allowing the bladder to ﬁ ll to larger volumes [de 
Groat WC, 1993].
2.2.4 AFFERENT PATHWAYS
Afferent activity arising in the bladder is conveyed to the central nervous system over both sets 
of autonomic nerves. Ascending routes transmitting both bladder sensation and trigger voiding, 
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travel in the lateral spinothalamic tract [Nathan and Smith 1958]. The most important afferents for 
initiating micturition are those running in the pelvic nerve to the sacral spinal cord. These afferents 
consist of small myelinated (Aδ) and unmyelinated (C) ﬁ bres, which convey impulses from tension 
receptors and nociceptors in the bladder wall [de Groat, 1997]. Electrophysiological studies in the 
cat have shown that Aδ afferents respond to passive distension and contraction of the bladder. These 
afferents are activated at 5-15 mmHg intravesical pressure; this pressure range corresponds to the 
ﬁ rst sensation of bladder ﬁ lling. 
High threshold C ﬁ bres (unmyelinated) afferents have also been detected in cat bladder. Under normal 
conditions, the large majority of these afferents do not respond to bladder distension, and therefore 
are termed silent C ﬁ bres. But many are activated by chemical irritation of the bladder mucosa or cold. 
After chemical irritation or cold water irrigation (Bors’ ice water test), C ﬁ bres exhibit spontaneous ﬁ ring 
with the bladder empty and increase ﬁ ring during bladder distension. Activation of C ﬁ bres facilitates 
the micturition reﬂ ex and decreases bladder capacity. Administration of capsaicin, a neurotoxin that 
desensitises C ﬁ bres, blocks facilitation, but the neurotoxin does not block the micturition reﬂ ex in 
normal animals, indicating that C ﬁ bres pathways are not essential for normal voiding [de Groat, 1997; 
Fall et al., 1996].
2.3 ALL OR NOTHING
When sufﬁ ciently activated, mechanoreceptors of the bladder trigger a coordinated response via the 
pontine centre: a spinobulbospinal reﬂ ex. The reﬂ ex detrusor contraction generates an increased 
bladder wall tension and also a stronger activation of the bladder mechanoreceptors. In turn, this 
reinforces bladder output and leads to further increase in pressure which in its turn enhances receptor 
activation. This control mechanism is considered as a positive feed-back, self-generating to a large 
extent once initiated and explain the all-or-nothing behaviour of the parasympathetic motor pathway 
to the bladder. Once urine pass the urethra, contraction is further enhanced by reﬂ ex excitation from 
urethral receptors [Fall M et al., 1991].
2.4 SAFETY ROUTES
The system of interacting neural networks can easily become unstable. Any stimulus that increases 
intravesical pressure may trigger a full-blown micturition reﬂ ex. Fortunately the micturition cyclus is 
modiﬁ ed by several pathways. The best known spinal mechanism is the guarding reﬂ ex where reﬂ ex 
activation of the urethral sphincter is enhanced in response to bladder mechanoreceptor activation. 
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An analogous mechanism is the Edvardsen‘s reﬂ ex which, in response to increased intravesical 
pressure, will activate the sympathetic inhibitory efferents [Fall M et al., 1991]. Other spinal inhibitory 
systems are signals arising from the afferent anorectal branches of the pelvic nerves, the dorsal 
clitoral and penile branches of the pudendal nerves and various nerves from the lower limbs. They 
activate the inhibitory sympathetic neurons and inhibit the bladder motoneurons via direct sacral 
route [Lindstrom et al., 1989; Fall et al., 1991]. 
2.5 CENTRAL PROCESSING
Stimulation and lesioning studies in the cat have revealed localisation of speciﬁ c areas controlling 
micturition. Sacral inputs from the bladder terminate in the ventrolateral periaquaductal gray area 
(PAG). Here signals are processed and projected to the micturition centre. A discrete dorsomedial 
region in the pons (M region) contacts dendrites of the parasympathetic bladder motor neurons 
producing bladder contraction and relaxation of anal and urethral sphincters. Bilateral lesioning of the 
M region in cats produces detrusor-sphincter dyssynergia.  The M region or Pontine Micturition Centre 
(PMC) or Barrington’s nucleus receives information from various regions of the brain. Cortical regions 
(medial frontal gyrus and anterior cingulated lobe) as well as subcortical regions (medial preoptic 
region of the hypothalamus, the septum and amygdale) all send projections to the M region. These 
pathways explain emotional and homeostatic inﬂ uences on micturition and indicate that micturition 
may begin in ideal circumstances [Holstege et al., 1986; Blok and Holstege 1994]. Stimulation of a 
more lateral region (L region) projects directly to the nucleus of Onuf in the sacral cord and produces 
both contraction and relaxation of the external urethral sphincter in cats and rats; bilateral destruction 
induces bladder hyperactivity and urinary incontinence. As the PMC/ M region facilitates bladder 
activity, the L region regulates the bladder storage function through stimulation of the pelvic ﬂ oor 
muscles. Stimulation of the L region results in strong excitation of the pelvic ﬂ oor and increase in 
urethral pressure. 
Emotions or psychological stressors can have profound inﬂ uence on voiding. For example psychogenic 
retention or anxiety is associated with non-relaxation of the bladder neck or acontractility of the
detrusor. The role of basal ganglia, parietal, frontal cortex and cerebellum has been documented 
by studies describing lower urinary tract dysfunction after CVA, epilepsy and intracranial tumours. 
Although both excitatory and inhibitory effects have been described, the net effect is often overactivity 
resulting in overactive detrusor and incontinence [Morrison J, 2002].
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2.6 STORAGE AND FILLING
Under normal conditions, the urinary bladder and the outlet exhibit a reciprocal relation in effecting 
the storage and elimination of urine. During ﬁ lling, the bladder neck and proximal urethra are closed 
and the intraurethral pressure range from 20 to 50 cm H2O. During this time the detrusor muscle 
is quiescent, allowing the intravesical pressure to remain low (5-10 cm H2O) over a wide range of 
bladder volumes. Information about the degree of ﬁ lling is conveyed by the pelvic nerve through the 
lumbosacral cord to the periaquaductal grey (PAG). Bladder ﬁ lling is a primarily passive phenomenon 
that is dependent on the intrinsic properties of the vesical smooth muscle and the inactivity of the 
parasympathetic efferent pathway [de Groat, 1997].
During ﬁ lling the activity of the sphincter increases reﬂ ecting increased efferent ﬁ ring from the 
pudendal nerve (Onuf).  Pudendal motorneuron ﬁ ring occurs when the bladder is ﬁ lled or following 
sudden increase in intravesical pressure: the guarding of continence reﬂ ex. Hypogastric ﬁ ring is 
initiated by a lumbosacral intersegmental spinal reﬂ ex: pelvic afferents enter the sacral cord and 
ascend to thoracolumbar sympathetic preganglionic ﬁ bres. The storage reﬂ ex represents a negative 
feedback mechanism whereby elevations in intravesical pressure trigger inhibitory input to the 
bladder and allow greater urine accommodation.
When the bladder is ﬁ lled to such a degree that voiding can take place, PAG activates neurons in 
the PMC/M region. Descending axons projected to sacral preganglionic neurons are responsible for 
bladder contraction and urethral relaxation, as well as inhibition of pudendal motoneurons in Onuf’s 
nucleus, which innervate the striated external urethral sphincter [Steers WD, 1998; Blok, 1998]. 
For micturition, the initial event is a reduction of intraurethral pressure, which reﬂ ects a relaxation 
of the pelvic ﬂ oor and the paraurethral striated muscles. Then the urethra shortens and the bladder 
neck opens. Changes in the urethra are quickly followed by contractions of the detrusor and a rise in 
intravesical pressure that is maintained until the bladder empties.
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Candidates for Percutaneous Posterior Tibial Nerve Stimulation were mainly patients with idiopathic 
voiding dysfunction. Meaning that patients with an obvious neurological disorder that caused their voiding 
dysfunction complaints were excluded. Also inﬂ ammation, bladder outlet obstruction or other treatable 
causes were exclusion criteria for PTNS treatment. Neurological and non-neurological causes for voiding 
dysfunction as well as the pathophysiology are summarized in this chapter.
3.1 BLADDER OVERACTIVITY
A European study of nearly 17, 000 subjects over the age of 40, reported that 16.6% of the participants 
(or an estimated prevalence of 22.2 million) have symptoms consistent with OAB. As this age group is 
increasing, the impact of OAB will increase in the future. Quality of life surveys document that urinary 
frequency, urgency and nocturia are some of the most bothersome aspects of voiding dysfunction 
[Milson et al., 2001]. Detrusor overactivity is commonly seen in neurological disease or after 
neurological injury. Diseases at or above the brain stem, involving the spinal cord or distal to the spinal 
cord often results in detrusor overactivity. Aging, inﬂ ammation, bladder outlet obstruction or irritation 
of the bladder wall can induce overactivity. Furthermore gender and depression can predispose 
to overactive bladder complaints. When there is no speciﬁ c cause, the overactivity is deﬁ ned as 
idiopathic. Storage failure can also occur in the absence of detrusor overactivity, secondary to pain or 
hypersensitivity. Interstitial Cystitis or painful bladder syndrome is a classic example [Wein, 1998].
 
3.1.1 NEUROLOGICAL CAUSES
DISEASES AT OR ABOVE THE BRAIN STEM
Disorders at or above the brain stem often results in detrusor overactivity. Examples are 
cerebrovascular disease, dementia, concussion, brain tumour, cerebellar ataxia, normal pressure 
hydrocephalus, cerebral palsy, Parkinson’s disease and Shy-Drager syndrome. Cerebrovascular 
disease includes thrombosis, occlusion and hemorrhage and can lead to ischemia and infarction of 
variably sized areas in the brain. The effect on micturition depends on localization and size of the 
damage. After an initial acute episode urinary retention may occur. The most commonly long-term 
dysfunction is detrusor overactivity. Cerebral infarction causes plasticity in GABA (Gamma-amino 
butyric acid) mediated inhibitory neurons and glutaminergic excitatory transmission, resulting 
in OAB. In 44 to 83% of the patients overactivity is accompanied by incontinence shortly after the 
“cerebral shock”, in 80 % continence will be regained.  Estimations place the incidence of underactivity 
or acontractility as high as 20%. Dementia disease is poorly understood but involves atrophy and loss 
of gray and white matter of the brain, particularly in the frontal lobes. If voiding dysfunction occurs, 
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this results often in incontinence. This can be due to detrusor overactivity or weak striated sphincter 
or failure of mentation with micturition inappropriately timed. Parkinson’s disease is a degenerative 
disease that affects the dopaminergic substantia nigra and corpus striatum pathway, resulting in a 
dopamine deﬁ ciency and cholinergic predominance in the corpus striatum and loss of pigmented 
neurons characterized by the intracytoplasmatic inclusion bodies called Lewy bodies. Projections 
of dopamine containing neurons from the substantia nigra have opposing effects on the bladder. In 
Parkinson‘s disease excitatory signals for micturition are increased whereas rostral ﬁ bres that elevate 
the micturition threshold are inhibited. This results in a net excitatory effect on micturition reﬂ exes 
with a reduced volume threshold and unstable bladder contractions. Voiding dysfunction occurs in 
35 to 70 % of the patients. 50 to 70% of the symptoms consist of urgency, frequency, nocturia and 
incontinence. The remainder has obstructive complaints. The most common urodynamic ﬁ nding is 
detrusor overactivity with synergic micturition. Pseudodyssynergia may occur as a delay in striated 
sphincter relaxation at the onset of voiding. Also impaired detrusor contractility can occur. Detection 
of poor sphincter control is important as desobstructive prostatectomy can result in such cases to 
worsening of voiding complaints and /or incontinence.
DISEASES PRIMARILY INVOLVING THE SPINAL CORD 
Such diseases are for instance multiple sclerosis, spinal cord injury and disease, neurospinal 
dysraphism, tabes dorsalis, pernicious anemia and poliomyelitis. Multiple Sclerosis is caused by an 
autoimmune-induced focal neural demyelination, generally characterized by axonal sparing, in the 
brain and spinal cord. Demyelination causes reduced conduction in axonal pathways, resulting in 
various neurological abnormalities. This process commonly affects the laterocorticospinal (pyramidal) 
and reticulospinal columns of the cervical spine that might lead to voiding dysfunction and sphincter 
dysfunction. 50 to 90% of the patients will have urinary complaints at some point. Lower urinary tract 
symptoms may represent the sole initial complaint in up to 10% of patients. Detrusor overactivity is the 
most commonly detected urodynamic abnormality. When present, coexistent sphincter dyssynergia 
is present in 30-65% of the patients. Hypo- or acontractile detrusor activity can also occur. Spinal cord 
injury can be divided in complete or incomplete lesions and in suprasacral and sacral cord lesions. 
Sacral spinal cord begins at spinal column level T12 to L1. The spinal cord terminates in the cauda 
equina at approximately the spinal column level of L2. After a spinal shock phase, with a ﬂ accid 
bladder and competent bladder neck, complete suprasacral spinal cord lesions will result in detrusor 
overactivity with internal sphincter synergia and external sphincter dyssynergia. This is mediated by 
spinal micturition reﬂ ex that emerges in response to a reorganisation of synaptic connections in the 
spinal cord. Capsaicin-sensitive C ﬁ bres, normally silent, mediate spinal reﬂ exes. These C ﬁ bres are 
also thought to play a role in upper motoneuron disease such as Parkinson’s disease and multiple 
sclerosis. Plasticity in dorsal root ganglia cell of the bladder manifests in enlargements of these cells 
and increased excitability. Also NGF is involved in hypertrophy of these cells. 
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DISEASES DISTAL TO THE SPINAL CORD
Spinal stenosis, radical pelvic surgery, herpes zoster, diabetes mellitus and Guillain-Barré are 
examples of disorders distal to the spinal cord that can cause overactive bladders. Occasionally 
patients with disc prolaps may have overactive bladder complaints due to irritation of the nerve roots. 
Generally these patients will present with difﬁ cult voiding. In spinal stenosis symptoms may range 
from cervical spinal cord compression to cauda equina syndrome. Herpes Zoster may lead to detrusor 
hyperreﬂ exia probably due to nerve root irritation. However urinary retention during the ﬁ rst days 
or weeks is the result of viral invasion of the sacral dorsal root and posterior nerve roots. Diabetes 
mellitus is the most common cause of peripheral neuropathy in Europe and North America. The classic 
example of voiding dysfunction due to diabetes is that of a neuropathy affecting complete emptying 
of the bladder. However detrusor overactivity may also be seen. The cause for neuropathic changes 
must then be sought outside the bladder.
3.1.2 NON-NEUROLOGICAL CAUSES 
Aging, inﬂ ammation, bladder outlet obstruction or irritation of the bladder wall or idiopathic detrusor 
overactivity can induce overactive bladder complaints. Bladder outlet obstruction often produces 
detrusor hypertrophy and detrusor overactivity ( DO). Obstruction induced DO has been attributed to a 
denervation supersensitivity. Bladder outlet obstruction stimulates an increased expression of certain 
genes (e.g. GAP-43) which has been associated with axonal sprouting. It suggests enhancement or 
de novo development of new spinal circuits following bladder obstruction. Bladder outlet obstruction 
appears to initiate the morphological and electrophysiological afferent plasticity via a mechanism 
involving Nerve Growth Factor NGF. NGF is responsible for the growth and maintenance of sympathetic 
and sensory neurons and has been shown responsible for neuronal regrowth after injury. NGF content 
is increased in obstructed bladders and can result in neuron enlargement and development of urinary 
frequency. Relief of obstruction might reverse the neuroplasticity to normal voiding. Also inﬂ ammation 
is accompanied by neuroplasticity in sensory nerves. 
Reduced threshold for bladder afferents occurs. Increased expression of the early-mediated gene c-
fos, has been detected in lumbosacral cord and increased expression of nitric oxide synthase occurs 
in bladder afferent neurons [Birder et al., 1998; Vizzard 1996]. The neuroplasticity and involvement of 
NGF in inﬂ ammation conditions resemble to that of bladder obstruction.
The lower urinary tract changes with age even in the absence of disease. Bladder contractility, capacity 
and ability to postpone voiding decline in both sexes. In women, urethral length and maximum 
closure pressure deteriorate, whereas in half of the men prostate enlargement causes urodynamic 
obstruction. Prevalence of detrusor overactivity increases and postvoid residuals increase. The 
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mnemonic “DIAPERS” or Delirium, Infection, Atrophic urethritis/ vaginitis, Pharmaceuticals, Excess 
urine output, Restricted mobility and Stool impaction commonly contributes to geriatric incontinence. 
Nearly 60% of the incontinent institutionalized persons revealed to have OAB. The distinction between 
detrusor overactivity and central nerve lesions such as past stroke or Alzheimer’s disease is at high 
age often unclear. Elbadawi et al. found abundant protrusion junctions and abutments on detailed 
ultra structure smooth muscle studies. These changes are thought to be involved in the increased 
electrical coupling and generating overactivity [Elbadawi et al., 1993]. Some studies found an 
increased response to α-adrenergic excitatory response and decreased β-adrenergic inhibitory 
response resulting in a net contracting effect of noradrenaline in the aged bladder in contrast to the 
relaxing effect of noradrenaline in young bladders. This ﬁ nally might reduce the functional capacity and 
result in urinary frequency and urgency in the elderly patients [Wein, 1998]. Wolfe et al. suggest that 
depression, anxiety, feeding disturbances, pain, irritable bowel syndrome, ﬁ bromyalgia and changes 
in voiding are associated with disturbances of serotonin or 5-hydroxytryptamine (5-HT) [Wolfe et 
al., 1997]. The strongest evidence for this theory is the remarkable effect of selective serotonin re-
uptake inhibitors (SSRI-s) in this group of patients. Pharmacological data suggest that 5-HT inhibits 
micturition reﬂ ex pathways. Thus reduced 5-HT transmission may lead to enhanced bladder activity 
and lowered volume threshold for voiding [Zorn et al., 1999]. Reviews suggest that women are more 
prone to urge incontinence and depression than men, and that both conditions are more common at 
times of hormonal changes [Morrison J, 2002]. Levels of 5-HT are substantially lower (nearly 50%) in 
female brains. In rats, administration of estradiol increases the density of 5-HT receptors in the brain. 
Furthermore estradiol modiﬁ es cognition, emotions, pain and autonomic function by acting on 5-HT 
neural pathways. Data support the linkage of reduced activity of 5-HT and hormonal inﬂ uences, and 
depression and overactive bladder. 
Idiopathic detrusor overactivity can be diagnosed when all other possible causes are excluded. 
Idiopathic detrusor overactivity seems to respond better to anticholinergics than the neurological 
forms suggesting increased local release of acetylcholine (Koelbl H et al., 2002)
3.1.3 PATHOPHYSIOLOGY OF OAB  
Disturbances of peripheral nerves and tissue can cause bladder overactivity. A new appreciation is 
that long-term events involves growth factors, such as NGF, neurotransmitters and prostaglandins, 
that provide communication between muscle and nerve. NGF can induce regrowth and sprouting of 
affected neurons and hereby affect micturition. Common features of human and animal overactive 
bladders showed increased spontaneous myogenic activity, fused tetanic contractions, altered 
responsiveness to stimuli, characteristic changes in smooth muscle ultrastructure (e.g. protrusion 
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junctions and ultra-close abutments between smooth muscle cells, which is rarely seen in normal 
tissue) [Elbadawi et al., 1993].
Detrusor smooth muscle bundles are not well coupled as in most visceral smooth muscles. This poor 
coupling prevents that under normal conditions, spontaneous activation of a bundle resulting in a 
synchronous activation of bladder wall smooth muscles. Denser innervation allows more synchronous 
activation and thus detrusor activity. This theory correlates with the ultrastructural ﬁ ndings of close 
abutments and protrusion junctions in muscle strips of overactive bladders. Increased excitability 
combined with greater connectivity could result in generation of a focus of electrical activity that can 
rapidly spread and produce an involuntary contraction [Mills et al., 1999].
 Section of bladder wall from overactive human bladder frequently showed patchy denervation of 
muscle bundles [German et al., 1999]. The denervated areas become inﬁ ltrated with connective 
tissue elements such as collagen and elastin, also hypertrophy of smooth muscle is seen. Animal 
experiments showed that spinal section or urethral obstruction resulted in increase of size of both 
afferent roots of the dorsal root ganglia as the efferent neurons from the pelvic plexus [Steers et al., 
1990]. After spinal injury electrophysiological measurements showed a shorter delay in micturition 
reﬂ ex. The hypothesis is that neuronal reorganisation remodulates the spinobulbospinal pathway into 
a purely spino-spinal pathway. In these overactive bladders, ice water test can trigger the activation 
of -normally silent- C ﬁ bres. Intravesical instillation of capsaicin or resiniferatoxin is then an effective 
treatment for many overactive bladders [Geirsson et al., 1993; Geirsson et al., 1997].
The patchy denervation suggests the death of some intrinsic neurons most likely due to ischemia. 
Experiments showed that a rise in intravesical pressure higher than 40 cm water can seriously 
compromise the bladder wall blood supply [Brading et al., 1999; Greenland et al., 1996]. Increased 
metabolic demand is seen in hypertrophic wall due to outﬂ ow obstruction or detrusor sphincter 
dyssynergia. Increased workload of the bladder increase the release of NGF. This may induce sprouting 
and new abnormal connection of axon terminals between interneurons or motoneurons with for 
instance the silent C ﬁ bres [Steers et al., 1996]. 
Coolsaet et al. suggest that urgency is triggered by local distortions in the bladder wall [Coolsaet et al., 
1993]. This would activate a population of nerve ﬁ bres that might speciﬁ cally mediate the sensation of 
urgency. In overactive bladders this activity might spread because of increased electrical connectivity 
and result in premature sensation of urgency and involuntary rise of pressure. This theory supports 
the working of anticholinergics suppressing the urgency feeling and overactivity caused by the 
overactive sensory nerves, but still allow normal micturition. 
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3.1.4 TREATMENT
 
First behavioral therapy educates the patient, informs him or she about lifestyle changes and 
retrains the bladder by time-voiding or pelvic ﬂ oor physiotherapy. This requires motivated patients. 
Furthermore, treatment is directed toward inhibiting bladder contractility (by means of anticholinergics 
or injection of botulinum toxin), decreasing sensory input (for example by instillation with capsaicin), 
mechanically increasing bladder capacity (Helmstein procedure), or increasing outlet resistance 
(bulk injection or suspension of the urethra), either continuously or just during increasing intra-
abdominal pressure. Electrical stimulation has been used to treat disorders of both bladder storage 
and emptying. If conservative methods fail surgical option include denervation procedure (e.g. sacral 
rhizotomy) to augmentation cystoplasty [Wein et al., 1998].
3.2 URINARY RETENTION
Absolute or relative failure to empty the bladder results from decreased bladder contractility with a 
decrease in magnitude or duration, increased outlet resistance or both. Decreased detrusor activity 
may result from temporary or permanent alteration in neuromuscular mechanism that initiates or 
maintains detrusor contraction. 
3.2.1 NEUROLOGICAL CAUSES:  
DISEASES AT OR ABOVE THE BRAIN STEM
Acute urinary retention can occur after CVA; but has also been described in brain tumours in the frontal 
cortex or posterior fossa. In Parkinson’s disease also impaired detrusor contractility can occur.
DISEASES PRIMARILY INVOLVING THE SPINAL CORD
 In the spinal shock phase after spinal cord injury, retention is the rule. A complete sacral spinal cord 
lesion or a lesion of the sacral roots, result in skeletal ﬂ accidity below that level. This results in detrusor 
acontractility and attempted voiding that is insufﬁ cient to decrease residual urine to less than 10% of 
bladder capacity. For patients with MS obstructive symptoms with urinary retention occur in 2% to 
52%. Also here the form of acute retention may be the sole initial complaint of MS. 
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DISEASES DISTAL TO THE SPINAL CORD
Disc prolaps can compress the spinal roots in L4-L5 and L5-S1 vertebral interspaces. If voiding 
dysfunction is present, the most urodynamic ﬁ nding is that of a normal compliant acontractile 
bladder associated with normal innervations or incomplete denervation of the perineal ﬂ oor 
musculature. Laminectomy may not always reverse the bladder function. Radical pelvic surgery 
like abdominoperineal resection and radical hysterectomy can cause pelvic plexus injury and lead 
to voiding dysfunction. It has been estimated that in 15 to 20% of affected individuals, the voiding 
dysfunction is permanent. The injury may be a consequence to denervation, tethering, or encasement 
of the nerves in the scar, direct bladder or urethral trauma, or bladder devascularisation. Adjuvant 
chemotherapy or radiation may play a role as well. Generally there will be a failure of adequate bladder 
contraction. Diabetes mellitus is the most common cause of peripheral neuropathy in Europe and 
North America. The classic example of voiding dysfunction due to diabetes is that of a neuropathy 
affecting the sensory afferent pathways causing an insidious onset of impaired bladder sensation. The 
danger of increased overdistension and decompensation eventually occur. Urodynamically impaired 
sensation, increased capacity, decreased contractility, impaired ﬂ owmetry and increased residual 
volumes characterize the diabetic cystopathy [Wein et al., 1998]. Herpes Zoster may produce urinary 
retention after viral invasion of dorsal sacral roots and posterior nerve roots. But also the painful 
mucosal eruptions can play a role in inhibition of the micturition.
3.2.2 NON-NEUROLOGICAL CAUSES
BLADDER OUTLET OBSTRUCTION AND RETENTION
Increased outlet resistance is generally seen in men and most often secondary to prostate 
hyperplasia, but it may be due to a failure of coordination of the striated or smooth sphincter, to a 
urethral stricture or bladder neck dysfunction. Striated sphincter dyssynergia is a common cause 
of functional obstruction in patients with neurological disease or injury [Wein et al., 1998]. Urinary 
retention is fairly common in adult men, but in women it occurs less. Potential causes are neurological, 
pharmacological, anatomic, myopathic, functional or psychogenic. Bladder outlet obstruction in 
women is seen because of urethral stricture, dysfunctional voiding, true sphincter dyssynergia, 
urethra diverticulum, primary bladder neck obstruction, or after anti-incontinence surgery. The Fowler 
syndrome refers to a particular syndrome of urinary retention in young women in the absence of 
any overt neurological disease (Fowler, 1999). On concentric needle electrodes examination of the 
striated muscles of the urethral sphincter, Fowler described a unique EMG abnormality with complex 
repetitive discharges and decelerating bursts. These patients often have polycystic ovaries, raising 
the possibility to a hormonal abnormality.
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POSTOPERATIVE URINARY RETENTION
Postoperative urinary retention is a well recognized but poorly understood event. Its incidence 
quoted overall as 4 to 25 %. Contributing factors are traumatic catheterisation, bladder overdistension, 
diminished awareness of bladders sensation, decreased bladder contractility, increased outlet 
resistance, decreased micturition reﬂ ex activity, nociceptive inhibitory reﬂ ex and pre-existent outlet 
pathology. The incidence of voiding dysfunction after radical pelvic surgery is estimated to be 20% to 
68% and in 15-20% of affected individuals the dysfunction is permanent.
INHIBITION OF VOIDING REFLEX AND NON-NEUROGENIC IMPAIRMENT
This can occur secondary to painful stimuli, especially if it arise from the pelvic or perineal areas ( e.g. 
seen with herpes infection) or such an inhibition can be psychogenic. Non-neurogenic impairment of 
bladder function can be the result of overdistension, severe infection or ﬁ brosis [Wein et al., 1998].
 
3.2.2 PATHOPHYSIOLOGY OF URINARY RETENTION
Bladder outlet obstruction has been postulated to be associated with partial denervation, owing to 
damage of the intrinsic innervation of the bladder smooth muscle from a combination of pressure and 
ischemia [Turner et al., 1997]. A breakdown of the structure and function of the proteins that enable the 
smooth muscle cells to take up, store, and release calcium, would affect the calcium activation of the 
contractile mechanism [Zderic et al., 1998]. Voiding dysfunction secondary to diabetes is a peripheral 
and autonomic neuropathy that ﬁ rst affects sensory afferent pathways, causing the insidious onset 
of impaired bladder sensation. This results in a gradual increase in time interval between voiding, 
without sensing any real urgency. If this continues, detrusor distension, overdistension, and 
decompensation ﬁ nally occur. Hyperglycemia is proposed to lead to microvascular and neurologic 
complications, the neurologic sequelae ultimately resulting in a loss of myelinated and unmyelinated 
ﬁ bers, Wallerian degeneration, and blunted nerve ﬁ ber reproduction and function [Clarck et al., 1995]. 
The proposed mechanisms include increased accumulation of polyols (sorbitol) inhibiting synthesis 
of myoinositol. This in turn depresses phosphoinositide metabolism and decreases Na+-K+-ATPase 
activity. Hyperglycemia also leads to the formation of advanced glycosylation end products of glucose. 
One also suggests that diabetes diminishes sodium pump activity, thereby inhibiting agonist-induced 
contractions in bladder smooth muscle by an increase in intracellular sodium concentration, the 
latter acting to diminish calcium inﬂ ux. In elderly detrusor underactivity is usually idiopathic. In the 
absence of obstruction or neuropathy, it is characterized at cellular level by widespread degenerative 
changes of both muscle cells and axons [Elbadawi et al., 1993]. When it causes incontinence, 
detrusor underactivity is associated with “overﬂ ow incontinence” (<10% of geriatric incontinence). A 
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mild degree of bladder weakness occurs quite commonly in older individuals. Reduced energy supply 
(ATP) results in a decrease in tonic response of the urethra and pressure, contributing to urine loss in 
women. In men fatigued aged bladder generates a less strong and less sustained contraction resulting 
in a decreased ﬂ ow rate and increased residual volume even in the absence of any obstruction. 
Animal experiments support the theory that aging is associated with progressive reduction in the 
ability of generating energy by oxidative phosphorylation, and reduce the capacity to sustain bladder 
contraction. Gilpin et al. found that the amount of nerve per square mm detrusor muscle decreased 
with age in both women and men, just as it happens for skeletal muscles [Gilpin et al., 1986]. With 
aging a decrease in bladder sensation is found, which is strongest in the eight and ninth decade.
3.2.3 TREATMENT 
Treatment of emptying failure generally consists of attempts to increase intravesical pressure or 
facilitate the micturition reﬂ ex (for example by neuromodulation), to decrease outlet resistance 
(transurethral desobstructive resection of hyperplasic prostate tissue or coordinated physiotherapy) 
or both. If all else fails or the attempt is impractical, catheterisation is an effective way of circumventing 
emptying failure [Wein et al., 1998].
 
3.3 DEFINITIONS
During the past years, terminology describing lower urinary tract dysfunction has been changed. An 
effort in this thesis was made to conform to the ICS recommendations. This paragraph summarizes 
relevant terminology frequently used in the thesis [Abrams et al., 2002]. 
Increased daytime frequency: the patient considers that he or she voids too often.
Nocturia: the patient has to wake at night one or more times to void.
Urgency: the complaint of a sudden compelling desire to pass urine, which is difﬁ cult to defer.
Urinary incontinence (UI): the complaint of any involuntary leakage of urine.
Stress UI: the complaint of involuntary leakage of urine on effort or exertion, or on sneezing or 
coughing.
Urge UI: the complaint of involuntary leakage accompanied by or immediately preceeded by 
urgency.
•
•
•
•
•
•
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Mixed UI: the complaint of involuntary leakage associated with urgency and also on exertion, 
effort, sneezing or coughing.
The report suggests that UI should be described by specifying relevant factors such as type, frequency, 
severity, precipitating factors, social impact, effect on hygiene and quality of life, the measure used 
to contain the leakage, and whether or not the patient seeks or desires help because of UI. This 
information illustrates the impact of LUTD on patients’ life. In our studies urodynamic investigation, 
bladder diaries and quality of life questionnaires correspond well to the ICS recommendations.
Overactive bladder syndrome – urge syndrome –urgency/frequency syndrome: this syndrome is 
deﬁ ned as the complaints of urgency, with or without urge incontinence, usually with frequency 
and nocturia.
These terms are usually suggestive for urodynamically demonstrable detrusor overactivity, but can 
be due to other forms of urethro-vesical dysfunction.
Bladder diary: the diary lists voiding time, volumes, incontinence episodes, pad usage and other 
information such as ﬂ uid intake, degree of urgency and degree of incontinence.
Detrusor overactivity: an urodynamic observation characterised by involuntary detrusor 
contractions during the ﬁ lling phase which may be spontaneous or provoked.
In the latest report there is no longer a limit deﬁ ned for the amplitude of an involuntary detrusor 
contraction. In the PTNS urodynamic data detrusor overactivity was deﬁ ned as an increase of 
15 cm water pressure (the deﬁ nition conforms to the deﬁ nition in 1998) or of lower amplitude if 
accompanied with a distinct sensation of urgency.
Detrusor overactivity incontinence: this is UI due to involuntary detrusor overactivity.
Detrusor underactivity is the contraction of reduced strength and/ or duration, resulting in prolonged 
emptying and/ or failure to achieve complete bladder emptying within normal time span.
Acontractile detrusor is one that cannot contract. 
Post void residual (PVR) is the volume left in the bladder at the end of micturition. In the PTNS 
urodynamica data PVR was measured to recalculate the cystometric capacity. Our observation that 
natural ﬁ lling had an impact on the cystometric capacity was presented on the ICS congress in 
2001 and later published [Heesakkers et al., 2003].
•
•
•
•
•
•
•
•
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OBJECTIVE 
To determine the prevalence of female urinary incontinence (UI) and its impact on quality of life.
SUBJECTS AND METHODS
In a Dutch national postal questionnaire survey, 1460 spouses of 1771 men in the town of Boxmeer, 
age-stratiﬁ ed and randomly selected, were asked to participate. The prevalence of UI in the women 
was assessed in two ways. First, a total score on a short UI-speciﬁ c questionnaire differentiated 
them into three groups, i.e. no symptoms (score 0-2), minimally (3-6) or severely incontinent (7-14). 
Second, a self-reported UI prevalence was calculated by asking respondents if they ever had urine 
loss. To conform to the International Continence Society (ICS) standard deﬁ nition, spouses were also 
asked to complete a general (Short Form -12) and a lower urinary tract disease-speciﬁ c  quality of life 
questionnaire, and were asked about their need to seek help.
RESULTS
The questionnaires were returned by 1071 women (mean age 57 years, range 29-79; response rate 
73%); 34% were regarded as minimally and 12 % as severely incontinent. The self-reported UI rate was 
41%. Disease-speciﬁ c and general quality of life was signiﬁ cantly lower for women with UI than for 
those with minimal or no urine loss; 38% of incontinent respondents had consulted a physician for 
their UI, and among respondents with minimal complaints this was 28%.
CONCLUSIONS
Up to 46% of the married female population had some degree of UI, and severe UI signiﬁ cantly 
compromised their quality of life
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4.1 INTRODUCTION 
Despite urinary incontinence (UI) being more openly discussed during recent years, the real prevalence 
of this distressing and disabling condition remains unclear. It is estimated that worldwide about 200 
million people have urinary incontinence [Abrams, 1999]. For the Netherlands, ofﬁ cial governmental 
bodies estimate the overall prevalence of urinary incontinence to be approximately 800 000 men 
and women using a so-called “broad” deﬁ nition [Piepenbrink JF, 2000]. For a population of 16 million, 
this prevalence percentage is 5% and in sharp contrast with recent Dutch population-based studies, 
reporting UI rates of 23-57 % [van Geelen JM et al., 2000; van der Vaart CH et al., 2000; Rekers H et 
al., 1992; Kok et al., 1992].  This may be explained by the use of different deﬁ nitions for UI. Dutch 
governmental bodies used the following deﬁ nition: “Two or more episodes of involuntary urine loss per 
month, regardless of the amount of leakage”. In a recent Dutch population-based study, Van der Vaart 
et al. used a positive response to one of the following questions as deﬁ nition of incontinence: “Have 
you ever experienced involuntary urine loss during coughing, sneezing or physical exertion?” and 
“Have you ever experienced involuntary urine loss on occasions of strong urge to micturate?” Possibly, 
many women afﬁ rmed these latter questions on remembering accidental episodes of urine loss from 
the past, resulting in a high prevalence percentage of 57%. Also in international publications extensive 
variation in prevalence of UI is well recognized and depends on which deﬁ nition of severity is used 
or in which context the questions were asked [Hunskaar S et al.,1998; Hampel C et al., 1997; Temml 
C et al., 2000; Hannestad YS et al., 2000; Moller LA et al., 2002; Fultz NH et al., 2000]. Nevertheless 
the prevalence of severe or signiﬁ cant UI has a narrower range than any form of incontinence (10-40 
% versus 3-17 %) [Hunskaar S et al., 2002]. The ICS deﬁ nes UI as: “the complaint of any involuntary 
leakage of urine”[Abrams P et al., 2002]. The report states that UI should be further described by 
specifying relevant factors such as type (stress, urge and mixed UI, nocturnal enuresis, continuous 
enuresis and other types), frequency, severity, precipitating factors, social impact, effect on hygiene 
and quality of life (QoL), the measures used to contain the leakage and whether or not the individual 
seeks or desires help because of UI. The new ICS report aims to facilitate comparison of results and 
enable effective communication between investigators, but no proposals or guidelines have been 
offered about how to classify UI by frequency or severity, how to calculate the impact on social life or 
how to measure the leakages and classify the results. The guideline does not indicate the period of 
assessment and therefore does not distinguish actual and historical UI. This incomplete guideline still 
hinders good comparison of epidemiological studies.
In 1998 the Urepik-study was instituted in four countries to evaluate Lower Urinary Tract Symptoms 
(LUTS) and the impact on QoL of men and their partners; the present report presents the outcome of 
this study in 1071 Dutch community-dwelling married women. Urinary loss is still underestimated 
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by Dutch governmental institutes and Dutch publications give widely varying estimates depending 
on which deﬁ nition of severity was used. Therefore, different scoring (i.e. no UI, mild and severely UI 
versus self-reported UI) was used within the same dataset to show the effect on prevalence. Second, 
an additional questionnaire inventoried the spouses’ disease-speciﬁ c and general QoL and their need 
to seek help within a period of 1 month. An effort was made to describe UI in most of its facets to 
conform to the ICS standard deﬁ nition and thus allow future comparison in epidemiological studies.
4.2 PATIENTS AND METHODS
 
A postal survey was carried out in the town of Boxmeer (The Netherlands) in 1999. Questions 
addressed the prevalence and the impact on QoL of LUTS related to benign prostatic enlargement, 
erectile dysfunction and UI among males aged 40 to 80 years. This survey was part of an international 
project (the Urepik-study: Urological Epidemiology in Europe and Korea) co-coordinated by the 
European Institute of Oncology in Milan (Italy). Study centres from The Netherlands (Nijmegen), 
The United Kingdom (Birmingham), France (Auxerre) and South-Korea (Seoul) participated in this 
project [Boyle P et al., 1998]. Boxmeer, a small town in the South of the Netherlands, of 20, 000 
inhabitants of which 4 067 men aged 40-80 years (Centraal Bureau voor Statistiek, kerncijfers 1997 
http://www.nbs.nl/nl/ cijfers/kerncijfers/ accessed 2001). Using data from the council administration 
an age-stratiﬁ ed sample was drawn of 1 771 males with an increasing chance of being selected 
with increasing age. Their spouses (1460) were also asked to participate and to complete generic 
and lower urinary tract disease-speciﬁ c questionnaires. The prevalence of UI was evaluated in two 
ways. First, a short questionnaire elicited the frequency and quantity of urinary leakage, the use of 
pads and the occurrence of stress UI during the past month (Table 1). This questionnaire was used 
previously in a Dutch incontinence survey [Milani AL et al., 1995]; it was discussed and evaluated 
and thought to be a valuable and informative questionnaire as (at that time) there was no consensus 
on which questionnaires should be used. The score range was 0 to 14, and groups were deﬁ ned as 
0-2 (no symptoms), 3-6 (mild symptoms) and 7-14 (severe symptoms). Second, a subjective self-
reported UI rate was obtained asking respondents directly if they ever experience urinary leakage as 
the following question “Urinary incontinence means no complete control over your bladder that can 
lead to involuntary urine loss. Do you ever have involuntary urine loss?” Only a positive or negative 
answer was possible. This latter deﬁ nition equates well to the new ICS deﬁ nition: “ the complaint of 
any involuntary leakage of urine”.
Two internationally accepted and validated questionnaires were used to measure respondents’ QoL: 
the benign prostatic hyperplasia (BPH) Impact Index (BII) [Barry MJ et al., 1995] and the Short-Form 
(SF) 12 questionnaire. Although the BII was constructed for assessing LUTS in men, we considered 
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the separate questions also valid to measure disease-speciﬁ c QoL for women with UI. General QoL 
was assessed with the SF-12 questionnaire, calculating a physical component score (PCS) and mental 
component score (MCS).  High values represent a better QoL. The outcomes can be compared with 
standardized population-based scores with a mean of 50 and a SD of 10 [Gandek et al., 1998]. 
All data were calculated using sampling weights based upon the ratio of the number of women in 
each age group in the samples to the number of women in the age group in the population. This was 
necessary because a stratiﬁ ed random sample of male respondents was used and the number of their 
spouses selected in each age group was not proportional to the number of women in the population. 
For the analysis, percentages and mean values were used. Differences in means were tested using 
analysis of variance and t-tests. For all statistical analyses SAS vs. 6.12 computer software was used 
(SAS Institute Inc., Cary, NC, USA).
Table 4.1: Incontinence speciﬁ c questions modiﬁ ed by Vierhout et al., and age weighted prevalence (%) (100% minus 
missing values).
%
A. During the past month: How often have you leaked urine?
0    Never 54.5
1    Not more than once a week 19.6
2    More than one but less than three times a week 10.0
3    More than 3 times a week 6.0
4    Nearly always 8.6
B. During the past month: If you experienced urine loss, how much did you leak?
0    I never leak 50.2
1    Some drops 32.2
2    A small stream 11.4
3    Protection material or clothes soaking wet 4.9
4    Leaking through pads or clothes 0.3
C. During the past month: how often did you use protection material
0    Never 68.1
1    Occasionally 21.4
2    Nearly always 3.9
3    Always 5.8
D. During the past month: Did you lose urine on coughing or sneezing?
0    Never 31.1
1    Occasionally 45.0
2    Nearly always 13.5
3    Always 9.3
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4.3 RESULTS
 
In all, 1 071 questionnaires were completed and further evaluated (response rate 73 %); roughly 1 % of 
respondents returned an incomplete questionnaire. The mean (range) age of respondents was 56.9 
(29-79) years, the mean parity 2.6 and 145 (13.5%) women were childless. The answers to the four 
incontinence questions are listed in Table 1. Scoring of the four questions categorized 12% (95% CI 10-
14%) of the respondents as severely UI (score 7-14) and 34% (95% CI 31-37%) as minimally UI (score 
3-6). About 68% of the participants had symptomatic stress UI. To the direct question: “Have you ever 
lost urine?” nearly 40% (95% CI 37-43%) afﬁ rmed this; more than a quarter of these self-perceived 
incontinent women lost drops of urine only incidentally. 
There was no relationship between the mean parity or age and the presence of UI; only in the oldest 
category (70-79 years) were there signiﬁ cantly more complaints of UI (Figure 1). Of respondents with UI, 
38% had consulted a physician for their UI; among respondents with minimal complaints this was 28%.
There was a clear relationship between involuntary urine loss and disease-speciﬁ c QoL (BII); more 
severe UI was signiﬁ cantly associated with a higher BII score on each question (chi-square, p < 
0.01; Table 2). Respondents with UI had more physical discomfort, were more worried about their 
health, more troubled and more frequently hindered in their social activities because of their urinary 
complaints. However, respondents who provided the most negative responses were few. This survey 
showed that 5% were troubled by their UI and that 3% felt restricted in their daily activities because of 
their leakages. There was no correlation between disease-speciﬁ c QoL and age. There was
a signiﬁ cant relation between UI and overall QoL (Table 3). For women with UI and for those self-
reporting UI, the PCS and MCS on the SF-12 were lower (p< 0.01).  
Table 4.2:  Prevalence of urinary incontinence (UI) by age in 1071 women (mean age 56.9, range: 29-79 years) according 
to different classiﬁ cations (total score and self-reported prevalence conform to the standard ICS deﬁ nition). 
Age
UI deﬁ nition All ≤
44y
45-
49y
50-
54y
55-
59y
60-
64y
65-
69y
70-
74y
75-
79y
N=1071 % 138 140 163 169 179 149 102 31
UI Score
Score 0-2 54 59 45 50 55 58 62 56 31
Score 3-6 34 34 41 38 34 32 24 29 31
Score 7-14 12 7 14 12 11 10 14 15 38
Score >3  46 41 55 40 45 42 38 44 69
Self-reported
“no”     60 60 49 55 63 70 67 69 45
“yes” 40 40 51 45 37 30 33 31 50
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4.4 DISCUSSION 
 
Constructing a clear view of the prevalence of UI is not straightforward: the different approaches 
investigating the prevalence of incontinence in these 1071 women resulted in a wide variation in 
prevalence, from 12% (severe UI) and 40% self-reporting any leakage, to 46% (minimal and severe UI 
together). The criterion used by Dutch government bodies appears to underestimate the incontinent 
population. However, this study shows a much lower percentage than was found in the study by van 
der Vaart et al. [van der Vaart et al., 2000] (57% of women aged 45- 70 years). It therefore seems 
to be worthwhile to differentiate UI in different categories, a statement supported by the fact that 
a quarter of those who self-reported incontinence were only leaking some drops of urine less than 
once weekly, which may exclude them from the deﬁ nition of minimal UI.  Sandvik et al. [Sandvik H et 
al., 1993; Sandvik et al 2000] introduced such a UI severity index, using two questions and a simple 
scoring system. Recently, the index was compared to a 48h pad test and validated by a Scottish study 
[Hanley J et al., 2000] and used in the large Norwegian EPINCONT study [Hannestad YS et al., 2000]. 
Unfortunately, the UrEpiK study did not use the incontinence severity index but the questions used 
Figure 4.1:  Age speciﬁ c prevalence of incontinence according to UI score 
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       Incontinence category
Score 0-2 3-6 7-14
Number N=1064 N=578 N=355 N=131
1. Over the past month, how much physical discomfort did any urinary 
problem cause you?
0. None
1. Only a little
2. Some
3. A lot
94
5
1
62
32
6
27
37
30
6
2. Over the past month, how much did you worry about your health because 
of any urinary problem?
0. None
1. Only a little
2. Some
3. A lot
97
2
1
82
15
3
56
27
15
2
3. Overall, how bothersome has any trouble with urination been during the 
past month?
0. Not at all bothersome
1. Bothers me a little
2. Bothers me some
3. Bothers me a lot
95
3
1
1
65
29
5
1
26
36
29
9
4. Over the past month, how much of the time has any urinary problem kept 
you from doing the kinds of things you would usually do?
0. Not at all bothersome
1. Bothers me a little
2. Bothers me some
3. Bothers me a lot
99
1
93
6
1
66
22
8
2
2
Table 4.3:  The BPH Impact Index (BII) consisting of 4 questions, measures disease speciﬁ c quality of life on a scale of 
0-13; high score represent a lower quality of life. Percentage of responses to BII items. 
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were similar, dividing severity into ﬁ ve rather than four levels and quantity into ﬁ verather than two 
levels. Moreover, it seemed useful to ask if protection was used, as an indicator of the severity of 
UI, and if there was a stress factor involved. Again, every effort that can result in an internationally 
accepted questionnaire should be encouraged.
In the present study there was a remarkable difference between the symptom- and perception- based 
UI rates (46% versus 40%). The most likely explanation for this was the context in which the survey 
questions were presented. Fewer women saw themselves as incontinent when they had to complete 
the confronting question “Do you ever have involuntary urine loss”, probably viewing it as a natural 
phenomenon or even denying it. However the four questions (scoring for severity, quantity, protection 
and stress component) detected more spouses that had experienced urinary loss, representing “any 
form of urinary loss”. Second, the difference could be explained by the different time restrictions used 
within the questions. Information was speciﬁ cally asked about the situation in the past month for 
the four UI-speciﬁ c questions. For the direct question there was no period indicated. Many women 
may have had transient UI in the past without considering themselves as incontinent at present. A 
spontaneous remission rate of 12 % was reported previously [Hunskaar S et al., 1998]. There was no 
apparent age-related prevalence of urine loss for women aged <70 years, although a small peak in 
prevalence at the perimenopausal age; this tendency was also reported previously [Hunskaar S et 
al., 1998]. 
Disease-speciﬁ c QoL was lower among respondents having urinary leakage, but few respondents 
reported the most negative responses. This survey showed that 5% were troubled by their incontinence 
and that 3% were feeling restricted in their daily activities because of their leakages. Also van der Vaart 
et al. and Lagro-Janssen et al. [Lagro-Janssen Al et al., 1990] found that patients with UI were only a 
little bothered by their urine loss.
Women with UI scored signiﬁ cantly worse than those without on the mental and physical aspects of 
the QoL inventory. The negative impact of incontinence on vitality, social functioning, role-emotional 
and mental health (the MCS of the SF-12) is not surprising, but the important consequences for 
physical health are not so evident. Perhaps, this ﬁ nding reﬂ ects the fact that women with UI restrict 
their everyday activities to avoid the occurrence and consequences of involuntary urine loss, and 
experience this as physical impairment. On the other hand, some co-morbidities (e.g. musculo-
skeletal disorders or neurovascular diseases) can result in impaired mobility and consequently in 
functional UI.
That only 38% of respondents with UI sought medical advice for their UI suggests, on the one hand, 
that urine loss is still a condition that these women do not want to talk about, and on the other hand 
that some respondents may see urine loss as a part of the ageing process. 
Last, UI has important socio-economic implications; in the USA the direct healthcare costs relating 
to UI were more than $10 billion in 1987 [Hu T, 1990]. For the Netherlands it was estimated that in 
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Table 4.4:  General quality of life was assessed using the SF-12 questionnaire calculating a physical component score 
(PCS) and mental component score (MCS).  High values present better quality of life.  
UI deﬁ nition SF-12                                SF-12
N=1071 % MCS ANOVA PCS ANOVA
UI Score
Score 0-2 54 52.4 49.9
Score 3-6 34 50.8 49.3
Score 7-14 12 49.5 p=0.0004 43.6 p=0.0001
Self-reported 
“no”     60 52.1 49.5
“yes” 40 50.5 p=0.004 48.1 p=0.02
1999, 136 million Euros were spent on incontinence materials and aids. Other invisible expenses for 
absenteeism, extra protection materials, textile and laundry were not considered. If national expenses 
on UI products and aids were based on the present prevalence rates, estimated expenditures may 
increase substantially. For macro-economic planning it is therefore evident that exact prevalence 
ﬁ gures become available. More clarity about the real prevalence is needed because UI has a large effect 
on the individuals’ well-being, and may greatly inﬂ uence strategic and macro-economic planning.
 
4.5 CONCLUSION
 
In conclusion, up to 46 % of the married women in Boxmeer had some degree of UI; the prevalence of UI 
assessed by a population-based, postal survey depends heavily on the deﬁ nitions used (prevalence 
of 12-46%). Using a deﬁ nition that considered relevant UI of the recent past, within a speciﬁ ed 
period, is warranted for epidemiological purposes. A consensus within the ICS on guidelines that 
classify severity of UI using a standard questionnaire and measures would make the results from 
epidemiological studies more consistent. 
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Using electrical eels, ancient Egyptians believed in the heeling capacity of 
electrical shocks. This chapter brieﬂ y reviews the evolution from Galvani to 
Posterior Tibial Nerve Stimulation, from Macaca apes to urological patients. It 
describes the PTNS procedure and the inclusion and exclusion criteria.
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5.1 HISTORICAL BACKGROUND
Bioelectrical phenomena have intrigued mankind for centuries. In 2750 BC detailed images of 
catﬁ sh possessing electrical organs were found on an Egyptian tomb. In the works of Socrates and 
Hippocrates the ”numbing” ability of these ﬁ sh was described, but the ﬁ rst medical application of 
electrical stimulation was described by Largus (46AD). Torpedo ﬁ sh, electric eels and rays were used 
to treat headache and gout by placing a living black torpedo on the spot which was in pain [Kellaway, 
1946; Schmidt and Tanagho, 1979; Sheon, 1984; Devinsky, 1993]. It took until the mid-eighteenth 
century to further explore bioelectrical processes. The development of the electrostatic generator and 
battery enabled physicians to further explore electrical therapy and its usage increased dramatically. 
In 1791 Galvani observed a muscle twitch when he accidentally electrostimulated a frog leg. Further 
experiments with electricity followed. In the mid-nineteenth century, Duchenne conducted extensive 
studies on the use of electricity in medicine during the century. Most physicians had electrotherapeutic 
machines in their ofﬁ ces and prescribed electrotherapeutic baths and belts for home use [Devinsky, 
1993]. In 1848 the induction coil stimulator, producing a train of stimuli that could tetanise skeletal 
muscles, was introduced. The bladder was one of the ﬁ rst organs to be activated through stimulation 
of the cervical cord by Budge [Schmidt and Tanagho, 1979]. It took the development of the transistor 
(1950) for the ﬁ rst heart pacemaker to be implanted in 1960 which proved that medical implanted 
devices could function properly [Mullet, 1987]. Soon the ﬁ rst implantable electrodes in the urological 
ﬁ eld followed. For decennia electrostimulation has been applied to achieve voiding, to induce 
contraction of the external sphincter, to inhibit or abort detrusor activity or to relieve pelvic pain.
In 1963 Caldwell developed a sphincter stimulator to treat stress incontinence. The ﬁ rst implanted 
electrodes on the bladder wall elicited detrusor contraction but this method was limited by erosion and 
ﬁ brosis and the painful supraphysiological current needed for adequate stimulation [Habib, 1965].  As 
the bladder can be stimulated directly but also indirectly via the nerves, other stimulation modalities 
were searched for. The S2-S4 roots are involved primarily in bladder control, with the S3 roots mainly 
innervating the detrusor and levator muscles [Hasan, 1996]. S3 nerve root contains sensory ﬁ bres 
from the pelvic ﬂ oor, parasympathetic motor efferents to the detrusor and motor ﬁ bres to the pelvic 
sphincters and the pelvic ﬂ oor muscles.
In 1969 Brindley developed an electrode for long-term stimulation of the spinal roots S2-S3, and in 
1972 the ﬁ rst patient received a Brindley Sacral Anterior Root Stimulator. Later the implantation was 
combined with de-afferentation or dorsal rhizotomie to overcome neurogenic detrusor overactivity 
resulting in an enlarged bladder capacity. Also here stimulation is at a painful supraphysiologic level 
and thus only available for paraplegic patients [Brindley, 1977; Brindley, 1993; Saurwein 1990].
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In 1878 Saxtorph used intravesical stimulation to treat urinary retention. In 1959 Katona et al. 
described a technique of intraluminal electrotherapy for various disorders of the gastrointestinal tract, 
and later for neurogenic bladder dysfunction [Katona, 1975]. Later in 1990 Madersbacher et al. reported 
good results for patients with neurogenic bladders treated by intravesical stimulation [Madersbacher, 
1990]. It is thought that the electrostimulation depolarises the bladder mechanoreceptors and 
increases the bladder awareness. This treatment involved a time-consuming schedule as repeated 
sessions several times per week were needed and as it was combined with intensive bladder training. 
Special equipment and trained personnel were required. 
Neurophysiology teaches us that afferent anorectal branches of the pelvic nerves and the dorsal 
clitoral and penile branches of the pudendal nerves can activate the inhibitory sympathetic neurons 
and inhibit via direct sacral route the bladder motoneurons. These reﬂ exes will not be suppressed 
during micturition and are capable of interrupting detrusor contraction. 
During the sixties, intra-anal and intra-vaginal probes were designed to exercise the pelvic ﬂ oor and 
to inhibit detrusor overactivity. Fall treated patients with therapy resistant urgency and incontinence. 
Treated for an adequate period of at least three months, they improved substantially: bladder capacity 
increased, continence was obtained and in some patients detrusor overactivities were abolished. 
However small bleedings, vaginal pain, discharge and local necrosis was seen due to technical 
failure. After revision of the devices no serious side effects were seen [Fall M, 1978; Fall 1984]. Kock 
et al. showed that rectal digital stimulation could abort detrusor overactivities [Kock et al., 1963]. 
Janež et al. studied the urethra and bladder responses on anal electrical stimulation. In 55 patients 
with different urethra-bladder dysfunctions, only 50% of the patients showed normal reciprocal 
response [Janež et al., 1979]. In 1979 Merril treated patients with acute rectal stimulation: detrusor 
reﬂ ex threshold increased or bladder overactivities were abolished in 4 out of 20 patients. As they 
became dry, they received an implant. One of them only needed stimulation every 4 days, the interval 
required to control uninhibited detrusor contractions varied between 4 to 12 hours [Merril, 1979]. 
In 1996 Trsinar compared 73 children with anal MES to 21 controls.  32% became dry, 44% improved 
(>50% improved in urinary complaints), in the control group no changes were seen [Trsinar, 1996]. 
Esa applied anal plug stimulation for 30 minutes every 3 days to 1 week in 43 patients. 64% in the 
urgency/frequency group and 43% in the stress UI group was found to be successful. Urodynamic 
results did not correlate with the subjective improvement nor did the acute effect correlate with the 
chronic effect and subjective improvement. Especially the OAB group who had cerebral infarction, the 
anal plug stimulation was most effective [Esa, 1991].
In 1977 Teague transrectally stimulated the pudendal nerve in dogs which resulted in an increased 
urethral pressure and detrusor inhibition. Post stimulation effect occurred in all stimulations 
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concerning the urethral pressure and in 4 dogs the post stimulation inhibition on the detrusor was 
seen. Direct pudendal stimulation was less than after transsection at Th 8, suggesting that the 
mechanism of direct pudendal nerve stimulation in dogs is organised in the spinal cord and not in 
brain centra [Teague, 1977]. Nakamura investigated the pudendal branches. In ten out  the twenty-
two patients inhibition of detrusor overactivity was achieved by continuous dorsal penile nerve 
stimulation, the detrusor overactivity could be suppressed in seven out of ten patients but the dorsal 
clitoral stimulation seemed less effective [Nakamura, 1984].
Anorectal and pudendal stimulation seemed to be quite successful to restore normal voiding. It is 
thought that Aδ ﬁ bres are activated which give return to urge feeling and normal micturition pattern. 
Pudendal, vaginal electrodes stimulated the large somatic C ﬁ bres which will inhibit the small 
afferent Aδ ﬁ bres comparing to the pain gate control theory postulated by Melzack. Sensory output 
from the skin modulates pain perception and response on spinal segmental level [Melzack, 1965]. 
Unfortunately, due to the uncomfortable set-up, anorectal and pudendal stimulation is known as a low 
compliant therapy. Therefore other stimulation sites have been searched for. 
Sacral Nerve Stimulation was introduced in the late eighties. An electrode was introduced through 
the sacral foramen to stimulate mainly S3 and connected to an implanted stimulator. The working 
mechanism is not yet clear but remarkable results were seen. Contraction of the bladder, hypertrophy 
and increased efﬁ ciency of the striated urethral sphincter was induced by prolonged electrostimulation 
of the sacral roots. Increased efﬁ cacy of the sphincter was thought to be due to hypertrophy and 
forming of intermediary fast but less fatigue-resistant ﬁ bres [Tanagho, 1993]. In addition contraction 
of the sphincter inhibits or aborts detrusor activity through a normal reﬂ ex. Sacral segmental nerve 
stimulation by a permanent foramen S3 electrode achieved detrusor inhibition by chronic stimulation 
of afferent somatic sacral nerve [Bosch et al., 1995]. The mechanism is believed to be comparable 
with the pain gate control theory postulated by Melzack. Sensory output from the skin modulates 
pain perception and response on spinal segmental level [Melzack, 1965]. Bosch et al. implanted 
a permanent foramen S3 electrode in 18 out of 31 patients. Fifteen of them (83%) were treated 
successfully. Though it has been shown to be an effective treatment, it was a costly and invasive 
procedure with a high revision rate (in 4 out of 18 patients) [Bosch, 1995]. After 7 years of experience 
Bosch et al. concluded that neuromodulation lead to symptomatic improvement and decrease or 
disappearance (in 46%) of detrusor overactivity. After 4 years some deterioration was seen [Bosch 
et al., 2000]. Weil et al. described a success rate of 52,8% (19 out of 36 patients, intention-to-treat 
based) after an average long-term follow-up of 37,8 months. All symptoms except urgency improved 
signiﬁ cantly [Weil et al., 1998]. Urodynamics showed signiﬁ cant increase of bladder capacity 
and volume at ﬁ rst sensation. The volume at ﬁ rst unstable bladder contraction increased but was 
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not statistically signiﬁ cant. Thirty seven re-operations have been performed, mostly to overcome 
technical problems. Nowadays the stimulator is implanted in the buttock resulting in less pain at the 
implantation site and a lower re-operation rate [Scheepens et al., 2001].
Parallel to the development of the SNS non-invasive ways to stimulate S3 were explored. 
Transcutaneous Electrical Nerve Stimulation (TENS) on the S3 segment is a useful alternative 
treatment modality in patients with detrusor overactivity. Webb et al. noticed 54% of the patients to 
become continent with S3 TENS [Webb, 1992]. Hasan et al. also reported these success ﬁ gures in 
1996. In his trial 20 patients received no TENS, S3 TENS or T12 TENS. The study revealed signiﬁ cant 
changes in urodynamic parameters in the group on S3 stimulation [Hasan , 1996]. Hasan investigated 
the urodynamic effect during TENS over the tibial nerve, however no signiﬁ cant changes were seen. 
Webb and Powell could abolish detrusor overactivity in 11 out of 24 patients (46%), a larger volume at 
ﬁ rst contraction was seen and 54% was considered continent [Webb and Powell, 1992]. TENS therapy 
unfortunately may induce skin irritation and allergy at the stimulation site due to chemical and 
mechanical irritation [Hasan et al., 1996; Oosterwijk et al., 1994]. Consequently, other stimulation 
approaches were searched for. 
In 1997 magnetic resonant stimulation of the spinal cord was successfully used to suppress 
detrusor overactivity and the sensation of urge in all 12 patients. The effect remained for 70 seconds. 
Unfortunately 2 patients found the stimulation uncomfortable or painful. The stimulator is bulky, 
expensive and the stimulating coil could be overheated. Using a computer-triggered conditional 
magnetic suppression it was possible to suppress overactive contractions and to increase cystometric 
capacity. The mechanism is postulated to induce activation of the sensory parasympatic pathway 
producing inhibition of parasympatic efferents both directly and also possibly via sympathetic 
pathways [Mc Farlane, 1997].
Bladder inhibition is also provided by limb afferents. These reﬂ exes serve to prevent urine leakage 
during physical activity.  Research focussed on the effect of stimulation of afferent nerves in the lower 
limb. In cat experiments Lindström and Sudsuang showed detrusor inhibition through stimulation of 
the myelinated afferents of the hip adductor muscles [Lindstrom and Sudsuang, 1989]. Okada et 
al. tried to stimulate the thigh muscles for 20 minutes, every day for 2 weeks, and they observed 
increased bladder capacity in 11 out of  19 patients (>50%). In six of these 11 there was clinical 
improvement (carry-over effect) for several weeks to months [Okada, 1998].
Inspired by acupuncture points over the tibial and peroneal nerve to overcome bladder overactivity, 
Mc Guire et al. applied electrostimulation over these nerves. In a woman with herniated intervertebral 
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disc and at a volume of 200ml, continue stimulation of the posterior tibial nerve kept her dry.  In a 
paraplegic man, detrusor overactivity could be suppressed for 4 hours. A female patient with detrusor 
overactivity and incontinence could control her bladder after common peroneal nerve stimulation. One 
female with Interstitial Cystitis was relieved from her symptoms for 3-4 hours [Mc Guire, 1983]. Kubista 
et al. found increased urethral pressures 30 minutes after acupuncture in 17 out of 20 patients. This 
phenomenon was nor seen in the control group nor in the placebo group [Kubista, 1976]. In 1999 
Stoller proposed percutaneous Afferent Nerve Stimulation of the posterior tibial nerve for treatment of 
bladder and pelvic ﬂ oor dysfunction [Stoller, 1999].
5.2 STOLLER AFFERENT NERVE STIMULATION (SANS) OR PERCUTANEOUS POSTERIOR 
TIBIAL NERVE STIMULATION (PTNS).
 In an abstract published in 1987, Stoller presented his acupuncture observations in Macaca Nemestrina. 
A subset of these apes demonstrated detrusor overactivities for more than 7 years. The application 
of acupuncture on locus SP6 reduced or eliminated detrusor overactivity. Repetitive stimulation 
lengthened the interval between detrusor contractions. The physical properties of the SP6 locus 
revealed marked decrease in skin resistance and impedance. Needle stimulation abolished detrusor 
overactivity, disruption of vascular or lymphatic circulation did not interfere with the treatment, but an 
intact peripheral neurosensory system was required for the therapy to be effective. Anesthetized limbs 
elicited no response [Stoller ML, 1987]. Stoller proposed Stoller’s Afferent Nerve Stimulation or SANS 
for treatment of bladder and pelvic ﬂ oor dysfunction [Stoller, 1999].  In 1999 SANS was introduced 
in the Netherlands and later renamed Percutaneous Posterior Tibial Nerve Stimulation (PTNS). The 
afferent stimulation of the tibial nerve was introduced as a non-invasive method, simple to perform 
and of low cost. The ﬁ rst results included ﬁ gures from 4 sites in the US and 5 sites in Europe. The 
preliminary study showed a success rate of 73%. No harmless effects were seen. In the Netherlands 
success rate was 60 % [van Balken et al., 2001] Success was obtained if micturition lists showed 25 
% improvement of parameters or if subjectively the complaint no longer played a predominant role in 
their lives. 
5.3 THE SANS USERS CLUB 
In 1999 the SANS Users Club in the Netherlands was established.  More than 25 Dutch urologists 
included patients with detrusor overactivity, pelvic pain or chronic voiding dysfunction. After careful 
selection, the candidates underwent PTNS in accordance with a written protocol. After 12 weeks, 
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the protocol booklets with treatment results, completed questionnaires and urodynamic ﬁ ndings 
were send back to the PTNS investigators (UMC St Radboud, Nijmegen). Also in Italy interest towards 
PTNS treatment rose. A close collaboration with Dr E. Finazzi Agrò from the department of Urology at 
the University Tor Vergata and IRCCS S Lucia in Rome resulted in reliable additional data. This thesis 
describes the analysis of data received from patients with overactive bladder syndrome and chronic 
voiding dysfunction. 
 
5.4 CANDIDATE SELECTION
All candidates were examined by a urologist. A careful history was taken to exclude other treatable 
causes (urinary tract infections, urolithiasis, bladder cancer, etc) or neurological diseases. Table 5.1 
lists all general and disease speciﬁ c inclusion and exclusion criteria. Patients included in the trial were 
patients with overactive bladder syndrome and chronic voiding dysfunction. Deﬁ nitions used in the 
protocol are described in chapter 3.
Primary treatment modalities such as pelvic ﬂ oor re-education or anticholinergics failed to relieve 
patients from their bladder complaints. Candidates underwent urodynamic investigation to identify 
baseline parameters and to exclude genuine stress incontinence. For urodynamic analysis a standard 
transurethral subtraction cystometry was conducted in the supine position. Sterile saline at room 
temperature was infused through a double lumen 8 F catheter at a ﬁ lling rate of 50 ml/min. The 
volume at which detrusor overactivity occurred was noted. Detrusor overactivity was deﬁ ned as an 
increase of 15 cm water pressure or of lower amplitude if accompanied with a distinct sensation of 
urgency. Methods, deﬁ nitions and units conform to the standards recommended by the International 
Continence Society, except where speciﬁ cally noted [Abrams et al., 2002]; [Abrams et al.; 1988].
Patients were asked to complete bladder diaries and quality of life questionnaires at baseline and 
throughout the study period on a regularly basis. For incontinence speciﬁ c quality of life the I-QoL 
questionnaire was used [Patrick et al., 1999]. For the estimation of generic functional status and well-
being, the MOS 36 items Short-Form health survey (SF-36) was completed [Ware et al., 1992]. Higher 
scores indicate better quality of life. Informed consent was achieved.
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General Inclusion criteria: General Exclusion criteria:
the patient has signed informed consent
the patient is older than 18
The patient has a documented normal urinary 
tract. 
The patient has an intact peripheric neurosensoric 
nervous system
If the patient is under medicamental treatment a 
60 day wash out period is necessary or the daily 
dosis should be kept unchanged during the study 
period
The patient understands the procedure, the 
advantages and possible adverse effects of 
Percutaneous Tibial Nerve Stimulation.
The patient shows an adequate muscular and 
sensoric response during the test stimulation
The patient agreed and is capable to complete 
bladder diaries 
The patient agreed and is capable to complete the 
quality of life questionnaires
The patient agreed and is capable to undergo the 
treatment as described in the protocol guidelines
•
•
•
•
•
•
•
•
•
•
The patient is mentally not capable to understand 
the protocol guidelines or not capable to sign 
informed consent
aged under 18
Medical conditions that could inﬂ uence th 
outcome of PTNS: pacemakers, deﬁ brillator, 
serious cardiopulmonic disorders
Pregnancy or the wish to get pregnant during the 
study period. If the patient becomes pregnant the 
PTNS treatment will be ceased immediately
Active urinary tract infection or recurrent urinary 
tract infections (> 4 times a year). Urinary 
ﬁ stula, bladder stones, cystoscopic abnormalities 
suggesting malignancies
neurogenic detrusor overactivity (CVA, Parkinson, 
Multiple Sclerosis)
uncontrolled diabetes or periferic neuropathy
The usage of  Elmiron®  or other bladder             
instillation products (DMSO, BCG, Heparine, etc)
•
•
•
•
•
•
•
•
Inclusion criteria: Overactive Bladder 
Syndrome
Inclusion criteria:Chronic voiding dysfunction
The patient has a documented detrusor 
overactivity: urinary frequency is more than 7 
times per day and / or the patient experience 
minimal one episode of urinary incontinence 
during three consecutive days recorded in their 
bladder diaries
The urine loss is not due to stress incontinence 
(based on the urodynamic investigation that is 
a part of the normal work up investigation for 
overactive bladder complaints)
The patient has a minimal bladder capacity of
100 ml
•
•
•
The patient has a documented detrusor 
underactivity or acontractile detrusor. The patient 
catheterises and fails to achieve complete bladder 
emptying on bladder diaries. 
•
Table 5.1:  In- and exclusioncriteria for PTNS procedure. 
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5.5 THE PTNS PROCEDURE
The patient was asked to sit in a frog position with the legs slightly benched and feet inverted. For 
PTNS a 34-gauge needle was inserted percutaneous, approximately 5 cm cephalic to the medial 
malleoleus of the right or left ankle (ﬁ g 5.1). A surface electrode was placed on the medial aspect of 
the ipsilateral calcaneus. The needle and electrode were connected to a low voltage (9 V) electrical 
stimulator (Urosurge, Coralville, Iowa, later: Urgent PC®, Uroplasty  Minnetonka, USA). The technical 
information is summarized in table 5.2. Stimulation current (0-10mA) with a ﬁ xed frequency of 20 Hz 
and a pulse width of 200 μsec, was increased until curling of the big toe or fanning of all toes became 
noticeable. If no clear motor response was found, the needle was removed and the insertion procedure 
was repeated. In most patients the motor response was accompanied by a sensory response of a 
radiating sensation spreading in the sole of the foot. The current was set at a well-tolerable level. During 
a session elevation of the current was allowed whenever fading of this sensation was experienced due 
to adaptation. Stimulation sessions lasted for 30 minutes and were repeated on a weekly basis for a 
period of 12 weeks in an outpatient setting. After the ﬁ rst 12 weeks, an evaluation through bladder 
diaries, QoL questionnaires and urodynamics were obtained. These ﬁ ndings in combination with the 
patient’s self-perception of reduced symptoms resulted in the decision if treatment was successful. 
Successful treated candidates underwent maintenance therapy. The intervals between stimulation 
sessions were chosen individually in order to maintain the acquired reduction of their complaints. 
PTNS | a new treatment option for lower urinary tract dysfunction52
Uroplasty, Inc. Tel: 866 258 2182, e-mail: info.usa@uroplasty.com
Uroplasty BV Tel: + 31 (0)46 423 79 20, e-mail: info.holland@uroplasty.com
Figure 5.1
Chapter 5 | From electrical fish to PTNS 53
Treatment Protocol for 
each treatment session
Caution: Federal law (USA) restricts this device to sale by or on the order of a 
physician.  For complete instructions for use, storage, warnings, indications, 
contraindications, precautions, adverse reactions and disclaimer of warranties, 
please refer to the insert accompanying each Urgent PC product. 
1. Check Battery Level 
Before beginning any treatment session, it is advisable to check 
the battery level. To check the battery level, turn on the Stimulator 
by pressing and holding the Power Button for approximately 2 
seconds. An audible tone will sound and icons will appear on the 
screen.  Battery replacement is recommended when there is only 
one line remaining in the Battery Level icon. To conserve battery 
power, the Stimulator may be turned off during patient preparation.
2. Insert the Needle Electrode
Locate the insertion site for the Needle 
Electrode by identifying the location on the lower 
inner aspect of either leg that is approximately 
three fingerbreadths (5 cm or 2”) cephalad to the 
medial malleolus and approximately one 
fingerbreadth (2 cm or ¾”) posterior to the tibia.
   To prepare the Needle Electrode insertion site, open the Lead Set 
packaging.  Remove and open the Alcohol Pad.  Use the Alcohol
Pad to clean the skin area surrounding the identified insertion site.
Place the patient in a comfortable position, supine or sitting, for 
easy access to the insertion site; for example, the patient may sit 
with the soles of the feet together and knees abducted and flexed. 
Open the sterile Needle Electrode package and remove the Needle 
Electrode/guide tube assembly.
Place the Needle Electrode/guide tube assembly over the identified
and cleaned insertion site in a position that creates a 60-degree 
angle between the Needle Electrode and the ankle.  Remove the 
stop plug in the guide tube to release the Needle Electrode.
   Gently tap the Needle Electrode head to pierce 
the skin. Once the Needle Electrode has 
penetrated the skin, remove the guide tube and 
advance the Needle Electrode using a rotating 
motion to facilitate entry.
Note: it is important to maintain a 60-degree 
angle with the Needle Electrode while 
advancing it in a path that is parallel to the tibia.  When 
appropriately inserted, about half of the tip of the Needle Electrode 
will be inserted in the leg, with about 2 cm (¾”) left exposed.
3. Connect Lead Wire to the Stimulator
 Plug the one-way fit connector of the Lead Wire 
into the Stimulator’s connection site.  Verify that 
the one-way fit connector is inserted correctly.
4. Attach the Surface Electrode
Remove the adhesive backing from the Surface Electrode.
Place the Surface Electrode near the medial aspect of the 
calcaneus on the same leg as the Needle Electrode insertion.
?
5. Attach Needle Electrode Clip
Depress the plunger on the Needle Electrode 
Clip to expose the connection hook at the tip. 
Loop the connection hook around the Needle 
Electrode and release.
6. Determine Current Setting for Therapy
Turn on the Stimulator by pressing and holding the Power button 
for approximately 2 seconds. An audible tone will sound and 
symbols will appear on the screen.
Enter Test mode by pressing and holding the Test button for 
approximately 2 seconds. The default setting for Test mode is level 
0 (0mA current). 
Using the Current Adjustment button, slowly increase the current 
while observing the patient’s foot for a response. Patient response
is generally a toe flex or fan, or an extension of the entire foot.
 
Once a patient 
response is observed, 
reduce current setting 
by one level and begin 
Therapy mode. 
If the incremental adjustment of amplitude fails to elicit toe flex or 
fan, press the Stop button and reposition the Needle Electrode 
slightly. Re-enter Test mode using the preceding instructions.
If repositioning the Needle Electrode and repeating the current 
step-up procedure fails to elicit patient response, discard the 
Needle Electrode.  Open the second Needle Electrode included in 
the Lead Set and repeat the procedure on the other leg.
7. Conduct Therapy 
After completing Test mode, Therapy mode can be entered by either:
1) Pressing the Stop button to end Test mode and then pressing 
    the Therapy button to start Therapy mode.
or 2) Pressing the Therapy button while the Test mode is still active. 
To ensure optimal treatment, the default current setting for Therapy
mode will be the final current setting in Test mode. However, the 
Current Adjustment button can be used to increase or decrease the 
current level at any time during Therapy mode.
Therapy mode time is automatically set for 30 minutes.
When the therapy time has elapsed, Therapy mode will 
automatically end, the current will be inactive, and the Stimulator 
will emit a series of three beeps.
8. Complete Treatment Session 
Turn off the Stimulator by holding down the Power button for 
approximately 2 seconds. 
Remove the Needle Electrode Clip from the Needle Electrode. 
Using a smooth, fluid motion, quickly remove the Needle Electrode 
from the leg. If bleeding occurs, apply slight pressure and bandage.
Disconnect the Lead Wire from the Stimulator and properly dispose 
of Lead Set components.
The treatment session is now complete.
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OBJECTIVE 
Recently, intermittent PTNS was introduced as a treatment modality ﬁ lling the gap between 
conservative and surgical therapies in patients with certain types of lower urinary tract dysfunction.
SUBJECTS AND METHODS
In a prospective multicentre trial PTNS was evaluated in 37 patients with symptoms of overactive 
bladder complaints and 12 patients with non-obstructive urinary retention. Results were recorded in 
bladder diaries and quality of life questionnaires (SF-36 and I-QOL) before and after treatment. Patients 
were classiﬁ ed as responders, including those in whom therapy was successful and chose to continue 
treatment after the initial 12 weeks, and non-responders, those who chose to stop treatment.
RESULTS
Overall, a positive response was seen in 60% of all patients. In patients with bladder overactivity a 
statistically signiﬁ cant decrease was observed in leakage episodes, number of pads used, voiding 
frequency and nocturia, and an equal increase in mean and smallest volume voided. Improvements 
were also seen in non-obstructive urinary retention, including number of catheterisations, total and 
mean volume catheterised and total and mean volume voided. Disease speciﬁ c quality of life and 
some domains of general quality of life improved, especially of bladder overactivity. Only mild side 
effects were observed.
CONCLUSIONS
PTNS is a minimally invasive and successful treatment option for patients with certain types of lower 
urinary tract dysfunction. 
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6.1 INTRODUCTION
Non-neurogenic lower urinary tract dysfunction is a common urological problem that strongly affects 
patient’s quality of life. Patients can complain of overactive bladder (OAB) with or without incontinence 
or present themselves with urinary retention. In most patients the etiology of these complaints 
remains unclear [Hasan et al., 1996]. Conservative treatment options for OAB complaints consist of 
behavioral techniques with and without biofeedback, bladder reeducation, pelvic muscle exercises 
or pharmacotherapy involving anticholinergics, antispasmodics and tricyclic antidepressants. 
Patients with non-obstructive urinary retention can be treated with clean intermittent or permanent 
catheterisation. For refractory cases more aggressive surgical procedures, like bladder distension, 
ileocystoplasty or urinary diversion have been advocated. However, a high recurrence and complication 
rate limits the widespread application of these treatments. 
Recently, continuous sacral root stimulation (Medtronic, Inc. Minneapolis, Minnesota) has been 
proposed as an alternative, less invasive therapeutic option for patients with non-neurogenic lower 
urinary tract dysfunction, not responding to conservative treatment [Bemelmans et al., 1999]. 
Although highly effective in select patients, this technique is expensive and requires explicit surgical 
skill.
PTNS is a technically less demanding and probably more cost-effective for management of lower 
urinary tract dysfunction. In this report we present our initial experience with this new neuromodulation 
technique in a prospective clinical trial. 
 
6.2 PATIENTS AND METHODS
Between November 1999 and March 2000, 15 male and 34 female patients were enrolled in a 
prospective clinical multicentre trial that received approval by the institutional review board. All 
patients were evaluated for OAB complaints and non-obstructive retention by history, bladder diaries 
and physical as well as urological examination, including urodynamics.
For the OAB group, the following inclusion criteria were used: increased urinary frequency: more than 8 
voids per 24 hours; urge urinary incontinence (urge UI) occurring at least 3 times weekly and/or phasic 
involuntary bladder contractions with concomitant incontinence on cystometry. Non-obstructive 
retention was distinguished by urinary retention, necessitating intermittent catheterisation at least 
4 times a day, without urodynamic signs of outﬂ ow obstruction, as deﬁ ned on the Abrams-Grifﬁ ths 
nomogram [Abrams et al., 1979].
The use of parasympatholytic medication or other pharmaceuticals inﬂ uencing bladder function (like 
anti-depressive agents) should have been stopped two weeks or longer prior to PTNS or had to be 
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continued without dose changes during the entire study. Speciﬁ c exclusion criteria for our study are 
given in the appendix.
Patients: 
A total of 10 men and 27 women with a mean age of 52.5 years (range 23 to 74) were treated for 
OAB. These patients lived with symptoms for a median period of 4 years (range 1-30). The symptoms 
were said to be induced by childbirth in 3, pelvic surgery in 9 (including 7 hysterectomies, 1 anterior 
prolapse correction and 1 Burch colposuspension) and other events in 3 patients, including fracture 
of the coccygeal bone, urinary tract infection, bowel infection.
The remaining patients had no history of any pelvic event prior to the onset of symptoms. Of the 37 
patients 32 (91.4%) received unsuccessful prior medical therapy, including anticholinergics with a 
mean number of 1.9 (range 1 to 5) drugs used. Almost half of all patients (48.6%) underwent up to 3 
surgical procedures, most frequently colposuspension, for symptoms. Other unsuccessful therapies 
included physiotherapy and/or biofeedback in 22 (59.4%), including transcutaneous electrical nerve 
stimulation or peripheral nerve evaluation in 5 (13.5%) and alternative therapies, such as Chinese 
herbs in 5 patients (13.5%). Physical examination did not show overt or neuro-urological abnormalities 
in any patients. 
There were 5 men and 7 women with a mean age of 50.8 years (range 36 to 64) treated for non-
obstructive retention. These patients had symptoms for a median of  3.5 years (range 1 to 36 years). 
Initiation of symptoms was related to childbirth in 1, pelvic surgery, including Wertheim’s-Meighs 
operation in 1 and Burch colposuspension in 1, other surgery, including hip replacement in 1 and 
inguinal hernia repair in 1 and benign prostatic hyperplasia without any effect of transurethral 
resection of the prostate in 1 patient. The remaining 6 patients had no history of any pelvic event 
prior to the onset of their complaints. Of the 12 patients 11 (92%) received unsuccessful medical 
therapy previously, including a-blockers or sympathomimetics. Almost half the patients (5 of 12) 
had undergone lower urinary tract surgery, mostly urethral dilatation or urethrotomy, for symptoms 
previously. Other unsuccessful therapies included physiotherapy and/or biofeedback in 3 (25%) 
and electrical stimulation in 1 patient. All patients were on clean intermittent catheterisation.  In 
addition, physical examination did not show overt or neuro-urological abnormalities in these patients. 
Urodynamic investigations revealed hypocontractile detrusor in all patients.
Treatment method:
PTNS was applied according to Stoller [Stoller, 1999]. Patients are in supine position with the soles 
of the feet together and their knees abducted and ﬂ exed (‘frog-position’). A 34-gauge stainless steel 
needle is inserted for approximately 3 to 4 cm about three ﬁ ngerbreadths cephalad to the medial 
malleolus, between the posterior margin of the tibia and the soleus muscle. A stick on electrode is 
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placed on the same leg near the arch of the foot. The needle and electrode are connected to a low 
voltage (9 volts) Urosurge stimulator (Urosurge Coralville, Iowa USA) with adjustable pulse intensity of 
0 to 10 mA., a ﬁ xed pulse width of 200 microseconds and a frequency of 20 Hz. The amplitude is slowly 
increased until the large toe starts to curl, or toes start to fan. If the large toe does not curl or pain 
occurs near the insertion site the stimulation device is switched off and the procedure is repeated. 
If patient’s large toe curls or toes start to fan stimulation is applied at an intensity well tolerated by 
the patient. If necessary the amplitude can be increased during the session. Patients underwent 12 
weekly outpatient treatment sessions, each lasting for 30 minutes. If a good response occurred the 
patient was offered chronic treatment.
Evaluation of results: 
After providing informed consent all patients completed bladder diaries as well as general and disease-
speciﬁ c quality of life questionnaires at study entry and completion of the 12-week treatment. In the 
24hour bladder diary frequency and voided volumes, number and volume of catheterisations, number 
of leakage periods, leakage severity as well as the number of pads or diapers used were recorded. 
The leakage severity was scored on a scale of 0 to 3 and included 0—no leakage, 1—leakage of some 
drops, 2—loss of a small amount and 3—loss of a massive amount of urine that required a change of 
clothes. General and disease speciﬁ c quality of life was evaluated using the 36-item short-form health 
survey (SF-36) and the adjusted quality of life questionnaire, respectively [Ware et al., 1992; Wagner 
et al., 1996] respectively. The SF-36 consists of 36 items regarding 8 distinct health status concepts 
and 1 item measuring self-reported health transition, including physical function, role-physical, pain, 
general health, emotional well-being, role-emotional, social functioning, energy and fatigue and change 
in general health. The maximum score for each domain is 100 and a high score relates to better quality 
of life. The quality of life questionnaire consists of 22 items, each with a 5 point response scale. As 
with the SF-36, a high score means good quality of life. 
Success was deﬁ ned as the patient request for continued chronic treatment for maintenance. 
Analysis was done on an intention-to-treat basis. Within the group comparisons of parametric results 
at baseline and 12-week treatment were conducted with the paired sample t-test. Statistical analysis 
was performed using SPSS 9.0 software (SPSS, Chicago, USA).
 
6.3 RESULTS 
6.3.1 Bladder overactivity
Of the 444 treatment sessions stimulation was performed on the right posterior tibial nerve with a 
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mean pulse intensity of 3.7 mA (range 1.4 to 6.8) per session in 265 (60%). Complications, including 
minor bleeding or a temporary painful feeling at the insertion site, were seen only rarely. Of the 37 
patients PTNS in 7 men and 15 women (59,4%) was considered successful because they requested 
continuation of therapy after completion of the 12-week treatment (group 1, responders). In 3 male 
and 12 female patients treatment was unsuccessful since they did not choose maintenance therapy 
(group 2, non-responders).
At completion of the 12-week treatment all 33 patients with increased urinary frequency had a 
signiﬁ cant improvement of voiding frequency during day and night (table 6.1 and ﬁ gure 6.1 A). When 
discriminating group 1 (21 responders) from group 2 (12 non-responders), these improvements 
appeared to be signiﬁ cant only in group 1. The smallest mean volumes and mean volumes voided 
also improved, whereas the largest volumes voided did not change in this group.
All patients (N=33) Group 1  (N=21) Group 2 (N=12)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Frequency 16.5 ± 6.8 -2.8
(-0.8;-4.9)*
16.1 ± 6.1 -4.8
(-2.7;-6.8)***
17.1 ± 8.3 +0.8
(+5;-3.3)
Nocturia 2.6 ± 2.3 -1
(-0.2;-1.8)*
2.5 ± 2.7 -1.4
(-0.4;-2.3)*
2.7 ± 1.6 -0.2
(+1.3;-1.6)
Smallest 
volume 
voided
65 ± 49.3 +14.2 (+32.8;-
4.5)
62.6 ± 52.1 +29.8
(+49.2;
+10.3)**
71 ± 44.8 -18.5
(+19.4;-56.4)
Largest 
volume 
voided
289.8 ± 161 +13.9
(+48.7;-20.9)
268.8 ± 146.4 +9.5
(+50.6;-31.6)
334 ± 188.5 +23
(+100.6;-
54.6)
Mean 
volume 
voided
140 ± 82.2 +19.3
(+40.3;-1.7)
133 ± 82.8 +35.1
(+62.6;+7.7)*
153.6 ± 83.7 -14 
(+8.5;-36.5)
Table 6.1:  Voiding parameters in 33 patients with OAB  
* p < 0.05  ** p < 0.005  *** p < 0.0005  
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A statistically signiﬁ cant overall decrease in incontinence was seen in the 30 patients who were 
urge urinary incontinent (table 6.2 and ﬁ g. 6.1, B). When comparing group 1 (18 responders) with 
group 2 (12 non-responders), improvements found in leakage episodes and number of pads used 
appeared to be greater in group 1. Leakage severity scores showed improvement in all patients, who 
were incontinent. In groups 1 and 2, general quality of life improved in regard to physical and social 
functioning in all patients with OAB. Mean physical functioning plus or minus SD was 53.7 ± 27.9 
(mean change +9.1 (95% conﬁ dence interval [CI]: +14.1; +4, p<0.005 and social functioning 64.7 
± 31.2 (mean change +10.3, 95% CI: +16.5; +4.1, p<0.005) at 0 weeks. In group 1 both scores also 
increased. Mean physical functioning plus or minus SD was 61.6 ± 26.3 (mean change +11.2 ,95% 
CI: +18.8; +3.5, p<0.05) and social functioning 70.6 ± 26.7 (mean change +11.6, 95% CI: +20.9; 
leakage epidodes
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Figure 6.1:  Before and after PTNS for responders, non-responders and both combined. A, voiding frequency. B, number 
of leakage episodes. Error-bar represents SD. ns, not signiﬁ cant.
All patients (N=30) Group 1 (N=18) Group 2 (N=12)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Mean ± SD
(0 weeks)
Mean change
(95% CI)
Leakage 
episodes
9.8 ± 5.6 -4.8
(-2.2;-7.5)**
9.8 ± 6.4 -6.2
(-2.9;-9.5)**
9.8 ± 4.4 -2.4
(+2.4;-7.3)
Pads used 6.3 ± 3.2 -2.5
(-1.2;-3.9)**
5.8 ± 2.6 -3.3
(-1.5;-5.1)**
7.1 ± 3.9 -1.3
(+0.9;-3.4)
Leakage 
severity
1.7 ± 0.5 -0.7
(-0.4;-1.0)** 
1.6 ± 0.5 -0.8
(-0.3;-1.3)**
1.9 ± 0.5 -0.5
(-0.2;-0.8)*
* p < 0.05 ** p < 0.005
Table 6.2:  Voiding parameters in 30 patients with OAB 
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+2.3, p<0.05) at 0 weeks. Only social functioning improved (55.9 ± 35.9 (mean change +8.4, 95% CI: 
+16.6; +0.2, p<0.05) at 0 weeks in group 2. Disease speciﬁ c quality of life showed improvement in all 
patients (60.3 ± 19.3 (mean change +12.3, 95% CI: +17.3; +6.8, p=0.00004), as well as in patients in 
group 1 (60.6 ± 18.2 (mean change +14.4, 95% CI: +22.3; +6.6, p<0.005) and group 2 (59.9 ± 21.5 
(mean change +8.5, 95% CI: +15.1; +2, p<0.05), respectively at 0 weeks (ﬁ g. 6.2A).
6.3.2 Non-obstructive retention group
Of the 144 treatment sessions stimulation was performed on the right posterior tibial nerve with a 
mean pulse intensity of 4 mA (range 2,5 to 7) per session in 87 (60%). As seen in patients treated for 
OAB, complications were rarely noted. Of the 12 patients PTNS was considered successful in 1 man and 
6 women (58,3 %) because they requested continuation of therapy after completion of  the 12-week 
treatment (group 3, responders). Treatment was unsuccessful in 4 men and 1 woman since they did 
not choose maintenance therapy (group 4, non-responders).
At completion of 12-week treatment all patients clearly had a decrease in number of catheterisations 
and mean and total volumes catheterised and an increase in mean and total volumes voided. However, 
statistical signiﬁ cance could not be obtained (table 6.3). When discriminating group 3 (7 responders) 
from group 4 (5 non-responders) these changes could also be observed in group 3, but not in group 4. 
In regard to quality of life hardly any signiﬁ cant improvement could be found in the adjusted disease 
speciﬁ c (ﬁ g. 2, B) or general quality of life questionnaire. The only exceptions appeared to be the SF-
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Figure 6.2:  Before and after PTNS for responders, non-responders and both combined. A, disease speciﬁ c quality of 
life scores in patients with OAB. B, non-obstructive retention. Maximum disease speciﬁ c quality of life score was 110. 
Error-bar represents SD. ns, not signiﬁ cant. 
Chapter 6 | The first results of PTNS as neuromodulative treatment
of lower urinary tract dysfunction 
65
36 score for emotional well-being, which increased (58,3 ± 12,2, mean change +14.3, 95% CI: +20.6; 
+7.9, p<0.005) in patients who thought treatment was successful (group 3), and the score for change 
of health, which signiﬁ cantly increased in all patients (45.8 ± 27.9, mean change +22.9 , 95% CI: 
+44.9; +1, p<0.05), but not in group 3 or in group 4 at 0 weeks, respectively. 
6.4 DISCUSSION
For treatment of refractory urinary tract dysfunction various methods of intermittent neuromodulation 
have been advocated, including intravesical, anal, vaginal, penile and perineal stimulation, and 
transcutaneous electrical stimulation of the suprapubic or sacral region and the posterior tibial 
nerve [Madersbacher, 1990; Merril, 1979; Janež et al., 1979; Lindström et al., 1983; Nakamura et al., 
1984; Vodušek et al., 1982; Fall et al., 1994; Walsh et al., 1999;  McGuire et al., 1983]. Because of 
poor results or uncomfortable stimulation sites, most of the aforementioned treatment modalities 
did not gain widespread acceptance. In the 1980s implantable neurostimulation electrodes became 
available for modulation of the sacral spinal nerves, especially S3 [Schmidt, 1988].  Stimulation 
could be performed continuously, leading to better results, but drawbacks included invasiveness of 
the procedure, the high costs involved and the limited service life of the stimulation device, which 
was 7 to 10 years. In addition, symptoms appear to recur almost immediately after discontinuation 
All patients (N=12) Group 3 (N=7) Group 4 (N=5)
Mean ± SD
(0 wks.)
Mean chang
(95% CI)
Mean ± SD
(0 wks.)
Mean change
(95% CI)
Mean ± SD
(0 wks.)
Mean change
(95% CI)
Number of 
catheterisations
5.3 ± 2,4 -0.8 
(+0.6;-2.3)
5.9 ± 2.6 -1.4
(+1.2;-4.1)
4.4 ± 2 0 
(+0.9;-0.9)
Mean volume 
catheterised
336 ± 171 -83.3 
(+27.4;-194)
325 ± 181 -131.9
(+63.2;-326.9)
351 ± 176 -15.4 
(+87.5;-118.4)
Total volume 
catheterised
1552 ± 776 -537 
(+175;-1249)
1707 ± 915 -921.4
(+284.5;-2127.4)
1335 ± 547 +1 
(+659.7;-657.7)
Mean volume 
voided
206 ± 192 +5.9 
(+113.2;-101.4)
141 ± 107 +94.3 (+233.3;-
44.7)
297 ± 258 -117.8
(+16.5; 252.1)
Total volume 
voided
919 ± 658 +173.8 
(+639.2;-291.7)
758 ± 567 +482.1
(+1164.7;-200.4)
1145 ± 774 -258
(+374.6;-890.6)
Table 6.3:  Voiding parameters in 12 patients with non-obstructive retention 
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of the stimulation [Bemelmans et al., 1999]. Therefore, the development of an easy applicable, non-
invasive or minimally invasive, cost-effective neuromodulation device, with good treatment outcome 
was anticipated. The recent advent of PTNS may offer urologists a treatment modality that meets the 
aforementioned criteria [Stoller, 1999; Klinger et al., 2000].
Stimulation of the tibial nerve was ﬁ rst described by McGuire et al in 1983 [McGuire, 1983] In studies 
of nonhuman primates with spinal cord injury, bipolar anal sphincter stimulation resulted in inhibition 
of detrusor activity. Similar results could be obtained by applying current through a transcutaneous 
electrode over the common peroneal or posterior tibial nerve, with a ground electrode being placed 
contralaterally over the same nerves. The idea of stimulating these nerves was based on the traditional 
Chinese practice of using acupuncture points over the common peroneal or posterior tibial nerves to 
affect bladder activity [McGuire, 1983]. Electrical stimulation of the tibial nerve was subsequently 
performed in 22 patients with detrusor overactivity, interstitial or radiation cystitis or neurological 
diseases with promising results, including continence in 12 and urodynamic improvements in 
7. However, in a prospective study by Geirsson et al in patients with painful bladder syndrome, 
transcutaneous tibial nerve stimulation or traditional Chinese acupuncture treatment revealed no 
difference in voiding frequency, mean and maximal voided volumes and visual analogue symptom 
scores before or after either one of the treatment modalities [Geirsson et al., 1993].
In our study percutaneous stimulation resulted in a success rate of about 60% of 49 patients with 
OAB or non-obstructive urinary retention. Although our deﬁ nition of success was a subjective one, 
responders differed signiﬁ cantly from non-responders in almost every semi-objective parameter. The 
same result was observed in disease speciﬁ c and several domains of general quality of life scores. 
Because our study was not placebo-controlled, the observed improvements might theoretically be 
the result of regression to the mean, synchronous other treatment or placebo-effect, rather then a 
positive response to PTNS. Regression to the mean is not likely as all patients included had to present 
with symptoms for at least 6 months (median 4 years). To prevent interference by other treatment 
modalities, concomitant physiotherapy during PTNS was not permitted, as was the case with starting 
parasympatholytic medication or other pharmaceuticals inﬂ uencing bladder function, including 
antidepressant agents, within 2 weeks before treatment. In patients who were already using any of 
the aforementioned drugs, medication had to be stopped 2 weeks before beginning PTNS or continued 
without dose changes during the entire 12 weeks. In placebo-controlled studies, success rates in the 
placebo group are usually much lower than the response rate of about 60% in our study. Because 
most patients had symptoms for a long period and had undergone various treatments before trying 
neuromodulation, it is not likely that they were highly susceptible to the placebo-effect of this 
treatment modality.  Nevertheless, to validate these data a properly designed placebo-controlled 
study is warranted. However, it can be anticipated that the feasibility of such studies will be difﬁ cult.
Not withstanding the promising results and only mild complications of this neuromodulation 
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technique found in our study, this therapy also has some disadvantages, including percutaneous 
insertion of the stimulation electrode, necessity of regular visits to the outpatient clinic and, the thus 
far, unknown results of chronic treatment in initially successful patients. In the near future most of 
the aforementioned problems may be solved by an implantable subcutaneous electrode, which can 
be radiographically stimulated by the patients at home and on a regular basis. Studies regarding long-
term results are ongoing, but results are not yet available. In conclusion, although thorough research 
is anticipated to improve patients’ selection criteria, optimize the technique and help learn more about 
the precise mode of action, PTNS is a promising, cost-effective and easily applicable treatment option 
for patients with lower urinary tract dysfunction.  
 
Exclusion criteria:
Age under 18 Uncontrolled diabetes
Symptoms existing for less than 6 months Diabetes with peripheral nerve involvement
Pregnancy or the intention to become pregnant 
during the course of the study 
Neurological disease like MS, M. Parkinson, CVA, 
spina biﬁ da or spinal cord lesion
Active urinary tract infection or recurrent 
urinary tractinfections (recurrent infections:
≥ 5 during the last 12 months), carcinoma in 
situ, bladder malignancy, interstitial cystitis
Change in parasympaticolytic medication or 
other pharmaceuticalsinﬂ uencing bladder 
function (like anti-depressive agents) within 2 
weeks prior to or during the study
Bladder or kidney stone Physiotherapy at the same time as the study
Severe cardiopulmonary disease
Bladder outlet obstruction (Abrams-Grifﬁ ths 
nomogram)
Use of Elmiron or bladder installations like 
DMSO,BCG, Chloropectin or Heparin
Transurethral instrumentation £ 4 weeks prior 
to or during the study
Appendix:  Exclusion criteria 
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OBJECTIVE 
The objective of this study was to evaluate the effect of PTNS for treatment of symptomatic overactive 
bladder syndrome (OAB) complaints.
SUBJECTS AND METHODS
 In a prospective multicentre study, 35 patients with complaints of OAB underwent 12 weekly 
sessions of PTNS at one of 5 sites in the Netherlands and one site in Italy. Bladder diaries, I-QOL and 
SF-36 questionnaires were completed at 0 and 12 weeks. Success was analysed using subjective and 
objective criteria. Overall subjective success was deﬁ ned as the willingness to continue treatment, 
whereas objective success was deﬁ ned as a signiﬁ cant decrease (to <50%) in total number of leakage 
episodes.
RESULTS
Twenty-two patients (63 percent) reported a subjective success. Twenty-four patients (70 percent) 
showed a 50 % or greater reduction in total number of leakage episodes. Sixteen (46 percent) of these 
patients were completely cured (i.e., no leakage episode) after 12 sessions. Quality of life parameters 
improved signiﬁ cantly. 
CONCLUSIONS
We conclude that PTNS is an effective, minimal invasive option for treatment of patients with 
complaints of OAB. Improvement was seen in subjective as well as objective parameters.
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7.1 INTRODUCTION
Treatment of chronic lower urinary tract dysfunction can be challenging and difﬁ cult. Behavioural 
and medical therapies in patients with urge incontinence often result in  unsatisfactory outcomes, 
leaving the refractory patient no other option but surgery (e.g. bladder transsection, phenolization, 
clam-ileocystoplasty) [Stephenson and Mundy, 2001]. To side-step surgery, electrostimulation offers 
an alternative for therapy-resistant urge incontinence. During the past decades electrical stimulation 
of the bladder, sacral roots and pudendal nerves has been explored with varying success. However, 
these treatments involve technical problems, high costs or low patient compliance because of  the 
discomfort of treatment procedures [Esa et al., 1991; Kock and Pompeius, 1963; Habib, 1967; Janez 
et al., 1979; Merrill, 1979; Schmidt, 1988; Dijkema et al., 1993; Bosch and Groen, 1995; Primus et 
al., 1996; McFarlane et al., 1997; Weil et al., 1998; Bemelmans et al., 1999]. Transcutaneous 
electrical nerve stimulation (TENS) of the S3 segment is a useful alternative in patients with detrusor 
overactivity [Webb, 1992]. Hasan et al. reported signiﬁ cant changes in urodynamic parameters in 
patients applying TENS for treatment of the overactive bladder. [Hasan et al.,1996a]. Okada et al. 
stimulated thigh muscles and observed clinical improvement for several weeks to months [Okada et 
al., 1998]. However, TENS therapy can induce skin irritation and allergy at the stimulation site due to 
chemical and mechanical irritation [Hasan et al., 1996b; Oosterwijk et al., 1994; Hasan et al., 1996a]. 
Consequently, other stimulation approaches were explored. Research focussed on the effect of 
stimulation of afferent nerves in the lower limb. In cat experiments, Lindström and Sudsuang showed 
detrusor inhibition through stimulation of the myelinated afferents of the hip adductor muscles 
[Lindström and Sudsuang, 1989]. Inspired by acupuncture points over the tibial and peroneal nerves, 
McGuire et al applied electrostimulation of these nerves to treat bladder overactivity. They reported 
restoration of bladder control in a small group of patients [McGuire et al., 1983]. Stoller proposed PTNS 
for treatment of bladder and pelvic ﬂ oor dysfunction [Stoller, 1999]. This study presents the results of 
a multicentre study using PTNS for the treatment of symptoms related to bladder overactivity.
 
7.2 PATIENTS AND METHODS
Between November 1999 and July 2000, 35 patients with therapy resistant OAB complaints were 
enrolled in an international prospective clinical trial in ﬁ ve sites in the Netherlands and one site in 
Italy. In all patients, an extensive medical history was taken, focusing on urinary symptoms, previous 
and present treatments, neurological disease, and medication. Physical examination was performed 
to rule out any relevant pathology such as urogynaecological or neurological abnormalities. 
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Symptoms existed for a minimum of 6 months. Inclusion criteria were at least one episode of 
symptomatic incontinence per 24 hours and the capability and willingness to ﬁ ll out questionnaires 
and to keep an accurate bladder diary. For this study urge urinary incontinence (urge UI) was deﬁ ned 
as the involuntary loss of urine associated with a strong desire to void. In all cases, urodynamic 
investigations were performed to conﬁ rm the diagnosis of incontinence accompanied with detrusor 
overactivity, and to exclude stress urinary incontinence. Exclusion criteria were all other treatable 
causes for the complaints (e.g. urinary tract infection, bladder stones, transitional cell carcinoma), 
pregnancy, age under 18, central or peripheral neurological disorders and severe cardiopulmonary 
disease. All patients gave their informed consent. Methods, units and deﬁ nitions used in this study 
conform to the standard recommended by the International Continence Society [Abrams et al., 1988; 
Abrams et al., 1999]. 
For PTNS a 34-gauge needle was inserted percutaneously approximately 5 cm cephalad to the 
medial malleolus of the right or left ankle. A surface electrode was placed on the medial aspect of 
the ipsilateral calcaneus. The needle and electrode were connected to a low-voltage (9 V) electrical 
stimulator. Stimulation current (0-10mA) with a ﬁ xed frequency of 20 Hz and a pulse width of 200 
msec, was increased until curling of the big toe or fanning of all toes became noticeable. If no clear 
motor response was found, the needle was removed and the insertion procedure repeated. In most 
of the patients the motor response was accompanied by a sensory response of a radiating sensation 
spreading in the sole of the foot. The current was set at a well-tolerable level. During a session, elevation 
of the current was allowed whenever fading of this sensation was experienced due to adaptation. 
Stimulation sessions lasted for 30 minutes and were repeated weekly for a period of 12 weeks in an 
outpatient setting.
Study outcome was based on subjective and objective criteria. Subjective success was deﬁ ned as the 
patients’ positive response resulting in the request for continuing treatment : these patients were 
called “responders”. Objective outcome was based on bladder diary variables. Patients were asked to 
complete a single-day chart at baseline and at 12 weeks of treatment. The bladder diary included 24h 
recording of voiding frequency, voided volumes, number of leakage episodes, incontinence severity 
on a scale from 1 to 3 (1= some drops, 2= small amount, 3= severe urine loss necessitating change 
of clothing) and number of pads used. A single-day chart was preferred as 24h recordings prove to 
be sufﬁ cient to assess patients voiding and incontinence pattern [Gisolf et al., 2000; Mazurick and 
Landis,2000; van Melick at al., 2001]. Objective success was deﬁ ned as a 50% reduction in leakage 
episodes (primary outcome measure). Secondary outcome measures were change in voiding 
frequency, incontinence severity, and the numbers of pads used. To assess change in voiding pattern, 
we used criteria proposed by Klingler et al., i.e., a posttreatment voiding frequency of 9-10 times per 
day (partial response to treatment) or 8 or less times a day (complete response) [Klingler et al., 
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2000].  Additionally, quality of life was assessed at week 0 and at week 12. For incontinence speciﬁ c 
quality of life assessment, the I-QoL was used containing 22 items, each with a ﬁ ve-point Likert-
type response scale. The 22 items were summed and then transformed to a scale of 0-100 for easier 
interpretation, with the higher scores representing better quality of life [Patrick et al., 1999]. For the 
assessment of generic functional status and well-being, the MOS 36 items short-form health survey 
(SF-36) was used containing eight subscales (physical function, role-physical, pain, general health, 
emotional well being, role-emotional, social functioning, energy/fatigue and change in general health) 
[Ware and Sherbourne, 1992]. Higher scores indicate better quality of life. 
Efﬁ cacy of PTNS was analysed for all patients on an intention-to-treat basis. Descriptive data were 
reported as median values and range, and as mean change with 95% conﬁ dence interval (CI) [Gardner 
and Altman, 1986]. Within-group comparisons of results were conducted by the Wilcoxon signed 
rank test. Tests were performed on a two-tailed basis and level of statistical signiﬁ cance was set at 
5%. To evaluate whether it is possible to predict subjective success with baseline characteristics we 
performed univariate and multivariate logistic regression analyses. In these analyses, subjective 
success was deﬁ ned as dependent variable. Odds ratios with their 95% conﬁ dence intervals were 
calculated as a measure for the predictive power of each characteristic. On the basis of the outcome 
of the multivariable analyses, we constructed a Receiver Operating Characteristic (ROC) curve to 
visualize the predictive power of the combination of the variables. The area under the ROC curve 
quantiﬁ ed this predictive power. Statistical analysis was performed using SPSS 9.0 software (SPSS, 
Chicago, USA).
  
7.3 RESULTS
Patients’ characteristics 
This study included a total of 35 patients with symptoms of OAB with incontinence (10 men, 25 females; 
median age, 57 years; range, 29-82 years). Table 7.1 shows an overview of baseline characteristics 
and treatments undergone for complaints prior to PTNS. Urodynamic evaluation showed detrusor 
overactivity in 23 patients, and no detrusor overactivity in 12. Stress incontinence was excluded in 
all cases.  
Baseline bladder diary and QoL data (table 7.2):
All patients presented with at least one episodes of urine leakage per 24 hours (range, 1 – 22, Table 
7.2). Nine patients (6 male, 3 female) did not use pads at baseline or at week 12. Italian patients 
presented with a signiﬁ cantly smaller number of leakages and less severe urine loss and they also 
scored lower on the incontinence speciﬁ c QoL score. SF-36 score was comparable between the two 
nationalities, indicating a similar generic functional status and well-being at baseline. 
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Table 7.1:  Baseline characteristics , previous treatments undergone for complaints  and survey data of 35 patients 
with OAB: 
Patients (n) All (35) NL (22) Italy (13)
Patients’ 
characteristics:
Median Range Median Range Median Range
Age in years (y) 57 29-82 57 30-82 50 29-77
Duration of  
symptoms (y):
4 1-56 5.5 1-56 3 1-11
Stimulation (mA): 3.9  1.4-6.8 4 1.4-6.8 4.1 2.5-6.1
Interventions for 
complaints
Number of 
patients 
(%) Number of 
patients
(%) Number of 
patients
(%)
Medication
-One
-Two
-More than two
34
13
15
6  
97
37
43
17
21
6
9
6
95
27
41
27
13
7
6
0
100
54
46
0
Pelvic ﬂ oor/bladder 
retraining:
18 51 12 55 6 46
Electrotherapy 10 29 4 18 6  46
Surgical intervention 
-One
-Two
-More than two
11
8
2
1 
31
23
6
3
11
8
2
1      
50
36
9
5
0
0
0
0
0
0
0
0
Bladder diary and 
QoL data:
Median Range Median Range Median Range
24h voids 12.5 6-32 14 7-32 12 6-16
Nocturia 2 0-5 2 0-5 2 1-5
Mean capacity 119 41-250 135 41-244 100 70-250
24h leakages 5 1-22 6.5 1-22 4 1-5
Severity of 
incontinence
2 1-3 2 1-2.8 2 1-3
24h pads 3.5 0-11 5 0-11 3 0-6
I-QoL 41 20-84 56 20-84 25 20-39
SF-36 total score 57 24-84 64 28-82 56 24-81
*Medication: anticholinergics (oxybutynin, tolterodine, ﬂ avoxate hydrocloride), 
antibiotics, alpha-blocker; Electrotherapy: TENS, PNE; Surgery: colposuspension.
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Subjective success:
One patient dropped out because of personal reasons before follow-up surveys could be completed. 
Thirty-four patients completed their bladder diaries and QoL questionnaires. Twenty-two of 35 patients 
(63%) considered their situation much better or improved and hence were called a therapeutic success 
(subjective success rate).
 
Bladder diary and QoL data statistics:
All voiding parameters improved signiﬁ cantly (see table 7.2). I-QoL score improved signiﬁ cantly for all 
Bladder diary data 
and Qol variable
Baseline Week 12 Mean 
change
Within- 
group 
comparison
N Median Range Median Range MC (95% CI) p valuea
All (nr 
responders)
35 
(22)
24h voids 34 12.5 6-32 10 4-20 -4.1
(-5.6;-2.5)
<0.01
Nocturia 33 2 0-5 1 0-7 -1.1
(-1.7;-0.6)
<0.01
Mean capacity 34 119 41-250 191 76-363 +61 
(+37;+86)
<0.01
24h leakages 34 5 1-22 1 0-16 -4.2
(-2.3;-6)
<0.01
Severity of 
leakageb
34 2 1-3 1 0-3 -0.9
(-1.4;-0.5)
<0.01
24h pads 34 3.5 0-11 0 0-10 -2.3
(-1.3;-3.3)
<0.01
I-QoL 35 41 20-84 75 0-100 +26
(+16; +35)
<0.01
SF-36 total score 34 57 24-84 62 24-81 +1.5
(-4.4;+7.4)
0.3
Table 7.2:  Bladder diary, Incontinence speciﬁ c quality of life (I-QoL) and generic functional status and well-being
(SF-36) data of 35 patients with OAB treated with 12 weekly PTNS sessions. 
a Within-group comparison: baseline versus 12 week values. Wilcoxon signed rank test: signiﬁ cance level set at 5%.
b Incontinence severity on a scale from 1 to 3 (1, some drops; 2, small amount; 3, clothes needed to be changed due to urine loss).
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patients. Non-responders did not achieve a higher I-QoL score after treatment (see table 7.3). For all 
patients, SF-36 questionnaire total score or scores on one of the eight health concepts did not change 
signiﬁ cantly. However, responders improved in emotional well-being (mean change in score +6 for 
responders compared to -9 for non-responders) and role-emotional domains (mean change +18 
versus -11), whereas non-responders scored signiﬁ cantly lower on the energy-fatigue item (mean 
change -15  for non-responders versus  +1 for responders) (see table 7.3).
Objective success; descriptive ﬁ gures:
A total of 24 patients (69 %) showed a reduction in incontinence episodes (primary outcome measure) 
of more than 50 percent; of these 24 patients 16 had no leakage episodes. When one of the secondary 
outcome measures was used to deﬁ ne objective success, the following ﬁ gures were found. 
Urinary frequency: 11 patients (31%) regained a normal voiding pattern (less than 8 voids per day); 
another 10 patients (29%) could decrease their voiding frequency to 10 times a day. In total, 21 
patients (60%) regained a voiding frequency of no more than 10 times per day. 
QoL change after  PTNS Responders
(n=22)
MC (95%CI)
Non-responders
(n=12)
MC (95%CI)
I-QoL-score +32 (+22; +44) +6 (-3; +16)
Total SF-score +6 (-0.7; +13) -7 (-18; +5)
8 domains:
Physical functioning +5 (-2; +12) +2 (-7; +10)
Role-physical +10 (-11; -31) -21 (-55; +13)
Pain +4 (-6; +14) -11 (-32; +11)
General health +2 (-4; +7) -3 (-14; +8)
Emotional well-being +6 (+0.6; +11) -9 (-27; +9)
Role-emotional +18 (+3; +34) -11 (-39; +17)
Social functioning +7 (-2; +15) +5 (-13; +23)
Energy/fatigue +1(-9; +11) -15 (-27; -2)
Chance in general health +6 (-4; +15) -3 (-16; +12)
Table 7.3:  Mean change (95% CI) in Incontinence speciﬁ c quality of life (I-QoL) and generic functional status and well-
being SF-36 (total score and  8 domains) 22 responders and 12 non-responders after 12 weekly PTNS sessions for OAB 
complaints.
QoL, quality of life; CI, conﬁ dence interval; mc,mean change
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Nocturia: 20 patients (57%) showed more than 50% decrease in nocturnal toilet visits. Incontinence: 
Severity of incontinence and number of pads used, decreased more than 50 % in 19 (54%) and 20 
patients (57%), respectively. The percentage of patients using protection material decreased from 74 
% to 47 % after 12 weekly sessions. If protection material was still being used, fewer pads were needed 
(table 7.4). 
Inﬂ uencing factors on outcome:
The results from the univariate and multivarite logistic regression analyses are presented in table 
7.5. None of the baseline characteristics proved to be a signiﬁ cant predictor for subjective success. 
However, this may also be due to the limited number of study participants. There was some suggestion 
that certain characteristics can predict outcome to a certain extent. For example, for each milliamp 
increase in stimulation intensity, the chance of subjective success is increased with a factor 1.6. In 
contrast, nationality and duration of symptoms seemed to be of minimal predictive value. When all 
variables are combined the area under the ROC curve (Figure 7.1) appears to be 0.83 (95% CI: 0.70-
0.97). The ROC curve constructed without the variables nationality and duration of symptoms did not 
alter its predictive power (0.80). 
Sort of pads % Patients (at baseline) % Patients (after 12 weeks)
None 25.7 54.3
Small hygienic pad 5.7 5.7
Incontinence towel 54.3 37.1
Diaper 14.3 2.9
Table 7.4:  Usage of pads by 35 patients with OAB complaints and incontinence, before and after 12 weekly PTNS sessions.
Baseline characteristics Univariate analysisOR
(95%CI)
Multivariate analysisOR
(95% CI)
Sex ( male versus female) 0.47 (0.11; 2.10) 0.24 (0.03;1.78)
Nationality (Italians versus Dutch) 0.54 (0.13; 2.23) 0.71 (0.08; 6.22)
Age (each increment of 1 year) 0.97 (0.92; 1.02) 0.95 (0.89; 1.03)
Duration of complaints
(each increment of 1 year)
0.98 (0.92; 1.05) 0.98 (0.87; 1.10)
Number operation (per operation) 3.37 (0.74; 15.32) 5.7 (0.57; 57.7)
Stimulation intensity
(each mA increment)
1.63 (0.83; 3.18) 2.4 (0.92; 6.26)
Table 7.5:  Univariate and multivariate logistic regression analyses of  baseline characteristics to calculate predictive 
value for subjective success in 35 patients with OAB complaints treated with 12 weekly PTNS sessions. 
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Side effects:
No serious side effects were reported, although transient pain at the stimulation site was noticed. 
Diarrhoea, cramps, headaches and lower back pain were reported but not considered to be related to 
PTNS nor by the doctors nor by the patients.
 
7.4 DISCUSSION
This paper describes a new method of neuromodulation through electrical PTNS in the treatment of 
OAB. The aetiology of non-neurogenic bladder overactivity is unknown, but the hypothesis is that 
there is an imbalance between inhibitory and excitatory impulses that govern bladder function. The 
mode of action of neuromodulation is also obscure, but it is believed to restore the balance within 
the central nervous system [Bemelmans et al., 1999]. The posterior tibial nerve is a mixed nerve, 
containing motor and sensory nerve ﬁ bres. Correct placement of the needle electrode induces a 
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Figure 7.1:  Receiver Operating Characteristic (ROC) curve constructed in order to visualize the predictive power of the 
combination of the variables (baseline characteristics, see table 7.5) of 35 patients with OAB treated with 12 weekly 
PTNS sessions.
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motor and sensory response. Centrally, the posterior tibial nerve projects to the sacral spinal cord in 
the same area where bladder projections are found (i.e., the sacral micturition centre and the nucleus 
of Onuf). These are most probably the areas where the therapeutical effect of neuromodulation of 
the bladder through PTNS takes place. PTNS has a clear carry-over effect: 30 minutes of stimulation 
induces a lasting beneﬁ cial effect. Cat experiments in which a 5-minute stimulation of afferent 
nerves resulted in more than 1 hour bladder inhibition, conﬁ rm the existence of this carry-over effect 
[Jiang and Lindström, 1999]. Perhaps some kind of learned behaviour is activated by intermittent 
stimulation as in PTNS. This supposition suggests that also higher regions within the cortical central 
nervous system are involved. Furthermore, in rats, PTNS exerted its inﬂ uence on c-fos expression, 
suggesting neuromodulation action [Chang et al., 1998]. Also activation of endorphin pathways at 
sites within the spinal cord could affect detrusor behaviour [Oosterwijk et al., 1994, Murray et al., 
1982; Clement-Jones et al., 1980]. Parallel to the gate control theory for pain, it can be suggested that 
stimulation of large somatic ﬁ bres could modulate/inhibit the thinner afferent A-delta or C ﬁ bres, thus 
decreasing the perception of urgency [Melzack and Wall, 1965]. By using 12 weekly sessions of PTNS, 
remarkable clinical results were obtained. Sixty-three percent of the patients with complaints of OAB 
reported a subjective success. These patients chose to continue treatment and were entered into a 
tapering protocol that individualizes the treatment frequency to the patients’ personal requirements. 
In practice, this tapering meant that they had to be treated every 2-3 weeks. Objective success criteria 
showed equally good results: 69% of the patients had a decrease in the number of incontinence 
episodes of more than 50%. Apart from a clear decrease of incontinence, signiﬁ cant improvements in 
voiding frequency, nocturia, mean bladder capacity, severity of leakages and numbers of pads were 
found. 31% of patients regain a normal micturition pattern; 29% achieved “only” a partial response. 
However, in this study, patients who had a high baseline urinary frequency feel comforted even having 
a “ pathological” number of voids per day. Surprisingly, before PTNS, nine patients never used pads (6 
males, 3 females) although they were all incontinent (three lost some drops, two experienced drops 
and small amounts of urine, four always leaked small amounts of urine). This ﬁ nding, underlines the 
stigmatic impact pads have on patients and how high the resistance to their use can be. Moreover, it 
seems debatable if the number of pads correlates well with severity or existence of urine loss. Some 
patients chose to change clothes several times a day rather than to wear protective means that are 
easily associated with mental regression. On the other hand some patients kept on using pads to be 
on the safe side. 
Although nationality was not of predictive value, Dutch participants were more prone to be successful. 
Furthermore, the intensity of stimulation of the tibial nerve seems to be of importance, requiring more 
basic research to investigate optimal stimulation parameters.  At baseline, Italian patients scored 
lower on the I-QoL instrument. This might be linked to cultural differences: perhaps Italian patients 
are more bothered by their incontinence then their Dutch counterparts. However, this ﬁ nding might 
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also be attributable to the age difference between the two groups, the Italian patients being younger. It 
can be postulated that younger patients are less willing to accept their incontinence than the elderly, 
a feature previously reported in a study evaluating the I-QoL questionnaire [Patrick et al., 1999]. If 
improvement in quality of life scores occurred, it surely reﬂ ected the positive effect obtained by the 
therapeutical intervention, because there was a noticeable difference between the post-treatment 
I-QoL score of responders and non-responders. Improvement in emotional functioning emphasizes 
how patients’ bladder dysfunction impaired daily activities before PTNS.
One possible explanation for the beneﬁ ts found in our patients is the placebo-effect. Because every 
therapy has a propensity to induce placebo-effects, percutaneous stimulation of the tibial nerve is 
no exception to this rule. The design of a good placebo-controlled PTNS-study seems tedious and its 
execution impossible. Reports of placebo-controlled pharmacotherapeutic trials for urge-incontinence 
show placebo-effects in 28-43% of the patients [Burgio et al., 1998; Madersbacher et al., 1999, Thuroff 
et al., 1991]. This suggests that a high success rate as was found in our study is not likely to be due 
to placebo-effect alone. 
Neuromodulation of the posterior tibial nerve is a simple way to treat this category of patient, i.e. those 
who have already undergone every possible type of conservative therapy and who might be on the 
verge of deciding to undergo irreversible surgical therapy. That PTNS is efﬁ cacious and at the same 
time cost-effective makes this therapeutic modality an attractive option for physicians and patients. 
At present, the introduction of a device for home-based treatment is under way. This device will enable 
patients to treat themselves at home as often as they consider it necessary and it will make this 
revolutionary technique for the treatment of urge-incontinence available for long-term use.
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OBJECTIVE 
To evaluate the effect of stimulation of PTNS for treatment of voiding dysfunction. 
SUBJECTS AND METHODS
Thirthy-nine patients with chronic voiding dysfunction necessitating clean intermittent catheterisation 
were enrolled in a prospective multicentre trial in the Netherlands (n=19) and in Italy (n=20). They 
underwent 12 weekly sessions of posterior tibial nerve stimulation (PTNS). Bladder diaries, an 
incontinence quality of life questionnaire (I-QoL) and the MOS 36 items Short-Form Health Survey 
were completed at 0 and 12 weeks. Subjective success was deﬁ ned by the patient’s positive response 
resulting in a request to continue treatment. Efﬁ cacy was based on analysis of the bladder diary 
data, comparing the baseline values with the data at 12 weeks. A reduction of 50 % or more in total 
catheterised volume was considered as an objective success (primary outcome measurement). 
RESULTS
Of the 39 patients, 23 (59 %) chose to continue treatment. Bladder diary data showed a 50% decrease 
in total catheterised volume in 16 (41%) of the 39 patients. Additionally, 10 patients (26%) noticed 
a reduction of 25% to 50% in their total catheterised volume. For all patients, the total catheterised 
volume decreased by a mean of –228 ml (range: -528; -49). I-QoL and SF-36 parameters improved 
signiﬁ cantly.
CONCLUSIONS
PTNS seems to be an effective, minimally invasive option worth trying in patients with idiopathic 
voiding dysfunction. Improvement was seen in objective micturition parameters as well as in 
subjective quality of life data.
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8.1 INTRODUCTION 
The presence of a signiﬁ cant amount of residual urine is indicative of voiding dysfunction and, in 
particular of a weak or acontractile detrusor or of functional or mechanical outlet obstruction. For men 
outlet obstruction due to benign prostatic hyperplasia is the main cause, but sometimes it can be 
due to impaired or absent detrusor contractions. In females, old textbooks used to ascribe retention 
to hysteria. Today the whole concept of voiding dysfunction in women is still not as well deﬁ ned as in 
men. In the absence of overt neuropathy and pathological disorders causing distortion or compression 
of the urethra, retention most commonly occurs following unrelated surgical procedures or childbirth 
[Farrar at el, 1994]. Furthermore, recent neurophysiologic research has revealed a new type of voiding 
dysfunction in young women. Sphincter electromyography has demonstrated an abnormal but 
characteristic activity: sound recordings from the urethral sphincter likened to whales sounds. This 
phenomenon, described as the Fowler syndrome, seemed to be associated with hormonal imbalance 
and polycystic ovaries. The striated urethral muscle ﬁ bres, hormonally sensitive, lose their membrane 
instability, resulting in abnormal activity [Fowler et al., 1994]. 
The inability to empty the bladder completely may result in urinary tract infections or overﬂ ow 
incontinence. Non-surgical treatment options are more or less discouraging. The use of cholinergic 
agents to stimulate detrusor contractions is debatable. Studies demonstrated patients beneﬁ ting 
clinically from treatment with distigmine but without statistically signiﬁ cant changes [Shah et al., 
1983; Tanaka et al., 2001]. Urethral dilation can be performed on empiric grounds, but often the patient 
is left no other option than lifelong clean intermittent catheterisation. Unfortunately, catheterisation 
is at the expense of quality of life. Electrostimulation was brought up as an alternative for therapy-
resistant voiding dysfunction and is preferred to urinary diversion, which may still be required as a 
last resort in some cases. Intravesical electrostimulation, conus implantation according to Nashold, 
and sacral root stimulation (SRS) introduced in the mid 1980s, were revolutionary concepts to regain 
bladder control [Katona et al., 1975; Nashold et al., 1974; Madersbacher et al., 1982; Schmidt et al., 
1979]. Restoring of voiding capability, decreased urinary tract infection rate, and an improved quality 
of life owing to alleviation of the need for clean intermittent catheterisation were found [Shaker et 
al., 1998; Jonas et al., 2001]. Unfortunately implantation is a costly invasive procedure sometimes 
complicated by battery failure, implant infection and electrode migration resulting in a high reoperation 
rate. The performance of intravesical stimulation is time consuming, requiring an intensive bladder 
training programme and external biofeedback to achieve the goal and the presence of experienced 
nurse and adequate facilities [Madersbacher et al., 1990]. Inspired by acupuncture points over the 
tibial and peroneal nerve to overcome bladder overactivity, Mc Guire et al. applied transcutaneous 
electrostimulation over these nerves [Mc Guire et al., 1983]. Stoller proposed PTNS for treatment of 
pelvic ﬂ oor dysfunction [Stoller, 1999]. The aim of this study was to determine the effect of PTNS 
among patients with idiopathic non-obstructive voiding dysfunction.
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8.2 MATERIALS AND METHODS
Between November 1999 and July 2000, 39 consecutive patients with idiopathic non-obstructive 
voiding dysfunction were enrolled in a prospective multicentre clinical trial in the Netherlands 
(Nijmegen and Utrecht, n=19) and in Italy (Rome, n=20). Patients underwent 12 weekly PTNS. 
Deﬁ nitions and criteria
All patients enrolled, failed in achieving complete bladder emptying, and 2 patients had complete 
urinary retention. The symptoms had existed for a minimum of 6 months. The inclusion criteria were 
one or both of the following: complete retention or failure to achieve complete bladder emptying and 
the need for clean intermittent catheterisation. The exclusion criteria were bladder outlet obstruction 
for men (deﬁ ned by the Abrams-Grifﬁ ths nomogram), any urogynaecological, central or peripheral 
neurological disorders, pregnancy, age younger than 18 years and severe cardiopulmonary disease 
[Abrams and Grifﬁ ths, 1979]. Urodynamic investigations consisting of medium-ﬁ ll water cystometry 
and pressure-ﬂ ow studies, were performed at baseline in all patients. The methods, deﬁ nitions and 
units conformed to the standards recommended by the International Continence Society, except 
where speciﬁ cally noted [Abrams et al., 1988]. All patients gave informed consent.
PTNS procedure has been extensively described in previous reports [van Balken, 2001; Klingler et 
al., 2000]. In brief, a percutaneous needle was inserted a few inches above the medial malleolus 
and connected to a low-voltage battery. Stimulation of the posterior tibial nerve gave a typical motor 
(plantair ﬂ exion of digit I or fanning of the toes) and sensory response (a tingling feeling spreading 
from the heel to the sole of the foot). Treatment consisted of 12 weekly sessions of 30 minutes each.
Primary outcome measure, positive response rate and quality of life
Study outcome was based on subjective and objective criteria. Subjective success was deﬁ ned as the 
patients’ positive response resulting in the request for continuing treatment. Objective outcome was 
based on bladder diary data. Patients were asked to complete a single-day chart at baseline and at 12 
weeks of treatment. Parallel to Blaivas’ proposals concerning how to assess efﬁ cacy of neuromodulation, 
a 50% reduction in total catheterised volume per 24h was taken as the primary outcome measure to 
assess objectively PTNS efﬁ cacy [Blaivas, 2001]. Disease-speciﬁ c quality of life and generic functional 
status and well-being (MOS Short-Form 36-items [SF-36]) were assessed at week 0 and at week 12 
[Patrick et al., 1999; Ware et al., 1992]. Higher scores indicated a better quality of life. 
Statistical analysis and predictive factors
The efﬁ cacy of PTNS was analysed for all patients on an intention-to-treat basis. Descriptive data were 
reported as the median values and range, and as mean change with 95% conﬁ dence interval (CI) 
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[Gardner et al., 1986]. Within-group comparisons of results were conducted by the non-parametric 
Wilcoxon signed rank test. Tests were performed on a two-tailed basis and level of signiﬁ cance was 
set at 5%. In order to evaluate whether it is possible to predict subjective success with baseline 
characteristics, we performed univariate and multivariate logistics regression analyses. We believe 
the most relevant outcome measurement is patients’ perception of the PTNS effect on their voiding 
disorder, because despite good improvement in bladder diary data, patients can experience the 
net effect as unsatisfactory and vice versa. Therefore, in these analyses, subjective, not objective, 
success was deﬁ ned as the dependent variable. Odds ratios with their 95% CIs were calculated as a 
measure of the predictive power of each characteristic. Statistical analysis was performed using SPSS 
9.0 software (SPSS, Chicago, USA).
 
8.3 RESULTS
Patient characteristics (table 8.1)
A total of 39 patients (12 men and 27 women; median age 53 years, range 28 to 77) were enrolled 
in this study. The baseline values are summarized in table 8.1. One patient catheterised 400 ml 
once daily, another catheterised aliquots of 74 ml four times daily. Bladder diary data illustrated a 
geographic difference in the baseline parameters and I-Qol scores: Italian patients presented with less 
severe voiding problems, but scored lower on the quality of life questionnaires.
Subjective success
Of the 39 patients,23 (59 %) chose to continue treatment. One patient dropped out of the study after 
six sessions because of aggravation of pre-existing arrhythmia, assumed not to be related to PTNS. 
Bladder diary data and QoL data analysis (See Table 2)
The bladder diary data were completed after 12 weeks by 38 patients (Table 8.2). All patients improved 
signiﬁ cantly in all bladder diary data except for the total voided volume. In contrast to Italian patients, 
the Dutch patients did not achieve signiﬁ cant changes in voiding (eg, mean change in total catheterised 
volume was -350 ml (95% CI: -862; +161) for the Dutch participants and -230 ml (95%CI: -328; -131) 
for Italian patients. The total catheterised volume per 24 hours stagnated in non-responders (median 
volume: 800ml at 0 weeks; 865ml after 12 PTNS sessions); responders improved after the 12 sessions 
(from 515ml to 190ml/24hours). For the patient group as a whole, quality of life parameters improved 
signiﬁ cantly: I-QoL, total SF-36 score and its subdomains of emotional well-being, energy-fatigue and 
change in health (p<0.01-0.05). 
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(% Of patients) All (39) NL (19) Italy (20)
Patient characteristics: Median Range Median Range Median Range
Male/female (n) 12/27 8/11 4/16
Age in years (y) 53 28-77 54 36-77 52 28-75
Duration of symptoms (y) 3 1-36 3 1-36 3 1-17
Current intensity (mA) 4 1.4-7.6 4 1.4-7.6 4.1 2.5-5.7
Treatments prior to PTNS (%): Number Percent Number Percent Number Percent
Medic. for complaints:
- One
- Two
31
19
12
80
49
31
16
12
4
84
63
21
15
7
8
75
35
40
Pelvic ﬂ oor/bladder retraining: 8 21 4 21 4 20
Electrotherapy: 5 13 1 5 4 20
Surgical intervention:
- One
- Two
11
8
3
29
21
8
9
6
3
48
32
16
2
2
10
10
Baseline voiding parameters: Median Range Median Range Median Range
Total catheterised volume 800 210-3000 1350 895-3000 375 210-1080
Mean catheterised volume 241 74-675 300 74-675 188 105-540
Number of catheterisations 2.5 1-10 5 2-10 2 1-4
Total voided volume 1000 95-2700 1050 95-2520 1000 420-2700
Baseline QoL score: Median Range Median Range Median Range
I-QoL 62 26-99 78 34-99 59 26-90
SF-36 65 19-92 57 19-92 65 20-92
Table 8.1:  Medical background and therapies used for urinary symptoms in 39 patients with idiopathic non-obstructive 
voiding dysfunction.
NL: The Netherlands; PTNS : percutaneous posterior tibial nerve stimulation; QOL: quality of life; SF-36: 36-item short form health survey.
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Objective success; descriptive ﬁ gures
In 16 (41%) of the 39 patients the 24hour total catheterised volume was reduced by 50% or more 
(primary outcome measure). Another 10 participants (26%) noticed a 25-50% decrement in their 
residual urine volume. At 12 weeks 7 patients catheterised only once daily. Four of them had residual 
urine below 100ml and another two had no residual urine on bladder diaries. Nobody became catheter 
free.
Factors inﬂ uencing outcome
Univariate logistic regression analysis showed that none of the baseline characteristics proved to be 
a signiﬁ cant predictor for subjective success. This may also be due to the small number of study 
participants. There was some suggestion that certain characteristics can predict outcome to a certain 
extent. For example, for each milliampere increment in stimulation intensity, the chance of subjective 
success decreased by a factor of 0.55 (Odds Ratio OR: 0.55; 95%CI: 0.33-1.0). The analysis further 
suggested that Italian nationality increase change of success (OR: 4.13; CI: 1.06-16.1). In contrast, age 
Week 0 Week 12 Mean change 
(95% CI)
Within-group 
comp:
Bladder diary data: Median Range Median Range MC
(95%CI)
P value
Total catheterised 
volume
800 210-3000 450 0-2450 -228
(-528; -49)
<0.01
Mean catheterised 
volume
241 74-675 163 0-163 -76
(-39; -113)
<0.01
Number of 
catheterisations
2.5 1-10 2 1-7 -0.5
(-0.9; -0.04)
0.024
Total voided volume 1000 95-2700 1260 50-310 +116
(+8; +323)
0.053
Quality of life 
scores:
56 8-91 67 56-86 +6
(+3; +10)
<0.01
I-QoL 62 26-99 86 0-100 +14
(+5; +22)
<0.01
SF-36 65 19-92 70 17-91 +7
(+3; +11)
<0.01
Table 8.2:  Bladder diary data after 12 weekly sessions with PTNS.
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(OR: 0.97;CI: 0.92-1.02), duration of symptoms (OR: 1.09; CI: 0.94-1.25), or the amount of baseline total 
catheterised volume (OR: 1.0; CI: 0.99-1.001) seemed to be of minimal or even no predictive value. 
The analysis was limited to univariate logistic regression because multivariate analysis appeared to 
be not feasible owing to the small number of participants and thus responders. 
Side effects
No serious side effects were reported. Transient pain at the stimulation site was noticed. Diarrhea, 
headaches, calf cramps and low back pain were reported. One patient did not complete the treatment 
because of aggravating pre-existent heart rhythm problems. However these adverse effects were not 
considered to be related to PTNS.
 
8.4 DISCUSSION
Nearly 60 % of the patients considered PTNS successful, and this ﬁ gures was supported by the objective 
criteria derived from the bladder diary data. Nevertheless, the high success rate of 74% reported in 
a recent Sacral Nerve Stimulation (SNS) report was not achieved [Jonas et al., 2001]. A possible 
explanation for this might be that for PTNS, we treated consecutive cases whereas in SNS studies, 
patients were already preselected by strict inclusion criteria such as the pelvic nerve evaluation test. 
The pioneers of intravesical electrostimulation reported promising high success rates. Katona treated 
420 patients with paralyzed bladders, 314 of them regained micturition control. In a rehabilitation 
program of Madersbacher et al., 28 of 30 patients with spinal cord lesions restored bladder function 
and ended up with residual volumes of less than 50 ml [Katona, 1975; Madersbacher et al., 1982]. 
Primus et al. reported 19 (54%) of 35 patients with neurogenic acontractile or hypocontractile bladders 
became catheter free after transurethral bladder stimulation [Primus et al., 1996]. 
PTNS resulted in 15 (39%) of 39 patients with a mean catheterised volume smaller than 100 ml 
(13 patients) or 0 (2 patients). As discussed recently by Blaivas, this parameter should not be 
used as outcome measurement: the mean residual volume can only be interpreted properly when 
catheterisation frequency is given [Blaivas, 2001]. For example, from these 15 subjects with a 
mean residual of 100 ml or less, only 6 reduced their catheterisation rate to once daily. In this study 
nobody became catheterisation free; even the 2 patients that had 0 residual after catheterisation, 
still continued catheterisation, probably to be on the safe side. The primary outcome measurement 
(greater than 50% reduction in 24hour residual volume) was found in 41%. 
PTNS is believed to relieve symptoms due to an overactive and underactive bladder, a phenomenon 
also seen in SNS [Jonas, 2001]. The underlying neurophysiologic mechanisms have not yet 
been elucidated. Remarkably, the results of univariate analysis in this study seem to indicate 
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that application of low current applied over the tibial nerve increases the change of successful 
outcome. This is in contrast to our previous results of PTNS treatment for an overactive bladder in 
which higher stimulation intensity seemed to be more successful. Schultz-Lampel et al. found that 
unilateral S2 low-intensity stimulation in cats induced excitatory effects on the bladder and higher 
intensities produced complete bladder inhibition [Schultz-Lampel et al., 1998]. In their experiment 
they also found frequency-dependent effects; because in our study a ﬁ xed frequency of 20Hz was 
used, such effects could not be evaluated. Low-current intensity selectively activates the largest 
diameter ﬁ bres ﬁ rst and, as stimulus intensity increases, successively smaller diameter ﬁ bres are 
recruited. Stimulus intensity-dependent activation of diverse ﬁ bres together with our statistical 
interpretation could suggest activation of different pathways and their particular action on bladder 
function. Nevertheless because of vagaries in current ﬂ ow owing to inhomogeneous character of each 
nerve, the recruitment of ﬁ bres by size may not always be perfectly related to stimulus intensity. 
Furthermore, actual current values depend on the type of stimulator, pulse characteristics, physical 
environment and type of stimulated nerve [Swett et al., 1981]. The use of thresholds or biological 
effectiveness -such as muscle contraction- to describe the current intensity used to stimulate nerves 
should be recommended, allowing comparisons between research groups. This creates an interesting 
topic for future investigation.
Interestingly, patients reported a more accentuated awareness of a desire to void, supporting the 
hypothesis of an excitatory effect on bladder function by PTNS, a feature also reported in various 
transurethral bladder stimulation studies. The recent work of Athwal et al., suggest that urge to void 
sensations and appreciation of bladder fullness are localised in distinct areas in the brain of healthy 
volunteers [Athwal et al., 2001]. The effect achieved by SNS returns to baseline values after switching 
off the device, as opposed to long-term effect of a few weeks after stimulation by PTNS. The long-term 
effect through PTNS could be explained by the carry-over effect found in cat experiments where a 
5-minute stimulation of afferent nerves resulted in a lasting effect of more than 1 hour [Jiang et al., 
1999]. 
The Italian patients improved more than the Dutch ones, and at ﬁ rst sight it seemed that the less 
severe baseline condition of these participants was of importance. However statistical analysis could 
not reveal one single important baseline characteristic - even the lower total catheterised volume 
at baseline- except for the fact that being Italian increases the change of success. Aside from both 
nationalities belonging to the same European white race: cultural differences may be important for 
subjective bother impact andquality of life scores, but not for objective urinary parameters. 
Before exploring the mechanism of PTNS on voiding disorders, the contribution of placebo-effect in this 
particularly patient group should be quantiﬁ ed. Every therapy has a susceptibility to induce placebo-
effects and certain aspects of PTNS could play an important role: meeting fellow-sufferers, intensive 
guidance and attention by medical care providers, and frequent completion of questionnaires and 
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charts. Therefore, in the future a placebo-controlled PTNS-study is mandatory. Unfortunately certain 
features of PTNS (e.g. electrical stimulation, motor and sensory response and use of needles) make 
the realization difﬁ cult. 
In conclusion, PTNS is an attractive ﬁ rst-line option. It is cheap, minimally invasive and easy to perform. 
However, to date, PTNS is still a young therapy modality requiring additional research to establish 
optimal stimulation parameters and valuable predictive factors.
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OBJECTIVE 
The aim of this study was to evaluate urodynamic changes after PTNS for the treatment of complaints 
related to overactive bladder syndrome and to search for urodynamic-based predictive factors.
SUBJECTS AND METHODS
Ninety consecutive patients with symptoms related to overactive bladder syndrome were enrolled 
in this study. Patients underwent 12 PTNS sessions. For evaluating objective success, the primary 
outcome measure was a reduction in number of urinary leakage episodes of 50% or more per 24 hours. 
Patients’ request for continuation of therapy was considered subjective success. This study focussed 
on urodynamic features at baseline and on changes found after 12 PTNS treatments. 
RESULTS
The objective success rate was 56% (leakages/24hours). Subjective success rate was 64%. Bladder 
diary data and quality of life scores improved signiﬁ cantly (p<0.01). Urodynamic data before and after 
PTNS stimulation, was available from 46 participants. Detrusor overactivity (DO) could be abolished 
in a few cases only. Increments in cystometric bladder capacity and in volume at DO were signiﬁ cant 
(p=0.043 and 0.012 respectively). Subjects without detrusor overactivity at baseline were 1.7 times 
more prone to respond to PTNS (OR: 1.75; 95% CI: 0.67- 4.6). The more the bladder overactivity was 
pronounced, the less these patients were found to respond to PTNS, the area under the ROC curve was 
0.644 (95% CI: 0.48-0.804). 
CONCLUSIONS
PTNS could not abolish DO. PTNS increased cystometric capacity and delayed the onset of DO. 
Cystometry seemed useful to select good candidates: patients without DO or with late DO onset 
showed to be the best candidates for PTNS. 
PTNS | a new treatment option for lower urinary tract dysfunction100
9.1 INTRODUCTION 
Electrostimulation has been exploited both for overactive bladder and for hypocontractile bladder 
alike. Recently, PTNS has been introduced for the treatment of lower urinary tract dysfunction. The 
tibial nerve is a mixed nerve containing L4-S3 ﬁ bres, and originates from the same spinal segments as 
the innervation to the bladder and pelvic ﬂ oor. Therefore, it is not surprising that efforts were made to 
stimulate these ﬁ bres to treat bladder disturbances [Mc Guire et al., 1983; Stoller, 1999; Klingler et al., 
2000; van Balken et al., 2001]. In previous studies, we have discussed extensively subjective success, 
quality of life scores and bladder diary data [van Balken et al., 2001; Vandoninck et al., 2003]  Therefore, 
this article presents the urodynamic features found in patients who underwent PTNS for symptoms 
of overactive bladder syndrome. Three issues will be addressed: First, the primary outcome measures 
based on charts and questionnaires will be described brieﬂ y. Second, the urodynamic changes after 
PTNS treatment will be discussed and lastly, the predictive value of baseline urodynamic parameters 
on treatment outcome will be reported. 
 
9.2 MATERIALS AND METHODS
Between November of 1999 and August of 2001, a total of 90 consecutive patients with a diagnosis of 
overactive bladder syndrome were enrolled in an international multicentre prospective clinical trial in 
ﬁ ve sites in the Netherlands and one site in Italy. Patients underwent 12 sessions of PTNS. Overactive 
bladder syndrome was deﬁ ned as urgency, frequency and/or urge urinary incontinence. For urgency 
and urge incontinence, International Continence Society (ICS) deﬁ nitions were used [Abrams et al., 
2002]. For this study, an increased urinary frequency was deﬁ ned as eight voids or more per 24 
hours. Stress urinary incontinence was excluded through urodynamic investigation.
Inclusion and exclusion criteria as well as the PTNS technique have been extensively described in a 
previous study [van Balken et al., 2001]. In short, the procedure was as follows: the posterior tibial 
nerve was located through percutaneous insertion of a needle a few inches above the medial malleolus. 
After connection to a low voltage stimulator (Cystomedix, Anoka, Minnesota, USA) and placement of a 
ground surface electrode on the ipsilateral calcaneus, the tibial nerve was stimulated. This resulted in 
a tickling sensation in the sole of the foot and ﬂ exion of the toes. 
Following the consideration of Blaivas on how to assess new treatment modalities, the subsequent 
parameters were evaluated: the number of leakage episodes, the amount of urine loss, urinary 
frequency, and subjective patient assessment [Blaivas, 2001]. A reduction in the number of 
leakage episodes of at least 50% on 24hour bladder diaries was taken as primary outcome measure. 
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Furthermore, a reduction in leakage severity of at least 50% was a secondary outcome measure 
(scale score 1: some drops; 2: small amount; 3: severe urine loss necessitating change of clothing). 
A reduction in urinary frequency was regarded clinically signiﬁ cant when a normal voiding pattern 
of less than 8 voids per 24h could be obtained. Patients’ request for continuation of treatment was 
regarded a subjective success and these patients were called “positive responders”. In addition, 
quality of life was determined at week 0 and at week 12. For incontinence speciﬁ c Quality of life the 
I-QoL was used [Patrick et al., 1999]. For the estimation of generic functional status and well-being, 
the MOS 36-items Short-Form health survey (SF-36) was completed [Ware et al., 1992]. Higher scores 
indicate better quality of life. All patients gave their informed consent.
Both at baseline and after 12 sessions, urodynamic investigations were performed in all patients. For 
urodynamic analysis a standard transurethral subtraction cystometry was performed in the supine 
position. Sterile saline at room temperature was infused through a double-lumen 8-French catheter at 
a ﬁ lling rate of 50 ml/min. The volume at which detrusor overactivity (DO) occurred was noted. DO was 
deﬁ ned as an increase of 15 cm water pressure or of lower amplitude if accompanied with a distinct 
sensation of urgency. Methods, deﬁ nitions and units conform to the standards recommended by the 
International Continence Society, except where speciﬁ cally noted [Abrams et al., 2002].
Descriptive data were reported as median values and range and with a median change and range. 
Within-group comparisons of results were conducted by the non-parametric Wilcoxon signed ranks 
test. Tests were performed on a two-tailed basis and level of signiﬁ cance was set at 5%. To evaluate 
whether it is possible to predict subjective success with urodynamic characteristics, we performed 
univariate and multivariate logistics regression analyses. The dependent variable was “subjective 
success” because this feature is the clinically most relevant outcome measure: despite good 
improvement in bladder diary data, a patient can experience the net effect as unsatisfactory and vice 
versa. Odds ratios (OR) with their 95% conﬁ dence intervals (95% CI) were calculated as a measure 
for the predictive power of each characteristic. Based on the outcome of the multivariate analyses, 
a Receiver Operating Characteristic (ROC) curve was constructed to visualize the predictive power 
of the combination of the variables. The area under the ROC curve quantiﬁ ed this predictive power. 
Statistical analysis was performed using SPSS 9.0 software (SPSS, Chicago, USA).
 
9.3 RESULTS
Baseline characteristics
90 patients (67 females and 23 males) with a median age of 51 years (range, 19-82 years) were 
enrolled in this study (See Table 9.1). Duration of symptoms ranged between 1 and 56 years with a 
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median of 4.5 years. A total of 80 of 90 bladder diaries were completed correctly and used for further 
analysis (10 of 90: 11% missing values). 60 of  80 (75%) of these patients were incontinent and 
leaked at least once a day.  From those patient who ﬁ lled in correctly the bladder diaries, 73 of 80 
(91%) patients had an increased urinary frequency at baseline and 7 of 80 (9%) had a normal voiding 
frequency of less than eight voids per 24 hours. 81 I-QoL and 82 SF-36 surveys were found suitable 
for further examination. At baseline, 82 urodynamic reports were suitable for evaluation. DO occurred 
in 48 of 82 (59%) patients. 
Parameter M N Baseline N End Change p value
24h bladder diary:
Leakages 30 60 5 (1;19) 59 2 (0;16) -3 (-19;+7) <0.01
Incontinence severity 30 60 2 (1;3) 58 1 (0;3) -1 (-3;+1) <0.01
Urinary frequency 10 80 13 (4;41) 75 10 (4;53) -3 (-18;+12) <0.001
Mean Voided Volume 11 79 135 
(20;327)
74 191 (47;410) +27 (-96;+200) <0.001
Quality of life scores:
I-QoL 9 81 49 
(20;100)
80 67 (20;100) +10 (-31;+88) <0.001
SF-36 11 79 57(10;93) 82 67 (13;93) +4 (-42;+56) <0.001
Cystometric data:
Cystometric capacity 7 82 263 
(30;745)
Subjects with DO 42 48 59%
Volume DO 42 48 150 
(30;350)
Pdet DO 42 48 41 (4;123)
   M: missing values at baseline because not complete or not relevant; N: number of valid values; Pdet DO: Detrusor pressure at DO. Data represent mean 
values with ranges in parantheses. Wilcoxon signed ranks test, signiﬁ cance level set at 5%.
Table 9.1:  24hour bladder diary data, urodynamic data and quality of life scores in 90 patients receiving 12 PTNS 
sessions for overactive bladder complaints.
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Evaluation after 12 PTNS sessions
Reduction in leakage episodes, severity of urine loss and urinary frequency
After 12 PTNS treatments 78 complete bladder diaries were available for evaluation (12 of 90:13% 
missing values). All parameters improved signiﬁ cantly (see Table 10.1). At baseline 75% of the subjects 
with daily incontinence was reduced to 44% (35 of 80) of subjects after 12 PTNS (35 of 78 incontinent; 
43 of 78 not incontinent, 12 of 90 missing values). End evaluation considered 23 of 60 (38%) patients 
dry, that is cured. However, four of these wished to discontinue treatment. An additional 11 of 60 
(18%) incontinent subjects achieved at least 50% reduction in the number of leakage episodes. This 
evidence resulted in a success rate of 56% (primary outcome measure). In positive responders 
a median reduction of 100% (+50; -100) was found whereas non-responders obtained a median 
reduction of 33% (+77; -100%). An at least 50% reduction in incontinence severity was found in 31 
of 60 (52%) subjects. Positive responders and non-responders achieved a median reduction of 100% 
and 23%, respectively. At baseline 7 of 80 (9%) had a normal voiding frequency of less than 8 voids 
per day, 12 subjects voided 8 to 10 times a day (15%). After 12 PTNS sessions 20 of 80 (25 %) subjects 
achieved a voiding frequency of less than 8 times (primary outcome measure) and another 25 voided 
8 to 10 times (31%) 
Patients’ assessment: subjective response and quality of life scores
58 out of 90 (64%) patients requested continuation of the therapy. I-QoL and SF-36 scores improved 
signiﬁ cantly as shown in Table 9.1.
Urodynamic proﬁ les
In only 46 patients, urodynamic investigations were performed at baseline and after 12 PTNS 
sessions. Therefore, post-PTNS treatment urodynamic ﬁ ndings are based on data of 46 participants 
only (36 females, 10 males; median age, 51). Comparable subjective success rates in this subgroup 
were found: 32 of 46 (70%) vs. 58 of 90 (64%), this ﬁ nding reduces the possible bias of having only 
successful patients undergoing a second urodynamic investigation. Baseline and end evaluation 
data are summarized in Table 10.2: a signiﬁ cant increment was seen in cystometric bladder capacity 
and in volume at which ﬁ rst detrusor overactivity  occurred. At baseline DOs were noted in 34 of 
46 participants (74%), 31 subjects continued to have DO, however these overactivities occurred at 
larger bladder volumes. In three patients, DO was eliminated, in three others de novo DO was noticed. 
Detrusor pressures recorded during the detrusor contractions decreased only slightly. 
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Inﬂ uencing factors on outcome
Taking the small number of participants into account (n=82, though in only 48 patients the features of 
DO could be analysed) analysis of potential predictive factors among baseline characteristics revealed 
one strong prognostic factor: subjects having DO at baseline (n=48) were less likely to respond to 
PTNS. A stable bladder enhanced the chance for a successful outcome of the PTNS therapy by 1.75 
times (OR: 1.75; 95%CI: 0.669-4.57). 
Univariate logistic regression analysis showed that none of the baseline characteristics (cystometric 
capacity, volume at DO, detrusor pressure at DO) proved to be a signiﬁ cant predictor for subjective 
success. This ﬁ nding may also be due to the small number of participants with overactive detrusor 
(n=48) There was some suggestion that the volume at DO, can predict outcome to a certain extent. 
For example, for each 100ml “delay in DO onset”, chance for success increased 1.5 times (OR: 1.0043; 
Parameter Baseline End Change p value Change in 
responders
n=32/46 (70%)
p value
24h bladder diary:
Leakages 4 (1;19) 3 (1;16) -2 (-19;+7) 0.001 -2(-19;+2) <0.01
Severity of leakages 2 (1;3) 1.85 (1;3) -1(-3;+1) <0.001 -1 (-3;+1) <0.01
Urinary frequency 13 (4;32) 9 (5;19) -3(-18;+8) <0.001 -3 (-18;+8) <0.01
Mean Voided Volume 135 (28;275) 205 (76;300) +50(-
50;+200)
<0.001 +62 (-50;+200) 0.001
Quality of life scores:
I-QoL 39 (22;94) 66(20;100) +9(-19;+88) <0.001 +19(-14;+88) <0.01
SF-36 54 (17;93) 64 (19;89) +5 (-42;+55) 0.003 +6 (-18;+56) <0.01
Cystometric data:
Cystometric Capacity 243 (30;745) 340 (70;500) +30 (-
324;+450)
0.043 +36 (-324;+450) 0.14
Subjects with DO 34/46 (70%) 34/46 (70%) 23/32 (72%)
Volume  DO 133 
(30;350)
 210 (50;375) +60 (-
183;+333)
0.012 +115(-
183;+333)
0.031
Pdet DO 35 (4-120) 41 (10-93) -5 (-63; 74) 0.67 -6.5(-46;+64) 0.69
Table 9.2: 24hour bladder diary data, urodynamic data and quality of life scores in 46 patients receiving 12 PTNS 
sessions for overactive bladder complaints.
Pdet DO: Detrusor pressure at DO; data represent mean values with ranges in parantheses. Wilcoxon signed ranks test, signiﬁ cance level set at 5%.
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95% CI 0.997, 1.012). However the three baseline characteristics showed no statistical signiﬁ cance, a 
multivariate analysis combining these three factors revealed a predictive power of 0.64 (OR: 0.644; 
95% CI 0.484, 0.804) (Figure 10.1) Also a slight tendency was seen that could support the idea that 
stronger stimulation inhibit detrusor overactivity: a participant having a 5 mA higher mean stimulation 
intensity had 1.8 times more change for success (OR: 1.13; 95% CI: 0.81; 1.6).  
9.4 DISCUSSION
The primary outcome measures that were taken to assess PTNS, were obtained in 56% of the patients 
with urinary leakage at baseline; 38% of them showed bladder diaries without any leakages, 52% of 
the patients noticed signiﬁ cant reduction in urine loss. Only 25% of all participants achieved a normal 
micturition pattern (less than 8 voids/24 hours). Patients treated by PTNS seem to regain their control 
on involuntary urine loss, but achievement of a normal micturition pattern is hardly feasible in most 
of them. Additionally, patients’ assessment was determined through QoL questionnaires (p<0.001) 
and the number of requests to continue the treatment (64%). All together, it seems that PTNS can 
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Figure 9.1: Receiver Operating Characteristic (ROC) curve constructed in order to visualize the predictive power of 
the combination of three variables (cystometric capacity, volume at DO, detrusor pressure at DO) of 46 patients with 
overactive bladder treated with 12 PTNS sessions.
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be considered as a new treatment modality that can be offered to patients with intractable OAB 
symptoms; nearly 60% of such patients will beneﬁ t from PTNS.
This study was mentioned to detect the impact of PTNS by looking to these patients in a more objective 
way, namely by determining urodynamic changes. Examination of 46 patients with overactive 
bladder syndrome who underwent 12 PTNS sessions, revealed signiﬁ cant urodynamic changes, 
namely increment of total bladder capacity and volume at DO. For positive responders, the increment 
in cystometric capacity was not signiﬁ cant, this could be due to the rather large baseline capacity 
positive responders already had, which only increased slightly. Non-responders started with a median 
baseline capacity of 155ml (range: 77-550) and ended up with a capacity of 250ml (range: 70-500). 
For positive responders this change was 300ml (range 30-745) at week 0 and 340 ml (range: 103-
500) after 12 PTNS sessions. These ﬁ gures strongly suggest that patients with small cystometric 
capacity were more prone to fail. Even though the cystometric capacity of non-responders increased, 
the resultant capacity seemed of small clinical value for this group as they chose not to continue with 
PTNS. Remarkably, logistic regression analysis could not point out baseline capacity as a prognostic 
factor for success (OR: 1.0008; 95%CI: 0.998-1.004). The patient group that underwent pre- and 
posturodynamic evaluation contained more patients with an overactive detrusor than the baseline 
group did. The reason for this ﬁ nding can be sought in the fact that mainly academic centres that 
participated received more second opinion patients often with intractable OAB with DO. Investigating 
the DO features revealed a signiﬁ cant delay in onset of DO. The clinical relevance of 60 ml increment in 
volume at which the ﬁ rst DO occurs seems perhaps questionable, but assuming a physiological ﬁ lling 
rate of 1 mL/min, such an increment would delay the onset of urge or urge incontinence provoked 
by the DO, with nearly one hour or in case of responders (+115ml) with nearly two hours [Klevmark, 
1999]! The reductions found in detrusor pressures during involuntary contractions were of minor 
size and presumable of minor clinical relevance. Furthermore, repetitive PTNS could not substantially 
decrease the number of subjects in whom detrusor overactivities were detected. Disappearance of DO 
was only seen in 3 of 90 patients. This rate is in contrast with Klingler et al., reporting an elimination of 
DO in 77% of the cases after 12 sessions of PTNS [Klingler et al., 2000]. It is questionable how relevant 
the ﬁ nding of persistent DO is in evaluating therapeutic effects of neuromodulation. In fact, many 
neuromodulation studies reported failures to suppress DO [Philp et al., 1988; Geirsson et al., 1993; 
Hasan et al., 1996; Groen,  et al., 2001]. Nevertheless, the presence of DO at baseline was found to be 
a strong predictive factor for therapeutic failure, especially when it occured early in the ﬁ lling phase. 
So, OAB complaints without DO were more prone to respond well to PTNS. In conclusion, it seems 
advisable to include only those patients without DO, or those with late onset DO.
A common remark questions how intermittent stimulation in PTNS possibly can succeed, compared 
with the continuous stimulation patients receive when a sacral root neuromodulator is implanted. 
The inhibitory and long-lasting effect through PTNS can be explained by experiments performed in 
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Macaca monkeys. It was shown that repetitive tibial nerve stimulation powerfully inhibits nociceptive 
spinothalimic tract cells through Aδ ﬁ bres, provided a high enough intensity was applied [Chung et 
al., 1984]. This inhibition was thought to act on a spinal level. Although these experiments were not 
focused on the complex micturition system, extrapolation of these ﬁ ndings to voiding dysfunction 
can be made. Hypothetically, repetitive PTNS inhibits pathologic afferent information from the bladder 
to supraspinal levels, resulting in a decreased awareness of pathological sensations (less urge) 
and delayed onset of DO. Similar studies on these spinothalmic cells, demonstrated long-lasting 
inhibition for 30 minutes. Inhibition occurred more powerfully as stimulation intensity increased 
[Chung et al., 1984]. This can explain a carry-over effect found upon intermittent stimulation. To our 
knowledge, no research have been performed investigating how long this inhibition occurs in human, 
or how strongly this nerve has to be stimulated. Determination of the exact intensity applied through 
PTNS stimulation is difﬁ cult because of the inhomogeneous character of each nerve, recruitment of 
ﬁ bres by size, physical environment and type of stimulated nerve [Swett et al., 1981]. A stronger 
stimulation will surely be more effective as has been already proved in human experiments using 
supramaximal stimulation in spinal cord patients [Sheriff et al., 1996]. Also, this study provided some 
evidence for better therapy outcome in those patients in whom stronger stimulation currents were 
used. Even though the real stimulation intensity that reached the tibial nerve remains unknown, a 
slight tendency was seen that could support the former ideas: a participant receiving a 5 mA higher 
mean stimulation intensity, had 1.8 times more change for success. Unfortunately, application of 
higher current intensity through percutaneous needling is hardly feasible in individuals with intact 
sensation. Finding a more adequate way to stimulate the posterior tibial nerve, with better placement 
of the electrode and controlled applied intensity should be aimed and searched for. 
Many factors seem to inﬂ uence the outcome of PTNS. Presumably, complex interaction of several 
factors, such as bladder retraining by frequently completed bladder diaries, release of enkephalines 
or other neurotransmitters through needling, decreased c-fos expression by tibial nerve stimulation 
and attribution of some placebo-effect, will play an important role and ﬁ nally add up resulting in a 
successful outcome. The urodynamic results refute, however, the possibility of a placebo-effect being 
the only explanation for the positive results found in this study.
 
9.5 CONCLUSIONS
PTNS sessions could not eliminate DO but resulted in increased bladder capacity and delayed onset of 
DO to such an extent that the patients experienced a clinical relevant decrease in leakage episodes, 
severity of incontinence and voiding frequency. The latter parameters can all be calculated from 
bladder diary data. Therefore, the value of urodynamic investigations to evaluate therapeutic effect of 
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neuromodulation is debatable. On the other hand, predictive factors related to cystometric parameters 
were found: patients with OAB but without DO are good candidates for PTNS treatment. When DO is 
present, it seems advisable to exclude those patients with severe forms of detrusor overactivity (i.e. 
early onset of DO) from PTNS treatment. In view of the facts that PTNS is an inexpensive treatment 
modality that is minimally invasive and simple to perform, it is an attractive ﬁ rst-line option for 
patients with overactive bladder syndrome before proceeding towards surgical interventions such as 
bladder augmentation or replacement. PTNS is a young therapy requiring further research, analysing 
predictive factors and optimal stimulation parameters.
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OBJECTIVE 
To determine urodynamic changes and predictive factors in patients with voiding dysfunction who 
underwent 12 percutaneous tibial nerve stimulations (PTNS).  
SUBJECTS AND METHODS
39 patients with chronic voiding dysfunction were enrolled in a prospective multicentre trial in the 
Netherlands (n=19) and in Italy (n=20). A 50% reduction in total catheterised volume per 24 h was 
taken as a primary objective outcome measure. Patients’ request for continuation of treatment 
was regarded as subjective success. Objective urodynamic parameters and bladder indices were 
determined. Odds ratios and their 95% conﬁ dence interval were computed as a measure for predictive 
power in order to reveal predictive factors (Pdet at Qmax, Qmax, BE, and BCI).
RESULTS
Primary outcome measure was obtained in 41%, an additional 26% reduced their 24h residual volume 
with more than 25%. 59% of patients chose to continue treatment. Detrusor pressure at maximal ﬂ ow, 
cystometric residual volumes and bladder indices improved signiﬁ cantly for all patients (p<0.05). 
Patients with minor voiding dysfunction were more prone to notice success (Odds ratio: 0.73; 95% CI: 
0.51-0.94).
CONCLUSIONS
PTNS is a young treatment modality, minimal invasive and easy accessible. It might be an attractive 
ﬁ rst line option for patients with (minor) voiding dysfunction. 
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10.1 INTRODUCTION
Voiding dysfunction can be caused by neurological disorders, post-surgical conditions, infravesical 
obstruction, bladder overdistension, inﬂ ammation, drugs, psychogenic factors, learned voiding 
dysfunction, detrusor myopathy and urethral sphincter dysfunction [Dorﬂ inger et al., 2001]. 
Therapeutic lower urinary tract rehabilitation includes pelvic ﬂ oor training, biofeedback, behavioural 
modiﬁ cation, catheterisation, electrical stimulation or bladder expression and bladder reﬂ ex triggering 
in case of neurogenic disorders [Abrams et al., 2002]. Patients might beneﬁ t clinically from cholinergic 
agents [Shah et al., 1983; Tanaka et al., 2001]. Other treatment modalities are urethral dilatation, 
insertion of intraurethral device or desobstructive surgery. Often clean intermittent self-catheterisation 
is the most effective therapy for chronic bladder emptying problems. Unfortunately catheterisation is 
at the expense of patients’ quality of life. During the last decades neuromodulation has gained interest 
as an alternative treatment for difﬁ cult to treat voiding dysfunction before proceeding towards more 
invasive surgical procedures. One of the newest modalities is percutaneous  tibial nerve stimulation 
(PTNS). The posterior tibial nerve is a mixed nerve containing L4-S3 ﬁ bres, originating from the same 
spinal segments as the parasympatic innervation to the bladder. The ﬁ rst results of PTNS for patients 
with voiding dysfunction were already extensively reported in previous papers [van Balken et al., 
2001; Vandoninck et al., 2003]. This paper focuses on urodynamic changes found in these patients 
and on determination of urodynamic predictive factors.
 
10.2 MATERIALS AND METHODS
Between November of 1999 and July of 2000, 39 consecutive patients with idiopathic non-obstructive 
voiding dysfunction were enrolled in an international prospective multicentre clinical trial in the 
Netherlands (n=19) and Italy (n=20). Patients underwent 12 weekly percutaneous stimulations of 
the posterior tibial nerve. 
Deﬁ nition and criteria
Idiopathic non-obstructive voiding dysfunction: all patients with abnormal detrusor function (detrusor 
underactivity or acontractile detrusor and postvoidal residual PVR) conform the deﬁ nitions from the 
standardisation report 2002 [Abrams et al.; 2002]. Prior to the study, all patients failed in achieving 
complete bladder emptying, two of them had complete urinary retention and thus all patients 
catheterised.
In all patients extensive medical history was taken focussing on urinary symptoms, previous and 
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present treatments, neurological disease and medications. Physical examination was done to rule 
out any relevant pathology such as urogynaecological or neurological abnormalities. Symptoms 
existed for a minimum of 6 months. Exclusion criteria were bladder outlet obstruction related to 
benign prostatic hyperplasia (using the Abrams-Grifﬁ ths nomogram), any urogynaecological, central 
or peripheral neurological disorders, including dysfunctional voiding due to pelvic ﬂ oor overactivity, 
pregnancy, age under 18 and severe cardiopulmonary disease. PTNS procedure was extensively 
described in a previous paper [van Balken et al., 2001]. In short, through percutaneous needling the 
posterior tibial nerve was stimulated above the medial malleolus. After connection to a low voltage 
stimulator (CystoMedix, Anoka, Minnesota, USA) and a ground electrode, this nerve was electrically 
stimulated which resulted in a sensory response (tickling sensation in the sole of the foot) and a 
typical motor response (plantair ﬂ exion of digit I or fanning of all toes). Treatment consisted of 12 
weekly sessions of 30 minutes each. All patients gave their informed consent.
Primary Outcome Measure, Positive Response Rate, and quality of life
In line with Blaivas’ proposals concerning how to assess efﬁ cacy of neuromodulation, 50% reduction 
in total catheterised volume per 24h was taken as primary objective outcome measure. Additionally 
the positive response rate and quality of life scores displayed patients’ assessment [Blaivas, 2001]. 
Request for continuation of treatment was regarded a subjective success and these patients were 
called “positive responders”. Quality of life scores were determined at week 0 and at week 12. For 
incontinence speciﬁ c quality of life the I-QoL was used [Patrick et al., 1999]. For the estimation of 
generic functional status and well-being, the MOS 36 items Short-Form health survey (SF-36) was 
completed [Ware et al., 1992]. Higher scores indicate better quality of life. 
Urodynamic data
Objective assessment of the efﬁ cacy of PTNS was done through urodynamic investigation and 
through calculating bladder indices. At baseline and after 12 PTNS sessions, a standard transurethral 
subtraction cystometry was performed in the supine position whereas the pressure ﬂ ow study was 
carried out in the sitting position. Sterile saline at room temperature was infused through a double 
lumen 8 F catheter at a ﬁ lling rate of 50 ml/min. The volume at which detrusor overactivities (DO) 
occurred was noted. DO was deﬁ ned as an increase of 15 cm water pressure or of lower amplitude 
if accompanied with a distinct sensation of urgency. Methods, deﬁ nitions and units conform to the 
standards recommended by the International Continence Society, except where speciﬁ cally noted 
[Abrams et al., 2002]. 
Bladder indices based on bladder diaries and urodynamics
An effort to measure bladder contractility and voiding efﬁ cacy was made. Bladder Contractility Index 
Chapter 10 | Posterior tibial nerve stimulation in the treatment
of voiding dysfunction: urodynamic data
115
(BCI) was derived from the formula:  BCI = Pdet x Qmax  +  5 x Qmax; such that a strong bladder 
contractility is a BCI of >150, normal contractility a BCI of 100-150 and a weak contractility a BCI of 
< 100 [Abrams et al., 1999]. BCI was thus calculated from the urodynamic measurements. Bladder 
voiding efﬁ ciency (BVE) reﬂ ects bladder contractility against urethral resistance and is measured 
according to the degree of bladder emptying: BVE = 100 x (voided volume /total bladder capacity). 
Total bladder capacity is deﬁ ned as the summation of voided volume and postvoidal residual volume 
[Abrams et al., 1999]. BVE was computed both from urodynamic and bladder diary data. Both bladder 
indices were determined at baseline and at week 12.
Statistical analysis and predictive factors
Efﬁ cacy of PTNS was analysed for all patients on an intention-to-treat basis. Descriptive data were 
reported as median values and range, and as mean change with 95% conﬁ dence interval (CI) [Gardner 
and Altman, 1986]. Within-group comparisons of results were conducted by the non-parametric 
Wilcoxon signed rank test. Tests were performed on a two-tailed basis and level of signiﬁ cance was 
set at 5%. In order to evaluate whether it is possible to predict subjective success with baseline 
characteristics we performed univariate and multivariate logistics regression analyses. In our 
opinion, the clinically most relevant outcome measurement is patients’ perception of the PTNS effect 
on their voiding disorder: despite good improvement in bladder diary data, patients can experience 
the net effect as unsatisfactory and vice versa. Odds ratios with their 95% conﬁ dence intervals (CI) 
were calculated as a measure for the predictive power of each characteristic. Statistical analysis was 
performed using SPSS 9.0 software (SPSS, Chicago, USA).
 
10.3 RESULTS
Patient characteristics
39 patients (12 men, 27 women) with a median age 53 years (range: 28-77) were enrolled in this 
study. Patients’ baseline characteristics and their medical history are summarized in Table 10.1. At 
baseline, one patient had a mean of 74 ml residual, catheterising four times a day on bladder diary 
data. All others had a mean residuals larger than 100 ml.
Primary outcome measure:  more than 50% decrement in 24h total catheterised volume
Bladder diary data were completed after 12 weeks by 38 patients. All patients improved signiﬁ cantly 
in all bladder diary data (See table 10.2). In 16 of 39 (41%) patients’ 24h total catheterised volume 
reduced with 50% or more (= primary outcome measure). Another 10 of 39 (26%) participants noticed 
a 25-50% decrement of their residuals. Thus, 26 (67%) patients noticed a reduction of 25% or more 
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in 24h total catheterised volume. A tendency to increment of the total voided volume was found 
(p=0.053). PTNS resulted in 15 of 39 patients with a mean catheterised volume smaller than 100 ml 
(13 patients) or zero (2 patients). Nobody became catheterisation free, even the two patients that had 
zero residual after catheterisation, still continued catheterising themselves once a day.
Subjective success:  positive responders
23 out of 30 patients (59 %) chose to continue treatment. In 13 out of these 23 patients the primary 
(% of patients) All (39)
Patients characteristics: Median Range
Male/female 12/27
Age in years (y) 53 28-77
duration of symptoms (y) 3 1-36
Current intensity (mA) 4 1.4-7.6
Treatments prior to PTNS (%): Number Percent
Medication  for complaints:
-One
-Two
311912 804931
Pelvic ﬂ oor/bladder retraining: 8 21
Electrotherapy: 5 13
Surgical intervention: 
-One 
-Two
1183 29218
Baseline voiding parameters: Median Range
Total catheterised volume 800 210-3000
Mean catheterised volume 241 74-675
Number of catheterisations 2.5 1-10
Total voided volume 1000 95-2700
Bladder Contractility Index 63 37-160
Bladder Voiding Efﬁ ciency (uds) 64 40-96
Bladder Voiding Efﬁ ciency (Bladder diary) 56 8-91
Baseline QoL score: Median Range
I-QoL 62 26-99
SF-36 65 19-92
Table 10.1: Medical background and therapies used for urinary symptoms in 39 
patients with idiopathic non-obstructive  voiding dysfunction.
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outcome measure (more than 50% reduction) was obtained, another eight subjects noticed a 
reduction of their 24h residual volume with more than 25%. For non-responders (n=16) the primary 
outcome measure was obtained in only two patients: two patients had more than 50% reduction in 24h 
catheterised volume and another two revealed more than 25% reduced residual volume. From these 
four patients, one patient stopped because of personal reasons, though she had nearly zero residuals. 
The other three persons noticed a good decrease in total amount of catheterised volume but they still 
had the same catheterisation rate and were thus not satisﬁ ed (e.g., from 5 x 340 to 4 x 220ml). One 
patient dropped out of the study after six sessions because of aggravation of pre-existing cardiac 
arrhythmia, assumed not to be related to PTNS.
Urodynamic data (See Table 10.3)  
At baseline 37 urodynamic investigations were performed (60% of these patients wanted to continue 
treatment: positive responders), after 12 PTNS sessions 27 patients (63 % positive responders) 
underwent a cystometry and pressure ﬂ ow study. Patients‘ cystometric capacity remained the same, 
detrusor pressure at maximal ﬂ ow increased signiﬁ cantly and a decrement in patient’s residual 
volume after the pressure ﬂ ow study was seen. Urodynamic examination revealed ﬁ ve patients 
(5 out of 39, 14%) with detrusor overactivity at baseline. After 12 treatment sessions involuntary 
detrusor contractions were seen in 3 participants, DO disappeared in two subjects and seven patients 
developed de novo DO. Added up, 10 participants had DO after 12 PTNS sessions (10 out of 27= 37%). 
Eight out of these 10 patients requested continuation of PTNS, mostly with a 2–3 weekly interval. 
Week 0 Week 12 Median change Statistics
diary data: N Median Range N Median Range N Median Range p value
Tot CV(ml) 37 800 210-3000 38 450 0-2450 37 -200 -2700; +700 <0.01
Mean CV(ml) 38 241 74-675 38 163 0-163 38 -80 -375; 247 <0.01
No of cath. 38 2.5 1-10 38 2 1-7 38 0 -7; 2 0.024
Tot VV (ml) 37 1000 95-2700 36 1260 50-310 36 275 -500; 1720 0.053
BVE 37 64 40-96 38 77 0-100 37 9.5 -38; 78 <0.01
Quality of life:
I-QoL 39 62 26; 99 39 86 29; 100 39 11 -2; 60 <0.01
SF-36 39 65 19; -92 38 70 17; 91 38 3 -18; 50 <0.01
Table 10.2: Bladder diary data and quality of life results after 12 weekly sessions with PTNS, median (range) and 
median change 
Tot CV: total catheterised volume; Mean CV: mean catheterised volume, Tot VV: total voided volume
BCI: Bladder Contractility Index. BCI<100: weak detrusor, 100-150: normal, >150: strong contractility.
BVE: Bladder voiding efﬁ cacy index based on the bladder diary data.
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Their total catheterised volume decreased with a mean of 51% (range: -26%, -87%). 
Bladder indices based on bladder diaries
Bladder voiding efﬁ cacy (BVE) increased signiﬁ cantly with a median change of +9.5% (range: -38; 
+78%). For responders this was +18.2% (range: -16; +78%).
Bladder indices based on urodynamic data
The urodynamically based BVE improved in a similar way (median change: +6%, range:  –9; +18%). 
Week 0 Week 12 Median change Statistics
N Median Range N Median Range N Median 
change
range p value
CC 37 500 165; 835 27 500 149; 800 27 0 -225; 300 0.930
P DI 5 37 16; 60 10 26.5 10; 48 3 1 -2; 3 0.59
VDI 5 150 50; 450 10 245 175; 480 3 70 -30; 130 0.29
P detr at 
Qmax
27 25 10; 70 24 33 10; 83 21 8 -5; 68 <0.01
Qmax 25 7 2; 27 25 10 4; 29 20 1 -12; 13 0.13
Residual V 31 270 35; 755 19 220 50; 450 19 -80 -280; 100 0.01
BCI 26 63 37; 160 25 83 5; 178 20 20 -52; 70 <0.01
BVE 31 56 8; 91 19 67 56; 86 19 6 -8.8; 18.1 <0.01
For subjective responders:
CC 22 500 165; 835 17 500 149; 650 17 0 -225;300 0.9
Pdet at Q 
max
16 25 10; 70 16 34 15; 59 13 8 -5; 31 <0.01
Qmax 16 8.5 2; 16 16 10 4; 29 13 1 -4; 13 0.1
Residual 
Volume
18 285 80; 755 9 130 50; 400 9 -100 -200; 10 0.01
BCI 16 65 37; 120 16 85 55; 178 9 11 -1.5; 18.1 <0.01
BVE 18 62.5 40; 83 9 73 60; 86 13 20 -15; 70 0.011
Table 10.3: Urodynamic results after 12 weekly sessions with PTNS, median (range) and median change (range) in 39 
patients with idiopathic non-obstructive  voiding dysfunction.
CC: Cystometric Capacity in ml
P DI: Pressure of Detrusor Instability in cm H2O
V DI: Volume at ﬁ rst Detrusor Instability in ml
Pdetr at Q max: Detrusor pressure at maximal Flow in cm H2O
Q max: Maximal Flow in ml/sec
Residual V: Residual Volume in ml
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Responders noticed a median percentage increase of +11% (range: -8; +18%). Baseline BVE was not 
different among responders (median BVE: 62; range: 40-83) and non-responders (median BVE: 64; 
range: 50-96) (p=0.6). The BCI rose with 20 points (range: -52, + 70) for all patients. Responders 
revealed an addition of 20 points (range: -15; +70) whereas non-responders noticed a median 
improvement of 15 points (range: -52; +25). At baseline 23 patients had a weak (BCI >100), two a 
normal (BCI 100-150) and one participant had a strong detrusor contractility (BCI >150). After 12 
PTNS sessions this was respectively seen in 20, 3 and 2 patients. The median baseline BCI score was 
not signiﬁ cantly different between responders (median BCI: 65; range: 37-120) and non-responders 
(median BCI: 59; range: 40-160) (p=0.8). 
Predictive factors
Univariate logistic regressions analysis showed that none of the baseline urodynamic characteristics 
or bladder indices proved to be a signiﬁ cant predictor for subjective success. This may be due to the 
small number of study participants. There was some suggestion that certain characteristics can 
predict outcome to a certain extent. For example, for each 10 cm water increment in baseline detrusor 
pressure at maximal ﬂ ow rate, the chance of subjective success increased with a factor 1.3 (Odds 
Ratio OR: 1.028; 95%CI: 0.977-1.083). Per 10 ml/sec increments in maximal ﬂ ow rate, the change for 
success increased with 1.7 (OR: 0.947 95%CI: 0.804; 1.112). A 30% higher baseline BVE score was 
found to result in 1.7 times more change for patients to notice success. A multivariate analysis 
combining four urodynamic factors (maximal detrusor pressure, maximal ﬂ ow rate, BVE and BCI) 
revealed a predictive power of 0.73 (OR: 0.73; 95% CI 0.51, 0.94) (See Figure 10.1). 
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Table 10.4: Univariable logistic regression analyses of  baseline characteristics to calculate predictive value for 
subjective success in 39 patients with non-obstructive voiding dysfunction treated with 12 weekly PTNS sessions. 
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Side effects
No serious side effects were reported. Transient pain at the stimulation site was noticed. Diarrhoea, 
headaches, calf cramps and low back pain were reported. One patient did not complete the treatment 
because of aggravating pre-existent heart rhythm problems. However these adverse effects were not 
considered to be related to PTNS.
 
10.4 DISCUSSION
The primary outcome measure was obtained in 41% of all patients (percentage based on intention-
to-treat). An additional 26% of patients noticed a reduction in 24h total catheterised urine by 25-50%. 
The total of these 2 ﬁ gures (67%) is comparable with the subjective response rate (59%). Nearly all 
responders also diminished their 24h residual volume with more than 25%. PTNS resulted in 15 out of 
39 patients with a mean catheterised volume smaller than 100 ml and even the two patients that had 
zero residual after catheterisation, still continue catheterisation. Presumably these patients wanted 
to be on the safe side by checking their residual volumes once daily. Since PTNS is a young treatment 
modality, optimal stimulation parameters still have to be searched for. More adequate stimulation 
speciﬁ ed for voiding dysfunctional patients and directly placed on the tibial nerve, could hopefully lead 
to catheterisation free results. The intention of this study was to determine more objective indicators 
of a successful outcome, namely derived from urodynamic investigations. The total cystometric 
capacity in patients did not change at all, most patients had a normal bladder capacity before entering 
the study and this remained unchanged. 
Surprisingly more detrusor instabilities (DI) were detected in patients with voiding dysfunction after 
the 12 weekly sessions (from 14 % to 37% of patients urodynamically investigated). Perhaps DI is an 
essential feature for a good outcome in PTNS for bladder emptying problems; the perception of DI may 
result in an accentuated awareness of bladder ﬁ lling and this is believed to “train” the complex neural 
regulation system of voiding. Although 8 out of the 10 patients with DI considered their treatments as 
successful, the number of participants is too small to draw conclusions from these DI-related data. 
Moreover, the value of the presence or absence of DI should be further investigated as some even 
questions the whole concept of DI since this phenomenon can be seen in asymptomatic persons 
[Zinner, 2000]. This study found improvement in detrusor pressure at maximal ﬂ ow, maximal ﬂ ow 
rate, cystometric residual volume and bladder indices. The Bladder Contractility Index increased for 
most participants but left the main part of patients in the “weak detrusor” classiﬁ cation, suggesting 
that PTNS is not acting strongly on the detrusor muscle itself. Unfortunately EMG records of the pelvic 
ﬂ oor and urethral striated sphincter were not available, it might be possible that PTNS also improves 
the detrusor-sphincter coordination. Uni- and multivariant analysis revealed no spectacular results: 
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participants with only minor voiding dysfunction were more prone to be successful. It seems therefore 
that patients with minimal voiding dysfunction are good candidates for PTNS. PTNS results in improved 
voiding parameters, higher quality of life and a high subjective response rate. 
PTNS is believed to relieve symptoms related to bladder overactivity and underactivity, a phenomenon 
also seen in Sacral Nerve Stimulation SNS  [van Balken et al., 2000; Jonas et al., 2001; Shaker et al., 
Hassouna at al.,2000]. The underlying neurophysiological mechanisms of such a bi-polar effect has 
not yet been elucidated. The result achieved by SNS returns to baseline values after switching off the 
device, as opposed to long-term effect of a few weeks after stimulation by PTNS  [Jonas et al., 2001; 
van Balken et al., 2000; Klingler et al.,2000]. Schultz-Lampel et al. conﬁ rmed by cat experiments the 
hypothesis of a rebound phenomenon as mechanism of action for induction of spontaneous voiding 
in patients with chronic retention [Schultz-Lampe et al., 1998]. 
The long-term effect through PTNS could be explained by the carry-over effect found in cat experiments 
where a 5-minute stimulation of afferent nerves resulted in more than one hour lasting effect [Jiang et 
al., 1999]. In rats PTNS exerted its inﬂ uence on c-fos expression suggesting neuromodulating action 
[Chang et al., 1998]. Presumably the combination of needling (resulting in a higher concentration 
of certain neurotransmitters), bladder retraining by completing voiding charts and induction of DI 
in some patients, and to some extent the attribution of a placebo-effect ( meeting fellow sufferers, 
having a very intensive guidance and attention given by medical care-givers) ﬁ nally results in a 
higher voiding efﬁ cacy. 
PTNS is a cheap treatment modality, minimally invasive and with a simple accessible stimulation site. 
However, in daily practice some logistic problems appeared, PTNS is a time consuming procedure 
both for clinicians as for patients. Positive responders need to have PTNS on a regular basis, hereby 
occupying precious out patient clinical time to treat new patients. Most investigators limit the number 
of sessions for this reason. In our clinic we started to train positive responders how to insert the 
needle themselves and how they can apply the stimulator at home. Besides more basic research 
investigating optimal parameters, development of an implantable stimulator might be very useful. 
In conclusion, PTNS is an attractive young treatment modality for patients with minor chronic voiding 
disorders, requiring further research to establish optimal stimulation parameters. 
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11.1 SUMMARY
The aim of this thesis was to demonstrate that PTNS is a useful alternative treatment option for 
patients with overactive bladder complaints or voiding dysfunction (chapter 1).
In chapter 2 a concise overview of the lower urinary tract anatomy and its innervation is given. In a 
brief but comprehensible way the process of micturition is illustrated. 
Detrusor overactivity is commonly seen in neurological disease or after neurological injury. Diseases 
at or above the brain stem, involving the spinal cord or distal to the spinal cord often results in detrusor 
overactivity. Aging, inﬂ ammation, bladder outlet obstruction or irritation of the bladder wall can induce 
overactivity. Furthermore gender and depression can predispose to overactive bladder complaints. 
When no speciﬁ c cause is found the overactivity is deﬁ ned as idiopathic. Storage failure can also occur 
in the absence of detrusor overactivity, secondary to pain or hypersensitivity. Interstitial Cystitis 
or painful bladder syndrome is a classic example of this [Wein, 1998]. Causes of OAB or voiding 
dysfunction are summarized in chapter 3. A rough sketch of the main ideas about pathophysiology 
of OAB and voiding dysfunction is also drawn. Years of research resulted in new insights, and thus 
deﬁ nitions changed once in a while. In 2002 the International Continence Society changed and 
adjusted a number of old terms and deﬁ nitions. Therefore a summation of the newest terms relevant 
to comprehend this thesis was added in this chapter. Also all terms in the published articles were 
adapted to conform to the ICS recommendations. 
Chapter 4 presents the results of the Boxmeer study. In 1998 a Dutch national postal questionnaire 
survey asked 1460 spouses to participate. They had to complete Urinary Incontinence UI speciﬁ c and 
quality of life questionnaires. 1071 women returned their questionnaires: 34% of them were regarded 
as minimally and 12% as severely incontinent. The self-reported UI rate was 40%. Disease speciﬁ c 
and general quality of life was signiﬁ cantly lower for women with UI than for those with minimal or no 
urine loss. 38% of incontinent respondents had consulted a physician for their urinary incontinence 
and among respondents with minimal complaints this was 28%. We concluded that 46% of the married 
population to some degree suffered from incontinence, and severe UI signiﬁ cantly compromised their 
quality of life. It was clear that the prevalence heavily depended on the deﬁ nition used. We also found 
that the self-reported percentage was quite high (40%) compared to the percentage of UI divided in 
different clinical relevant groups. An important factor is the patient’s request for help. Even in our 
view the relevance of the complaints is classiﬁ ed as “only” clinically minimal relevant, whereas the 
patients’ bother and quality of life can be seriously affected. 
Behavioral techniques, bladder re-education, biofeedback combined with e.g. anticholinergics or 
antispasmodics are primary options for overactive bladder complaints. For voiding dysfunction 
pelvic ﬂ oor relaxation, self-catheterisation or permanent catheterisation can bring a solution for some 
patients. Electrostimulation has also gained an important place in the treatment ﬂ ow chart. 
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In chapter 5 a brief synopsis illustrates the evolution from ancient electrotherapy to the newest 
modalities; the history from electrical eels to PTNS therapy. It informs about the Users Club, the group 
effort of more than 25 urologists in the Netherlands, the inclusion and exclusion criteria used in the 
studies and about the PTNS procedure and its equipment.    
Chapter 6 contains the very ﬁ rst results published in 2001. PTNS was used as neuromodulative 
treatment for lower urinary tract dysfunction. 37 patients with OAB complaints and 12 patients 
with voiding dysfunction, deﬁ ned as chronic non- obstructive urinary retention, received 12 weekly 
sessions. An overall response rate was 60%. 18 out of 37 patients with OAB and 7 out of 12 patients 
with voiding dysfunction declared that the therapy was successful. Analysis of the responder groups 
showed that their voiding characteristics improved signiﬁ cantly.
Stimulated by these promising results, PTNS was applied in the Netherlands. Under the coordination 
of the Users Club and in cooperation with the Italian university of Rome more patients were included 
and treated. 
In chapter 7 the data of 35 patients with OAB complaints with incontinence are presented. In a 
prospective multicentre design patients received 12 weekly sessions and completed bladder diaries, 
quality of life and SF-36 questionnaires. Subjective success was deﬁ ned as the willingness to continue 
treatment, 63% of the patients received a maintenance treatment schedule. Objective success in this 
group was deﬁ ned as a signiﬁ cant decrease (>50%) in total number of leakage episodes. Bladder 
diaries showed that in 24/35 (70%) patients the number of episode was reduced to more than 
50%. 16/35 (46%) patients was even dry after the 12 sessions. Quality of life parameters increased 
signiﬁ cantly. 
In chapter 8 the results of the voiding dysfunction group are given. 39 patients necessitating 
clean intermittent catheterisation were enrolled in a prospective multicentre study. After 12 weekly 
sessions, questionnaire scores and data from the bladder diaries were analyzed. Also here subjective 
success was deﬁ ned as the wish to continue, whereas the objective primary outcome was deﬁ ned as 
a reduction of 50% or more in total catheterised volume.  59% of the participants asked for continuation 
of PTNS sessions. 41% of the participants showed a 50% decrease in total catheterised volume. 
Additionally 10/39 (26%) showed a 25-50% decrease. For all patients the total catheterised volume 
decreased by a mean of -228ml (range: -49;-528ml] Also in this study group quality of life and SF-12 
parameters improved signiﬁ cantly.
It was clear that a high percentage of the participants demanded maintenance therapy. This 
subjective success was nearly always illustrated by the improved bladder diary data. In our study 
participants were also asked to undergo an urodynamic investigation, at baseline and after 12 weekly 
PTNS sessions. These data provided us even more information and a possible guideline for selecting 
the right candidates. In chapter 9 the urodynamic ﬁ gures of the overactive bladder patients are 
presented. At that time 90 patients with OAB complaints were enrolled. In this group the subjective 
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success was 64%, a ﬁ gure not very different from previous studies. 56% had more than 50% reduction 
in incontinence episodes, 38% of the participant patients were dry. Before and after treatment, 
urodynamic data from 46 participants were available. Detrusor overactivity could be abolished in 
only a few cases, but increments in cystometric bladder capacity and in volumes at ﬁ rst detrusor 
overactivity were signiﬁ cant. Subjects that had no detrusor overactivity at baseline were 1.7 times 
more prone to respond to PTNS. A bladder with strong and early onset detrusor overactivity was found 
to fail to PTNS therapy. 
In chapter 10 the urodynamic data of the voiding dysfunction disorders are listed. 39 patients were 
enrolled and received 12 PTNS sessions. Surprisingly more detrusor overactivity was found after 12 
sessions (from 17 to 34%). Although the presence of detrusor overactivity was not requested to have 
a successful PTNS therapy, the awareness of bladder activity might help to re-educate the bladder. 
Detrusor pressure at maximal ﬂ ow, cystometric residuals and bladder indices improved signiﬁ cantly 
for all patients. Patients with only minor voiding dysfunction were more prone to notice success.
11.2 CONCLUSION
PTNS is a cheap treatment modality, minimally invasive and with an easily accessible stimulation site. 
The majority of participants asked for continuation of the treatment and received an individual based 
maintenance schedule. Not only subjective success was clear, also objective data were observable: 
episodes of urinary leakage decreased dramatically, total volume of catheterised volume decreased. 
Quality of life and disease speciﬁ c scores improved signiﬁ cantly. Urodynamic results conﬁ rmed 
the bladder diary ﬁ gures. Inﬂ uencing factors on the outcome were searched for, but the data were 
somewhat disappointing. The worst cases were mostly not sufﬁ ciently treated. Perhaps these 
subjects with such disabled bladders or micturition control, suffered from their disorder for too long 
with irreversible damage. Or they might have had an unknown or unfound neurological cause for their 
bladder complaints. 
11.3 FUTURE PERSPECTIVES
Logistical problems on the outpatient ward appeared. Positive responders needed to have PTNS on a 
regular basis, claiming clinical time to treat or enroll new patients. In our clinic, we started to educate 
responders on performing self-administered home-based PTNS. Meanwhile an implant device was 
developed (Subcutaneous Tibial Nerve Stimulation). The ﬁ rst results of this device are presented 
and will soon be published [van der Pal, 2006]. Many factors seem to inﬂ uence the outcome of 
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PTNS. Presumably, complex interaction of several factors, such as bladder retraining by frequently 
completed bladder diaries, release of enkephalines or other neurotransmitters through needling, 
decreased c-fos expression by tibial nerve stimulation and attribution of a placebo-effect, will play 
an important role and ﬁ nally add up resulting in a successful outcome. This thesis does not intend 
to reveal electrostimulations’ mystery. More basic research is needed to answer these questions. 
Hopefully future research will be able to distinguish different subgroups in this heterogeneous 
patient population so that each individual can receive a speciﬁ c efﬁ cient treatment. Is there a high 
placebo-effect included? The urodynamic results refute the hypothesis of a placebo-effect being the 
only explanation for the positive results found in this study. The placebo-effect is thought not to be 
stronger than in any other treatment given to a patient with OAB or dysfunctional voiding complaints. 
Excluding a strong placebo-effect, a randomized placebo-controlled study should of course be 
performed, keeping in mind that this is difﬁ cult to execute using 34 gauge needles and electrical 
current. More research, new insights and new developments are necessary.
Recent investigation of the suburothelium and its function will result in future targets. Resiniferatoxin 
intravesically or botulinum toxine submucosally are new treatment modalities. In the clinical setting 
botulinum toxin has gained a place in treatment of patients with detrusor overactivity. A method that 
takes minimal time for the urologist and that gives maximum effect for the patient. Unfortunately this 
is often a temporary effect and in time it seems that the patient becomes refractory for the toxin. It 
might be that these botulinum refractory patients still will be treated by neurostimulation. Functional 
brain imaging examins how the regions interact in order to achieve urinary continence. Similar to the 
recent development investigation of brain stimulation to overcome for example obesitas or parkinson, 
a development of such an electrode at the exact micturition area would not be science ﬁ ction anymore. 
Not to mention the hottest topic in urology: tissue engineering techniques. These techniques will be 
able to modulate stem cells to reinforce weak urethral sphincters or even create a normal contractile 
bladder. An exciting research time awaits us.
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12.1 SAMENVATTING 
Deze studie was opgezet om na te gaan in hoeverre PTNS een waardevol alternatief kon bieden voor 
patiënten met klachten van een overactieve blaas (OAB) of blaasledigingsstoornissen (hoofdstuk 1). 
In hoofdstuk 2 wordt een bondig overzicht gegeven over de anatomie van de lagere urinewegen 
en zijn bezenuwing. Op een beknopte maar duidelijke manier wordt het ingewikkelde proces van 
mictie geïllustreerd. OAB wordt vaak gezien bij neurologische aandoeningen of na een neurologische 
trauma. Afwijkingen ter hoogte van of boven de hersenstam, ruggenmergletsels of afwijkingen distaal 
hiervan, kunnen aanleiding geven tot detrusor overactiviteit. Ook leeftijd, onstekingsverschijnselen, 
blaashalsobstructie of irritatie van de blaaswand kan overactiviteit veroorzaken. Daarnaast 
spelen geslacht en depressie eveneens een rol. Wanneer geen speciﬁ eke oorzaak kan gevonden 
worden, spreekt men van idiopathische overactiviteit van de blaas.  Incontinentie kan echter ook 
plaatsvinden zonder de aanwezigheid van detrusor overactiviteit, bijvoorbeeld tengevolge van pijn 
of hypersensitiviteit van de blaas. Interstitieel cystitis of pijnlijk blaassyndroom is hier een klassiek 
voorbeeld van [Wein, 1998]. 
De verschillende oorzaken van detrusor overactiviteit en blaasledigingsstoornissen zijn samengevat 
in hoofdstuk 3. Daarnaast worden ook enkele denkpistes over de pathofysiologie geschetst.
Overactieve blaasklachten en blaasledigingsstoornissen worden al decennia aan onderzoek onder-
worpen, en dit deed de terminologie veranderen. In 2002 paste de International Continence Society 
(ICS) een aantal deﬁ nities en termen aan. Een kort overzicht van de nieuwste termen en deﬁ nities 
die relevant zijn om de thesis op een duidelijke manier te kunnen begrijpen werd aan het hoofdstuk 
toegevoegd. Alle oude termen in de al gepubliceerde artikels werden overigens vervangen om zo een 
uniform boekwerkje te creëren.
In hoofdstuk 4 worden de resultaten van de Boxmeer studie gepresenteerd. In 1998 werd middels 
een Nederlandse schriftelijke rondvraag 1460 echtgenoten gevraagd deel te nemen aan de studie. De 
levenskwaliteit van deze deelnemers werd door middel van Urine Incontinence speciﬁ eke vragen en 
vragenlijsten betreffende de levenskwaliteit gescoord. De prevalentie van urineverlies werd bepaald 
op twee manieren. Allereerst verdeelde de totale score de ondervraagden in drie groepen, te weten 
geen symptomen (score 0-2), minimale symptomen (score 3-6) en ernstige symptomen (score 7-14).
Vervolgens werd een zelfrapportage cijfer berekend door de ondervraagden te vragen of zij urineverlies 
hadden of niet. 1071 vrouwen beantwoordden de vragenlijst: 34% werd ingedeeld als minimaal 
incontinent en 12 % als ernstig incontinent. Het zelfrapportage cijfer was 40%. De ziektespeciﬁ eke en 
algemene levenskwaliteit scores waren signiﬁ cant lager voor vrouwen met urineverlies. 38% van de 
incontinente vrouwen had een duidelijke hulpvraag naar de huisarts toe. Voor vrouwen met minimale 
klachten was deze 28%. We konden uit deze studie concluderen dat 46% van de getrouwde vrouwen 
een of andere vorm van urineverlies hadden, en dat ernstig urineverlies signiﬁ cant hun levenskwaliteit 
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beïnvloedde. Tijdens de analyse van deze data werden we geconfronteerd met de moeilijkheid om 
deze score juist, naar klinische relevantie, te interpreteren. Het was duidelijk dat de deﬁ nitie het 
prevalentiecijfer beïnvloedde. Daarnaast was het zelfrapportage cijfer vrij hoog (40%) in vergelijking 
met de percentages van de klinisch relevante indelingen. Een belangrijk element is de hulpvraag van 
de patiënt. Zelfs, in onze ogen minimale klachten, kunnen voor de patiënt voldoende frustraties en 
een aangetaste levenskwaliteit opleveren. 
Leefstijl aanpassingen, blaastrainingen, biofeedback, eventueel gecombineerd met anticholinergica 
of antispasmodica, zijn de eerste keuze behandelingsopties voor OAB-klachten. Voor de 
blaasledigingsstoornissen kunnen bekkenbodemrelaxatie-oefeningen, intermittente zelfcathete-
risatie of een continue catheter een oplossing bieden. Electrostimulatie heeft ondertussen zijn plaats 
in het behandel-stroomdiagram verdiend. In hoofdstuk 5 wordt een korte synopsis gegeven over 
de evolutie van klassieke electrotherapie tot de nieuwste behandelingen; van het gebruik van de 
electrische aal tot het gebruik van PTNS. Het ontstaan van de User Club, een groepswerk van meer 
dan 25 urologen over heel Nederland, alsook de in- en exclusie criteria en de PTNS procedure worden 
geïllustreerd in het hoofdstuk. 
In hoofdstuk 6 worden onze eerste resultaten gepubliceerd (2001). 37 patiënten met OAB 
en 12 deelnemers met dysfunctionele mictieklachten, gedeﬁ nieerd als chronische niet-
obstructieve urineretentie, ondergingen de neuromodulatieve PTNS in 12 wekelijkse sessies. Het 
succespercentage bedroeg 60%. 18 van de 37 patiënten met OAB-klachten en 7 van de 12 patiënten 
met blaasledigingsstoornissen verklaarden de therapie als succesvol. Hun mictiepatroon verbeterde 
signiﬁ cant. 
Geïnspireerd door deze resultaten werd onder coördinatie van de SANS User club en in samenwerking 
met de Universiteit Tor Vergate in Rome een prospectieve studie opgezet in Nederland en Italië. 
In hoofdstuk 7 worden de data van 35 patiënten met een OAB met of zonder incontinentie beschreven.
In een prospectieve multicentre studie ondergingen deelnemers 12 wekelijkse sessies en 
vervolledigden plasdagboekjes, levenskwaliteit  vragenlijsten alsook de SF-36 vragenlijsten. Subjectief 
succes werd gedeﬁ nieerd als de vraag om de behandeling voor te zetten. 63% van de deelnemers 
kregen dan ook een individueel aangepast onderhoudsschema. Objectief succes werd gedeﬁ nieerd 
als de signiﬁ cante vermindering in aantal lekkages (>50%). Plasdagboekjes illustreerden dat dit het 
geval was voor 24/35 deelnemers (70%). 16/35 (46%) was zonder urineverlies na de 12 sessies. De 
levenskwaliteit verbeterde aanzienlijk.
In hoofdstuk 8 worden de resultaten van de groep met dysfunctionele mictieklachten gegeven. 39 
patiënten die dagelijks aan intermittente zelfcatheterisatie deden, werden geïncludeerd in deze 
multicentre studie. Na de 12 wekelijkse sessies werden de vragenlijsten en plasdagboekjes 
geanalyseerd. Ook hier werd het subjectieve succes gedeﬁ nieerd als de wens van de patiënt om PTNS
te continueren, terwijl het objectieve succes gehaald werd als het volume van het totaal gecatheteri-
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seerd met minstens de helft verminderde. 59% van de deelnemers vroegen om een onderhouds-
schema. 41% van de patiënten reduceerden hun residu met minstens de helft. Aanvullend vertoonden 
10/39 (21%) een vermindering in totaal gecatheteriseerd volume met 25-50%. Voor alle patiënten 
verminderde het totale residu met een mean van 228ml (range: -49;-528ml). Ook hier gingen de 
scores op de SF-36 en levenskwaliteit er signiﬁ cant op vooruit. 
Het was duidelijk dat een groot aantal deelnemers een onderhoudsbehandeling behoefde. Hoewel deze 
subjectieve succespercentages werden geïllustreerd aan de hand van de analyse van plasdagboekjes, 
werden er aanvullend urodynamische onderzoeken verricht om het objectieve succes data meer 
te kunnen bijstaan. Daarnaast kan urodynamisch onderzoek meer informatie kunnen verschaffen 
waaruit selectiecriteria zouden kunnen voortvloeien. 
In hoofdstuk 9 worden de urodynamische resultaten van de OAB-groep voorgesteld. 90 patiënten met 
OAB-klachten werden geïncludeerd. Het subjectieve succes was 64%, wat goed overeenstemde met 
de eerdere gepubliceerde succespercentages. 56% van deze deelnemers had 50% of meer reductie in 
het aantal episodes van urineverlies. 38% van deze patiënten konden als “droog“ worden bestempeld. 
Van 46 patiënten waren er vergelijkende urodynamische onderzoeken beschikbaar, namelijk van 
voor en na de PTNS-behandeling. Detrusor overactiviteit verdween bij slechts enkele patiënten. De 
toename in cystometrische capaciteit en het volume waarop de eerste detrusor activiteit verscheen 
was signiﬁ cant verbeterd. Deelnemers die geen urodynamische detrusor overactiviteit vertoonden 
in het begin van de studie, hadden 1.7 meer kans om succesvol te reageren op PTNS. Een blaas met 
sterke en vroegtijdige detrusor overactiviteit echter had meer kans om PTNS resistent te zijn.
In hoofdstuk 10 worden de urodynamische data van de patiënten met blaasledigingsstoornissen 
gepresenteerd. Hiervoor werden 39 patiënten geïncludeerd die een 12-wekelijkse PTNS-behandeling 
volgden. Opvallend was de bevinding dat meer detrusor overactiviteit werd gezien in de urodynamische 
analyse na 12 weken behandeling (van 17 naar 34%). Hoewel de aanwezigheid van detrusor 
overactiviteit niet een vereiste was om succesvol te reageren op PTNS, kan dit gegeven wel suggeren 
dat de gewaarwording van blaasactiviteit een vorm van blaas-educatie gaf. De detrusordruk op het 
moment van maximale ﬂ ow, de blaasresiduen en blaasindicatoren verbeterden bij alle patiënten. 
Patiënten met slechts een milde afwijking hadden meer kans op succes. 
12.2 CONCLUSIE
PTNS is een goedkope behandelingsoptie, minimaal invasief en toe te passen op een gemakkelijk 
bereikbare plaats van het lichaam. Het overgrote deel van de patiënten vroeg om de behandeling 
voort te zetten en ontving een individueel aangepast stimulatieschema. Niet alleen het subjectief 
succes was groot, maar ook de objectieve maatstaven spraken duidelijke taal: het aantal episodes van 
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urineverlies waren verminderd, het  totaal volume dat gecatheteriseerd diende te worden verminderde 
aanzienlijk. De levenskwaliteit van de deelnemers verbeterde, alsook ziektespeciﬁ eke scores. 
Urodynamisch onderzoek bevestigde de data uit de plasdagboekjes. Voorspellende factoren werden 
bestudeerd, maar de resultaten hiervan waren enigszins teleurstellend: weinig factoren konden het 
effect op succes voorspellen. Patiënten met een zeer ernstige blaashandicap waren vaak slecht te 
behandelen door PTNS. Waarschijnlijk gaat het hier om een groep patiënten die reeds lang gestoorde 
blaasfunctie hebben en dus een onherstelbare schade hebben opgelopen. Misschien hebben enkele 
onder hen een nog niet ontdekte neurologische aandoening. 
12.3 TOEKOMSTPERSPECTIEVEN
Toen de langdurige PTNS-behandeling een logistiek probleem werd, werd naarstig naar een oplossing 
gezocht: de implanteerbare stimulator, de Subcutaneous Tibial Nerve Stimulator. In afwachting van 
de eerste productielijn, werden sommige patiënten aangeleerd de naaldjes zelf te prikken en konden 
ze met een gehuurde stimulator zichzelf thuis behandelen. In 2004 werden de eerste stimulators 
subcutaan geïmplanteerd en spoedig volgden de resultaten [van der Pal et al., 2006]. 
Vele factoren lijken de uitkomst van PTNS te beïnvloeden. Waarschijnlijk resulteert de complexe 
interactie van verschillende factoren, zoals blaastrainingen, het regelmatig invullen van plasdag-
boekjes, de vrijstelling van enkephalines of andere neurotransmitters door acupunctuur, de 
verminderde c-fos expressie na stimulatie van de nervus Tibialis en de bijdrage van placebo-effect, 
tot een succesvolle behandeling. De grote hamvraag is natuurlijk: hoe werkt PTNS eigenlijk? Dit 
proefschrift is niet opgezet met de illusie om het mysterie van electrostimulatie eens eindelijk te 
onthullen. Basaal onderzoek kan ons een eind verder helpen in de zoektocht naar antwoorden. Zo 
divers als deze patiëntenpopulatie is, zo divers is ook hun onderliggend lijden. In de toekomst moet 
onderzoek voor elk individu kunnen uitmaken wat de onderliggende oorzaak is van hun blaasklachten 
en welke behandeling voor deze patiënt de meest efﬁ ciënte oplossing zal zijn. 
Hoe groot is het placebo-effect? Niet meer dan bij eender welke andere therapie, maar een 
gerandomiseerde placebo-gecontroleerde studie is hier natuurlijk op zijn plaats. Alleen is deze moeilijk 
uitvoerbaar als er gewerkt wordt met een naald en electrische stroom. 
Verder onderzoek, ontwikkelingen en inzichten zijn noodzakelijk.
Recent onderzoek naar het suburothelium en zijn functie zal resulteren in speciﬁ eke therapeutische 
targets. Resiniferatoxin of botulinum toxine zijn voorbeelden van zulke nieuwe behandelingen. In 
de klinische praktijk heeft botulinum toxine een plaats veroverd in de behandeling van patiënten 
met detrusor overactiviteit. Het is een methode die de uroloog een minimum aan tijd kost en een 
maximum aan resultaat oplevert voor de patient. Helaas betreft het hier vaak een tijdelijk effect 
en de patient lijkt in tijd echter refractair voor het toxine te worden. Misschien dat in de toekomst 
deze botox refractaire patiënten alsnog met de meer arbeidsintensieve neurostimulatie behandeld 
kunnen worden. Functionele beeldvorming van de hersenen onderzoekt onder andere hoe delen van 
de hersenen samenwerken om tot continentie te komen. Net zoals bij het recente onderzoek naar 
neurostimulering om bijvoorbeeld obesitas of parkinsonisme te genezen , zou het ontwikkelen van 
een electrode ter plaatste van het mictiegebied geen science ﬁ ction meer zijn, om nog maar te zwijgen 
van het meest besproken onderwerp van de urologie: de weefsel engineering technieken.
Deze technieken transformeren stamcellen zodat zwakke sluitspiercellen van de plasbuis versterkt 
kunnen worden of er zelfs een normaal contractiele blaas kan gemaakt worden. Er staan ons nog 
boeiende onderzoekstijden te wachten!
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LIST OF ABBREVIATIONS
5-HT:  5-hydroxytryptamine or serotonin
ATP: Adenosine triphosphate
BCI:  Bladder Contractility Index
BVE: Bladder Voiding Efﬁ cacy
CC: Cystometric Capacity
CI: conﬁ dence Interval
CVA: Cerebro Vascular Accident
DO: Detrusor Overactivity
GABA: Gamma-amino butyric acid
Hz: Hertz
ICS: International Continence Society
I-QoL: Incontinence Quality of life questionnaire
L region: Lateral region in the pons
LUTS: Lower Urinary Tract Symptoms
mA: milliampère
M receptors: Muscarinic receptors
M region: Medial region in the pons
NGF: Nerve Growth Factor
NO: Nitric Oxide
OAB: Overactive Bladder
OR: Odds Ratio
PAG: Periaquaductal Grey 
PMC: Pontine Micturition Centre
PNE: Pelvic Nerve Evaluation 
PTNS: Percutaneous  Posterior Tibial Nerve Stimulation
PVR: Post-voidal Residual
SF-36: MOS 36-items Short-Form Health Survey
SF-36: MOS Short Form 36 items questionnaire
SNS: Sacral Nerve Stimulation
SPSS: Statistical Package for the Social Sciences, version 9.0
SSRI: Selective Serotonin Re-uptake Inhibitors 
UI: Urine incontinence
VDO: Volume at ﬁ rst DO
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